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Chapter 1
General introduction
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1.1. GENERAL ASPECTS OF PSORIASIS
1.1.1. Definition & epidemiology
Psoriasis is a common and chronic skin disease characterised by epidermal 
hyperproliferation, premature terminal differentiation of the epidermal keratinocytes and 
cutaneous inflammation. The most characteristic lesions consist of sharply demarcated 
erythematosquamous plaques, particularly localised on the extensor prominences and the 
scalp. The prevalence of psoriasis in Caucasians varies between 1.5 and 3 %. Psoriasis is 
virtually absent in Eskimos and native American populations .1 The age of onset of 
psoriasis is variable with two peaks, an early onset type (16-22 years) and a late onset 
type (57-60 years ) . 2 Psoriasis is equally distributed between both sexes but tends to 
evolve earlier in females . 3 " 5
Fig. 1 a
Classical manifestations o f 
psoriasis: sharply 
demarca ted erythema tous 
and squamous lesions
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Fig 1 b Classical manifestations of psoriasis: sharply demarcated erythematous and 
squamous lesions
1.1.2. Clinical aspects
Psoriasis vulgaris is characterised by sharply demarcated nummular, palm-size 
and more than palm-size erythematosquamous plaques (figure 1). Its classical 
appearance permits a diagnosis 'a vue'. The efflorescences of the psoriatic plaque are 
erythema, induration and scaling; the intensity of these efflorescences may vary in 
severity depending on the stage of the lesions. Classical signs of psoriasis are the 'signe 
de la tache de bougie' (scratching the superficial scales of a lesion is like scratching a 
candle) and the 'signe d'Auspitz' (point-bleedings can be observed after removing the 
silvery scales). Sometimes, a clear peripheral zone, the halo of Woronoff, can be seen 
around a chronic psoriatic plaque. New lesions start as pin-point-lesions that may 
develop and coalesce together with other lesions into larger plaques. Psoriasis in general, 
is expressed as psoriasis vulgaris with a fairly symmetrical distribution pattern. The 
lesions can be localised anywhere, however, the face is usually spared whereas the 
extensor sites of elbows and knees and the scalp are preferentially involved with 
psoriasis . 1
4
A particular form is guttate psoriasis in which numerous psoriatic plaques can be 
observed all over the body. Psoriasis guttata is the most frequent manifestation in 
children after a streptococcal throat infection. Systemic triggering factors are thought to 
play a major role in this psoriatic phenotype . 1
Psoriasis can also be localised in the flexural areas like the armpits, genital region 
and groins. This manifestation is designated as psoriasis inversa and is seen in 2-6% of 
the patients with psoriasis. Psoriasis inversa is characterised by a sharply demarcated 
erythema; the scaling, which is characteristic for psoriasis vulgaris, is not observed.
Sometimes, erythroderma psoriatica may occur. This condition involves 
generalised erythema and scaling. The function of the skin is impaired and precautions 
have to be taken to protect the patient from dehydration and heath and protein loss. 
Therefore hospitalisation is indicated.
Fig. 2 Psoriatic lesion with pustules: psoriasis pustulosa
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A manifestation of psoriasis with a marked expression of the inflammatory 
component is psoriasis pustulosa (figure 2). In this condition macroscopic pustules can be 
seen, either all over the body (Zumbusch type), at palms or soles (pustulosis 
palmoplantaris, Morbus Andrews-Barber) or at the acra of fingers and toes 
(acrodermatitis continua of Hallopeau, figure 3).
K g - 3
Acrodermatitis continua o f 
I lallopeau
Extracutaneous manifestations of psoriasis are involvement of nails and joints. 
Characteristics of nail involvement in psoriasis are seen in 10-50% of the patients and 
comprise pits of the nail plate, distal onycholysis, subungual hyperkeratosis and the 'oil- 
spot' phenomenon (figure 4).
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Fig. 4 Nail psoriasis with distal onycholysis, pits and the oil-spot phenomenon
Psoriatic arthropathy is a complication of psoriasis that is seen in 5-10% of the 
patients and can also be observed in patients without cutaneous manifestations of 
psoriasis. The most frequent manifestation is arthritis with similar symptoms as occur in 
rheumatoid arthritis and M. Bechterew. The most pathognomonic manifestation is 
arthritis of the distal interphalangeal joints of the hands. Sometimes monoarthritis or 
polyarthritis of larger joints can be observed. Psoriatic arthritis is sero-negative. In 
patients with psoriatic arthropathy, an increased frequency of HLA-B27 and HLA-Bw38 
has been found . 6 ,7
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Psoriasis is a chronic disease, the clinical course is characterised by remissions 
and exacerbations. Although severe complications such as erythroderma, generalised 
pustular psoriasis and psoriatic arthropathy may occur, in general the course is mild. 
Psoriasis may exacerbate due to endogenous and exogenous factors such as infections, 
various drugs (p-adrenergic antagonists, lithium, cyclo-oxygenase inhibitors and 
antimalarials), endocrine factors, hypocalciaemia and (psychogenic) stress. The 
elicitation of a psoriatic lesion by an injury is known as the isomorphic phenomenon and 
has been described for the first time by Heinrich Koebner.1,8
In classical psoriasis, the diagnose is easy. In case of an atypical presentation, the 
differential diagnosis may comprise all other erythematosquamous skin diseases: 
seborrhoeic dermatitis, pityriasis rubra pilaris, parapsoriasis, mycosis fungoides, 
dermatophytic infections and secondary syphilis.
Table I The family-related risk to get psoriasis6
Family members with Risk (%)
psoriasis
One parent, no siblings 1 0
No parents, one sibling 7
One parent, one sibling 16
No parents, two siblings 16
Both parents 50
Second degree relatives 4
Third degree relatives 1 - 2
1.1.3. Genetics
A genetic predisposition plays an important role in the pathogenesis of psoriasis. 
In monozygotic twins, a concordance of 73% has been reported .9 The risk of getting 
psoriasis in case one of the relatives has the disease is shown in table I .6 Nowadays there 
is consensus about the polygenetic inheritance of the disease and about the fact that the 
disease may come to expression due to multiple exogenous factors. Despite of the 
commonly accepted polygenetic inheritance, it was shown in one family that a single 
gene abnormality of chromosome 17 was associated with the psoriatic phenotype .1 0 ,1 1  
The number of psoriasis-associated genes and the identity of these genes are relevant to 
the subtype, extension and course of psoriasis in the individual patient and also 
determine the sensitivity for exogenous stimuli. In literature, some genes have been 
described which are supposed to be associated with a more severe course of psoriasis 
including some major histocompatibility complex antigens for instance the HLA class I 
(CW6 ) and HLA class II (Dr7) genes which underlay multiple HLA associations in 
psoriasis . 1 2 ,1 3 In patients with Morbus Bechterew, an association with HLA B27 has been 
found and in these patients, psoriasis is more frequently seen .14 A polymorphism of the 
apolipoprotein E gene, and changes of the a-l-antitrypsine inhibitor gene and the
8
interleukin-l-receptor antagonist genes have also been demonstrated to be associated 
with psoriasis . 15 17
1.1.4. Histopatholoaical aspects
The histological picture of psoriasis vulgaris varies with the stage of the lesion but 
the general picture is characterised by parakeratosis, elongated rete-ridges, thinning of 
the suprapapillary epidermis and absence of the granular layer (figure 5). In the dermis, 
elongation and oedema of the papillae are seen with dilated and tortuous capillaries and 
an inflammatory infiltrate.
The dermal infiltrate is predominantly characterised by T-lymphocytes but 
polymorphonuclear leukocytes (PMN) are seen as well. The epidermis is infiltrated by T- 
lymphocytes. PMN aggregate in pustules and abscesses in the epidermis: micro­
abscesses of Munro in the stratum corneum and spongiform pustules of Kogoj within the 
stratum spinosum which are highly diagnostic for psoriasis .18
Acute changes in a newly developing lesion are mainly characterised by dermal 
changes (capillary dilatation, dermal oedema and a mononuclear infiltrate around the 
capillaries) although controversy still exists whether the initiating events in early 
psoriasis are located in the dermal or epidermal compartment. Future studies at the 
transcriptional level will provide relevant information on the initial molecular event in the 
development of the psoriatic lesion.
Fig. 5 Histology of a typical psoriatic lesion
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Early in the evolution of a lesion, PMN are thought to move from the capillary 
loops in the tip of the dermal papillae into the epidermis; this is called the phenomenon 
of the squirting papillae. The acute psoriatic lesion is further characterised by thickening 
of the stratum corneum and parakeratosis.
In pustular psoriasis, besides micro-abscesses, large macro-abscesses are formed 
in the epidermis. In the upper dermis an infiltrate of lymphocytes and PMN migrating into 
the epidermis can be observed. Epidermal acanthosis, parakeratosis and tortuosity of the 
capillaries further complete the micromorphological picture of pustular psoriasis.
1.1.5. Pathogenetic aspects: epidermal growth and differentiation versus 
inflammation
Numerous factors are involved in the pathogenesis of psoriasis. Table II 
summarises the cutaneous processes studied so far in lesional and clinically uninvolved 
skin of psoriatics. The significance and interpretation of the aberrations in uninvolved 
skin is difficult and remains a matter of dispute. A biopsy of uninvolved skin can also be a 
'preclinical lesion' and, on the other hand, abnormalities found in uninvolved skin may 
also be an effect of systemic dysregulations due to factors from active psoriatic plaques. 
Recently, these aspects have been reviewed by various authors .19,20
Table II Cellular and biochemical aberrations in different cell types in psoriasis
Cell type Aberration
in lesional Dsoriatic skin in uninvolved skin
Keratinocytes • hyperproliferation • normal or slightly increased 
proliferation
• aberrant differentiation • normal differentiation
• • abnormal cell signalling
• • normal production of cytokines
T-lymphocytes •
lymphocytes in dermis and epidermis
•
•
•
slightly increased number of T- 
lymphocytes in dermis; not in 
epidermis
PMN •
•
• not present
Monocytes • • essentially normal
Langerhans cells • • essentially normal decreased density
Fibroblasts • • increased proliferation
• altered extracellular matrix composition • altered extracellular matrix composition
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Several groups regard an abnormality in inflammation control of primary 
importance in the pathogenesis of psoriasis. Several observations of the last decade, 
indeed, are in favour of such supposition. Here, the observations will be summarised, 
which are relevant to the dilemma whether psoriasis might primarily be an 
immunedisorder or a disorder of epidermal growth and differentiation:
• On the histological level, in pin-point lesions and in the margin zone of spreading 
psoriatic plaques, T-lymphocytes have been reported to accumulate in the dermis 
before the appearance of PMN (micropustules of Kogoj) and before epidermal 
hyperproliferation and abnormal differentiation. However, in these studies, 
relatively 'late' markers for altered proliferation and differentiation were used .2 1 ,2 2  
A further criticism to these studies is the feasibility that the sensibility of the 
method of assessment is critical for early or late detection of a phenomenon.
•
of new lesions:
* Following streptococcal infections, flares of psoriasis occur.1
* Treatment of children with tonsillectomy has resulted in decreased expression 
of psoriasis . 23
* Recently, it has been shown that intradermal injection of bacterial 
superantigens in uninvolved psoriatic skin transplanted on severe combined 
immunodeficient (SCID) mice results into the development of the psoriatic 
phenotype although the specificity of this effect has also been discussed since 
addition of serum to normal cultured keratinocytes is also able to induce a 
psoriatic phenotype in vitro .24 ,25
•
* Patients with AIDS have more severe psoriasis .26
* Treatment with the specific T-lymphocyte inhibitor, cyclosporin, a well- 
established treatment of psoriasis has been shown to leave epidermal growth 
and differentiation unaffected in vivo but to have a strong effect on 
immunomodulatory functions .2 7
* Treatment with CD4 antibodies has been shown to improve psoriasis .28,29
* Treatment with IL-2 (DAB) has been shown to improve psoriasis30
Although these immunomodulations coincide with changes of the clinical 
expression of psoriasis, it remains to be shown whether coincidence also implies a
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specific and direct causal relationship. On the other hand, several observations 
suggest that epidermal proliferation and differentiation are major determinants of the 
psoriatic process:
• The lesional skin of psoriasis is characterised by a massive thickening of the 
epidermis and it is the excessive scaling -the result of the process of 
kératinisation- which is a most significant problem for the patients affected with 
psoriasis.
•
betamethason valerate, has been proven to exert its effect mainly by interfering 
with epidermal proliferation and kératinisation and less by modulating the 
inflammatory infiltrate. Although calcipotriol has some immunomodulatory 
effects, 3 1 calcipotriol so far, has not been shown to be effective in the well- 
established immunodermatoses (delayed type hypersensitivity, atopic dermatitis, 
lupus erythematosus).32,data on flle L E0 pharma
•
factors released by clones of T-lymphocytes derived from psoriatic lesional 
skin . 2 5 ,3 3 ,3 4  However, it remains to be demonstrated to what extent these effects 
are specific to psoriasis.
•
immune mechanisms. However, important abnormalities have been shown in 
signal transduction pathways in the symptomless skin before any lesion has
appeared . 2 0 ,3 5 "3 7
A joint venture of immunological mechanisms and epidermal processes seems a 
realistic supposition. In this thesis, attention is focused on epidermal growth and 
differentiation in psoriasis. The major target in this thesis will be the analysis of the 
modulation of epidermal growth and differentiation in psoriasis by antipsoriatic 
treatment.
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1.2. CURRENT TREATMENTS FOR PSORIASIS
1.2.1. Introduction
Psoriasis is a chronic skin disease and can be treated, not cured. Therefore, long­
term management is of utmost importance. In each patient with psoriasis, an individual 
therapy plan has to be made that may vary depending on the type of disease but also on 
the patient's health, time and expectations, taking efficacy and side-effects of the 
treatment into consideration. Often a combination of two or more therapies is used in 
order to enhance efficacy and to minimise side-effects. Topical therapies are the first 
choice of treatment; 3 8 phototherapy and systemic treatment are indicated if topical 
treatment is insufficient for reaching adequate control of psoriasis .1
1.2.2. Topical treatments
Emollients and keratolytics
Emollients and keratolytics are mainly fit for keeping the skin supple and for 
diminishing the effects of scaling. In general, a more active treatment is required.
Coal tar
Coal tar has been used as a safe and effective topical therapy for more than a 
century. Crude coal tar is a complex mixture of many hydrocarbons; it is not known what 
the exact active components are .39 In daily practice, tar is chosen in the case of pruritic 
psoriasis. Many vehicles can incorporate tar, for instance creams, ointments and 
shampoos. Crude coal tar paste is most effective but it involves a messy regime that 
often requires hospitalisation. More refined tars can be used at home; they are less 
effective but can be used as adjuvans, in stead of bland emollients. Better results are 
reached with combinations of tar and other therapies for instance the Goeckerman 
regime in which crude coal tar is combined with ultraviolet light, and the Ingram regime 
which combines tar with dithranol and phototherapy .4 0 "42
Dithranol
More than a century ago, a tree bark extract (chrysarobin), was discovered to 
have an important antipsoriatic potential. Dithranol (anthralin), a synthetic analogue of 
chrysarobin, has been used for over 80 years in the treatment of chronic plaque 
psoriasis .4 3 Dithranol is a yellow powder that can be incorporated in a cream, ointment, 
paste or stick. Effects and side-effects seem to be closely connected: staining and 
irritation of the skin appear to be inseparable of the antipsoriatic activity. Dithranol 
applications can be carried out according to many different regimes for instance the 
Ingram regime. The time honoured 24 hour dithranol applications are supposed to be
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most effective but, since this regime is messy and time consuming, it requires 
hospitalisation. Short contact applications and cream formulations have simplified 
dithranol treatment.43
Topical corticosteroids
For several decades, topical corticosteroids have been used extensively in the 
treatment of psoriasis. Topical corticosteroids are convenient to use and are able to 
induce fast remissions. But topical steroids also have disadvantages: discontinuation of 
topical steroids may result in a rebound phenomenon, resulting in a major relapse. Long­
term use of corticosteroids can cause atrophy or striae of the skin, allergic contact 
dermatitis and habituation, so that more frequent or more potent corticosteroid 
applications are required. Systemic adverse events have been described following high 
doses of corticosteroids namely an inhibiting effect on the hypophysis-adrenal cortex 
axis. Rapid induction of clearance in recalcitrant localised psoriasis can be obtained using 
potent corticosteroids .44 Low and medium potent steroids are used for maintenance 
therapy in mild disease. Intermittent therapy is often used to minimise adverse 
events . 1 ' 44
Hydrocolloids
It has been known for a long time that occlusion of psoriatic lesions has a 
beneficial effect.45 Nowadays, hydrocolloid dressings (HCD) are available in all qualities 
and sizes with a remarkable adhering capacity and a great wearing convenience. 
Occlusion is thought to at least partly improve the impaired barrier function of the 
psoriatic skin. So far, no significant clinical effect of occlusion as a monotherapy has been 
established . 4 5 ,4 6 In combination with other therapies, HCD have a significant effect.4 7 ,4 8  
Topically applied corticosteroids under HCD are thought to increase the bioavailability of 
the corticosteroid . 49 Increased bioavailability, in combination with the occlusive-effect of 
the HCD, can induce rapid remissions in localised recalcitrant psoriasis.
Vitamin D3 analogues
Vitamin D3 analogues are the main achievement in the development of topical 
treatment of psoriasis of the last decade. The usefulness of active vitamin D^  for psoriasis 
was established in the 1930's but the hypercalciaemic effects limited its use. In 1985, 
interest was reawakened by the report of a remarkable improvement of psoriasis in a 
patient during treatment of osteoporosis with oral 1-a-OH-vitamin D3 (alphacalcidol) . 5 0 " 53 
Later, others found topical application of l,25-(OH)2-vitamin D3 (calcitriol) to be 
beneficial for psoriasis as well. Calcipotriol, a novel vitamin D3 analogue with a lower 
hypercalciaemic potential and an antipsoriatic activity comparable to medium strength
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corticosteroids was developed as a safe and effective vitamin D3 formulation for the 
topical treatment of psoriasis. 5 4 "59 The most commonly encountered side-effect of 
calcipotriol is a transient irritant reaction, particularly of the facial skin .54 
Hypervitaminosis D3 may lead to hypercalciaemia .6 0 ,6 1 Calcipotriol ointment (50ng/g) up 
to 100 grams weekly is supposed to be safe. The use of larger quantities of ointment 
should occur under intensified supervision of blood parameters .5 5 ,6 1
1.2.3. Phototherapy
Sunlight and in particular ultraviolet radiation have a well-established effect on 
psoriasis. Phototherapy with UVB and photochemotherapy with topical or systemic 
psoralens in combination with UVA (PUVA) are mainly indicated in case of extensive 
psoriasis. Ultraviolet light induces a cascade of many biological processes that cause a 
proliferative and inflammatory response in normal human skin but in the psoriatic lesion, 
suberythematous doses of UV induce curative effects. Extensive use of UV sources 
accelerates ageing of the skin and PUVA increases occurrence of actinic keratoses and 
squamous cell carcinoma . 6 2 ,6 3 On the other hand, the fact that UV light has no systemic 
side-effects makes it a therapy that is especially suited for pregnant women with 
extensive psoriasis.
Phototherapy using narrow-band UVB with a maximum of energy at 311 nm is an 
optimised irradiation principle compared to conventional UVB phototherapy. In 
comparison to broad-band UVB therapy, narrow-band UVB is more effective and results 
in less erythema. The emission energy is lower which explains the relatively higher dose 
of narrow-band UVB irradiation required compared to conventional UVB irradiation for 
antipsoriatic treatment. This new UVB therapy is therefore relatively expensive. It is not 
yet clear whether the therapeutic benefit of narrow-band UVB therapy justifies this 
relatively expensive treatment.64,65
Topical PUVA with trioxalen and 8 -methoxypsoralen is mainly a popular treatment 
modality in Nordic countries . 6 6 ,6 7 Bath-PUVA reduces the occurrence of nausea which is 
often encountered during treatment with systemic psoralens. Interestingly, a decreased 
risk for skin malignancies was documented in patients treated with bath-PUVA with 
trioxalen compared to oral PUVA with 8 -methoxypsoralen .67
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1.2.4. Systemic treatments
Methotrexate
Methotrexate is a very effective drug which has been used for a long time in the 
treatment of psoriasis. Its main side-effects are the suppression of the haemopoeitic 
system and liver damage. These side-effects limit the use of methotrexate .68 However, 
provided that the guidelines for methotrexate treatment are taken into consideration, this 
treatment is a safe approach to recalcitrant psoriasis and psoriasis arthropathica .6 9 ,70
Retinoids
Retinoids are derivatives of vitamin A acid. Especially pustular psoriasis and active 
guttate psoriasis respond well to this treatment. Muco-cutaneous side-effects like dryness 
of the skin, reversible hairloss or hypertrichosis, generalised pruritus and paronychia are 
dose-dependent side-effects. Teratogenicity limits the use of retinoids in female patients 
of the childbearing age. Other side-effects are hypercholesterolaemia and 
hypertriglyceridaemia. The side-effect profile necessitates frequent follow-up visits with 
blood investigations .7 1
Cyclosporin
Cyclosporin is a relatively new therapy for psoriasis. Cyclosporin is a specific 
inhibitor of the T cell function and its mode of action is primarily via immunomodulation. 
Cyclosporin is primarily metabolised in the kidneys. The side-effects -mainly hypertension 
and renal impairment- limit the use of this antipsoriatic drug. Cyclosporin can be 
regarded as an important'short period intervention' in very severe psoriasis .2 7
Other systemic drugs
Systemic corticosteroids are capable of causing rapid remissions in extensive 
psoriasis. But the well-known adverse events of systemic corticosteroids limit their use. 
Major relapses after discontinuation of this therapy make it a therapy that is obsolete 
nowadays . 1 Azathioprine , 72 fumaric acid , 7 3 sulphasalasine , 7 4 hydroxyurea7 5 and FK50676 
are systemic medications which have not (yet) been registered for psoriasis. Occasionally 
these treatments might be of help in case of inefficacy of the other treatments or 
contraindications for the other treatments.
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1.2.5. Treatments of focal interests in the present thesis
Recently, the systemic treatment of psoriasis was the objective for two theses in 
the Netherlands, Dr. R.J. van Dooren-Greebe evaluated the efficacy and side-effects of 
methotrexate and acitretin .69 Dr. L. Witkamp evaluated efficacy and side-effects of 
cyclosporin and systemic tacrolimus (FK5 06).76,77 For patients with severe psoriasis 
systemic treatment is of major importance. The focus of the present thesis is the topical 
treatment of psoriasis. The topical application of antipsoriatic compounds provides the 
advantage of restricting the availability of a compound to the target tissue: skin. 
However, systemic absorption through the skin remains an important aspect in regard to 
safety of a topical therapeutic agent.
The last decade, major progress has been made in the topical treatment of 
psoriasis:
• Dithranol based therapies have been popularised by the introduction of short 
contact application schedules, new vehicles which permit easy washing off and 
new principles of care which aim for patient care in conjunction with patient 
instruction .4 3 ,7 8 ,7 9
•
Calcipotriol ointment was introduced as a treatment in most countries 1992.80 A 
limitation of the treatment is irritation of the skin. Its efficacy is comparable with 
betamethason valerate . 54 Combination treatments with topical or systemic 
antipsoriatics and the search for analogues with a low degree of irritation are the 
most recent developments concerning vitamin D3 analogues.
•
dressings is a 'high compliance approach' which is very effective .48 Safety and 
post-treatment remission characteristics are current areas of research.
In fact, these new leads are the focal interest in the present thesis and new 
information on these areas will be presented in this thesis.
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1.3. ANTIPSORIATIC MECHANISMS
1.3.1 Introduction
The aim of this section is to provide a review on the in vitro effect of established 
topical treatments for psoriasis on epidermal proliferation and differentiation. The cell- 
biological effects of most treatments have been studied on various in vitro models for 
inflammation, keratinocyte proliferation and differentiation. In the present thesis, focal 
attention is on epidermal proliferation and differentiation. Therefore the in vitro effects of 
treatments on keratinocyte growth an differentiation will be reviewed. For a review on 
effects of treatments on inflammation and immune mechanisms, the reader is referred to 
the literature . 19 As the present thesis is focused on topical treatments, for information on 
the effects of systemic treatments on epidermal proliferation and differentiation the 
reader is referred to the literature . 19
1.3.2. Antiosoriatic mechanisms of topical treatments and 
photof chemoHherapv
Tar
Data on the mode of action of this topical treatment are sparse. Tar is assumed to 
have an anti-mitotic effect in vivo .8 1 In vitro research on keratinocytes and cell cultures 
with other cell types confirms this assumption .8 2 ,8 3
Dithranol
Auto-oxidation of dithranol induces free radicals in the skin and alters the cellular 
and subcellular redox potential with a diversity of antipsoriatic effects.84,85 Dithranol 
inhibits key enzymes in the metabolism of the cell, interacts with mitochondria, probably 
resulting in the inhibition of proliferation of the psoriatic keratinocytes, which has been 
proven to be inhibited up to 98%. Transforming growth factor a-mRNA expression and 
epidermal growth factor receptor binding are inhibited as well due to dithranol.86
Topical corticosteroids
Corticosteroids act via binding to a specific receptor, that is a member of the 
steroid-hormone receptor superfamily. The corticosteroid-activated receptor modulates the 
transcription of target genes .8 7 Increased transcription of lipocortin, the inhibitor of the key 
enzyme in arachidonic acid metabolism phospholipase A2, results in reduced formation of 
arachidonic acid and its metabolites.8 7 In keratinocyte cultures topical corticosteroids have 
been shown to inhibit proliferation.88 To the best
18
of our knowledge no interference of corticosteroids with the kératinisation process has been 
reported so far.
Vitamin D3 analogues
Calcipotriol is the vitamin D3 analogue which has been introduced as a topical 
treatment of psoriasis five years ago .89 Recently the modes of action of vitamin D3 in the 
treatment of psoriasis have been reviewed.90 At the molecular level, two principles are 
relevant. Vitamin D3 binds to the vitamin D3 receptor and the ligand-activated vitamin Ds 
receptor transactivates various vitamin Ds responsive genes, resulting in interference with 
epidermal growth and differentiation in many cell types including the keratinocyte .91 The 
other principle is a direct effect of vitamin Ds on opening of transmembrane calcium 
channels, resulting in increased calcium concentrations in the keratinocyte.92 In 
keratinocyte cultures, it has been shown that calcipotriol, la,25-dihydroxy-vitamin D3 
(calcitriol) and la,24-dihydroxy-vitamin D3 (tacalcitol) inhibit proliferation of keratinocytes, 
enhance involucrin transcription, increase activity of transglutaminase and enhance 
cornified envelope formation .5 9 ,9 3 "9 7
Photo( chemo )therapy
Phototherapy (UVB) and photochemotherapy (PUVA) are well-established 
antipsoriatic treatments. Photo(chemo)therapy has a dual commitment to epidermal 
growth. On one hand, interference with DNA has been established, resulting in growth 
inhibition of keratinocytes in culture .98,99 On the other hand, due to UV radiation, a diversity 
of mediators of inflammation is released into the culture medium by keratinocytes, such as 
IL-1, IL-6 , TNF-a, NFkB and various arachidonic acid metabolites resulting in a diversity of 
effects on keratinocyte proliferation and differentiation .10 0 ,10 1
1.3.3. Models and phenomena of specific interest in this thesis
In the present thesis, the in vivo effects of topical treatments on epidermal growth 
and differentiation will be studied. The approaches for in vivo study and the markers of 
focal interest will be briefly introduced in this section.
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Models of focal interest
The studies on the in vivo effects of antipsoriatic treatments can be carried out on 
repeated biopsies taken from the existing psoriatic lesions during treatment. Using this 
approach, the cell-biological processes underlying the clearing process of the psoriatic 
plaque can be studied.
However, in the long-term management of psoriasis the therapeutic approach of 
the reappearance of new lesions is of utmost importance. Therefore, the induction of 
psoriatic hyperproliferation -the recruitment process of cycling epidermal cells- and the 
accompanying processes in epidermal differentiation should be impersonated in an 
experimentally reproducible in vivo model. Using such a model, the effect of antipsoriatic 
treatments on the induction of the recruitment of cycling epidermal cells and abnormal 
epidermal differentiation can be qualified and quantified. In vivo skin models have been 
developed to mimic certain aspects of the origin of the psoriatic lesion. Epicutaneous 
application of leukotriene B4 (LTB4) elicits cutaneous inflammation . 102 The LTB4 model 
mimics the movement of polymorphonuclear leukocytes (PMN) through the epidermis 
which is thought to be an early alteration in the formation of the psoriatic plaque .10 3 The 
response to tape-stripping is an in vivo model which permits studies on the induction of 
epidermal proliferation and proliferation associated abnormal differentiation. The effect of 
systemic treatments on epidermal proliferation and differentiation have been studied 
using this model. 104 106
For the studies on the in vivo effects of topical treatments, a new model is 
required which fulfils the following criteria:
i. Epidermal growth and differentiation characteristics should approach the 
situation in the psoriatic lesion.
ii. The trigger should not result in epidermal cell death or a major inflammatory 
infiltrate.
iii.The model should not damage the stratum corneum as topical drug availability 
is changed dramatically by stripping away the stratum corneum.
iv.The challenge can not be a topically applied chemical as the availability of the 
signal might be modulated by a topical treatment.
In the present thesis, besides the effects of different topical antipsoriatic therapies on 
lesional psoriatic skin, UVB challenged skin will be studied as a model for epidermal 
changes in a developing psoriatic lesion.
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Markers of focal interest
To obtain insight into cell-biological phenomena that are important in psoriasis, 
immunohistochemistry was applied, using the indirect immunoperoxidase technique. A 
panel of monoclonal antibodies giving information on epidermal proliferation, epidermal 
differentiation and cutaneous inflammation was used:
Proliferation
• Ki-67
The keratinocytes in the epidermis that actively participate in the cell cycle can be 
identified by the monoclonal antibody MIB-1, which is directed against the 
proliferation associated nuclear antigen, Ki-67.107,108 Nuclear MIB-1 staining 
implies that a cell has escaped from the G0 population, the population of cells that 
does not actively participate in cell division. The recruitment of cycling epidermal 
cells is the key-process in psoriatic hyperplasia. Ki-67 expression, assessed by 
MIB-staining is a most valuable approach to assess epidermal proliferation in 
psoriasis and the efficacy of antipsoriatic treatments on epidermal growth.
Epidermal differentiation
In human skin, the stratum corneum takes care of a major part of the barrier 
function of the skin. The keynote of the maturation of the keratinocytes from the basal 
layer to the corneal layer is the forming of a layer of corneocytes, the stratum corneum. 
This process is complex and involves the cross-linking of proteins and the formation of 
cornified envelopes. Epidermal differentiation is altered in the psoriatic skin .109 To obtain 
information about this process, a set of monoclonal antibodies directed against several 
cellular markers for keratinocyte differentiation was selected to characterise different 
aspects of the epidermal differentiation process:
•
The cytoskeleton of the psoriatic epidermis expresses an alternative set of 
cytokeratins, different from normal human skin. In the basal layer of normal 
human skin, cytokeratin 5, 14 and 15 are expressed and in the suprabasal layer 
cytokeratins 1, 2, 10 and 11 are encountered. In hyperproliferative epidermis 
cytokeratin 6  and 16 are expressed . 109 Cytokeratin 16 is found in 
hyperproliferative skin but also in damaged and recovering skin and is, nowadays, 
thought to be associated with disturbance of the epidermal integrity .1 1 0 " 112 In this 
thesis, the monoclonal antibody that was used to detect cytokeratin 16 is 
Ks8.12 . 1 1 3
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Ks8.12 is not monospecific for keratin 16 and also reacts with keratin 13 which is 
not present in normal adult human skin . 1 1 4 Significant correlations between 
Ks8.12 staining and clinical scores in psoriasis have been demonstrated .115  
Therefore Ks8.12 is considered a valuable marker to study treatment related 
changes in psoriasis.
•
Involucrin is a soluble protein precursor of the cornified envelope .11 6 The 
production of involucrin already starts in keratinocytes just above the basal layer 
of the epidermis . 109 At this point, the first steps in the organisation of the cornified 
envelope are taken. Using immunohistochemistry in normal human skin, only the 
fraction of the involucrin in the upper stratum spinosum and stratum granulosum 
is visualised. Since involucrin expression is not related to cytokeratin expression, 
involucrin is a distinct marker which is expressed in the phase which induces the 
final events of terminal differentiation. Involucrin is studied using the monoclonal 
antibody MON-ISO . 1 1 7
•
Filaggrin (filament aggregating protein), a histidine-rich protein, is present in the 
granular layer of normal human skin and one of its functions is the aggregation of 
cytokeratin filaments . 1 1 8 Filaggrin is precursed by profilaggin, which is deposited in 
keratohyalin granules and is broken down by proteolysis and dephosphorilation 
resulting in filaggrin. Breakdown products of filaggrin are urocanic acid and 
pyrrolidone carboxyl acid . 1 1 9 ,1 2 0 Urocanic acid is a physiological sun-protector and 
pyrrolidone carboxyl acid has a function in the hydration in the stratum corneum. 
In psoriatic skin, filaggrin is markedly decreased and only focally present. 
Filaggrin is a marker for late terminal differentiation and was studied to get insight 
into the complex process of altered differentiation in psoriasis.
•
Keratinocyte transglutaminase is a calcium-dependent enzyme that cross-links the 
constituents of the cornified envelope: involucrin, loricrin and keratolinin using e- 
(y-glutamyl)lysine isopeptide bonds . 1 1 6 ,1 2 1 " 126 Because of its calcium dependency, 
transglutaminase is marker that is directly influenced by vitamin analogues in 
vitro and in vivo . 9 5 ,1 2 7 ' 129 Transglutaminase activity has been localised 
histochemically in the granular layer of the epidermis and the 
immunohistochemical expression has been found in the upper spinous and 
granular layers . 1 2 3 ,1 3 0  In psoriasis, transglutaminase and its activity already appear 
in the lower stratum spinosum . 1 3 1 Transglutaminase is studied using a monoclonal 
antibody against human keratinocyte transglutaminase.
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Cutaneous inflammation
Increased accumulation of inflammatory cells in dermis and epidermis is an 
important and early characteristic of the histologic transition of clinically normal skin into 
a psoriatic plaque. In a chronic psoriatic plaque, the dermal inflammatory infiltrate 
mainly consists of mononuclear cells that are located diffusely in the stroma of the 
papillary and reticular dermis and around the dermal capillaries. In the epidermis, T- 
lymphocytes and PMN are the most important inflammatory cells.
•
The mononuclear dermal infiltrate of the psoriatic lesion mainly consists of T- 
lymphocytes. Immunohistochemically, T-lymphocytes were visualised by the 
monoclonal antibody DAKO-T11 that is directed against the CD2 epitope.
•
One of the proteolytic enzymes of the polymorphonuclear leukocyte (PMN) is 
human leukocyte elastase. A monoclonal antibody against elastase (DAKO- 
elastase) was used to visualise PMN.
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1.4. AIMS AND QUESTIONS
1.4.1. Immunohistochemical effects of topical antipsoriatic treatments
AIM 1: To study the in vivo effects of topical antipsoriatic treatments on epidermal 
proliferation and differentiation.
In particular the following questions were addressed:
inflammation? (chapter 2 .1 )
epidermis to dithranol treatment? (chapter 2.2 and chapter 2.3)
hydrocolloid dressing comparable to the response to a topical corticosteroid 
without a hydrocolloid dressing? (chapter 2.4)
1.4.2. Development of a new in vivo skin model
AIM 2: To develop a new model to study the induction of recruitment of cycling 
cells and proliferation associated differentiation characteristics in human skin in 
vivo and to study the effect of topical treatment on such a model.
In particular the following questions were addressed:
induction of recruitment of cycling epidermal cells and proliferation associated 
differentiation characteristics? (chapter 3.1)
•
recruitment of cycling epidermal cells and proliferation associated differentiation? 
(chapter 3.2)
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1.4.3. Clinical efficacy and safety
AIM 3: To study efficacy and safety aspects of topical treatments for psoriasis.
In particular the following questions were addressed:
• To what extent are new wash-off formulations of dithranol effective in the 
treatment of psoriasis and what about tolerance to these approaches? (chapters
2.2 and 2.3)
treatment of psoriasis and to what extent is the post-treatment remission period 
comparable with the topical corticosteroid without occlusion? (chapter 2.4)
in severe psoriasis? (chapter 4.1)
compare and contrast to classical in-patient dithranol treatment? (chapter 4.2) 
derivative with a low irritating potential? (chapter 4.3)
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Chapter 2
Immunohistochemical and clinical effects 
of the topical treatment of psoriasis
This chapter was based on the following publications:
C.J.M. van der Vleuten, E.M.G.J. de Jong, P.C.M. van de Kerkhof
Epidermal differentiation characteristics of the psoriatic plaque during treatment with 
calcipotriol. Arch Dermatol Res 1996; 288:366-272.
C.J.M. van der Vleuten, E.M.G.J. de Jong, P.C.M. van de Kerkhof
Epidermal differentiation characteristics of the psoriatic plaque during short contact 
treatment with dithranol cream. Clin Exp Dermatol 1996; 21:409-414.
C.J.M. van der Vleuten, M.J.P. Gerritsen, E.M.G.J. de Jong, M. Eibers, G.J. de 
Jongh, P.C.M. van de Kerkhof
A novel dithranol formulation (Micanol): The effects of monotherapy and UVB 
combination therapy on epidermal differentiation, proliferation and cutaneous 
inflammation in psoriasis vulgaris Acta Derm Venereol (Stockh) 1996; 76:387-391.
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immunohistochemical study on remission and relapse, (submitted)
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2.1. EPIDERMAL DIFFERENTIATION CHARACTERISTICS OF THE PSORIATIC 
PLAQUE DURING TREATMENT WITH CALCIPOTRIOL
2.1.1. Summary
Treatment of psoriasis with vitamin D3 analogues is well-established in the present 
dermatological practice. One of the clinical parameters of the psoriatic plaque that 
reduces early and markedly during treatment with the vitamin D3 analogue calcipotriol 
(Daivonex®) is scaling. Since scaling is the clinical manifestation of epidermal 
differentiation, early changes in immunohistochemical markers for differentiation 
(transglutaminase, involucrin and filaggrin) were studied in patients that had been 
treated with calcipotriol for four weeks. Markers for proliferation (Ki-67 antigen) and 
inflammation (polymorphonuclear leukocytes and T-lymphocytes) were studied as well 
and correlated with the differentiation characteristics.
Clinically, a major improvement was seen in all patients. A significant decrease of 
the percentage transglutaminase positive cell layers was observed in the first week of 
treatment, whereas, in literature, an increase of transglutaminase activity in epidermal 
cell cultures following incubation with calcipotriol has been reported. Involucrin 
expression was only slightly modulated in vivo. However, a major restoration of the 
filaggrin positive cell layer and an important reduction of the recruitment of cycling 
epidermal cells characterised the epidermal response to calcipotriol treatment. Markers 
for inflammation ( T i l  positive cells and elastase positive cells) also reduced substantially 
in the first week of treatment with calcipotriol.
From this study it may be concluded that inhibition of epidermal growth and 
recovery of the filaggrin positive cell layer are targets for the in vivo effect of calcipotriol.
2.1.2. Introduction
Vitamin D3 and its analogues have been shown to exert an important antipsoriatic 
effect. 1 In vitro and in vivo studies show a marked antiproliferative and keratinisation 
enhancing activity . 2 "6 Inflammation is also affected by active vitamin Ds derivatives . 6 ,7
Calcipotriol (Daivonex®) is one of the first line treatments for psoriasis. While 
treating patients with this therapy, it is our impression that scaling is one of the clinical 
parameters that diminishes early and obviously. So one might speculate that 
normalisation of epidermal differentiation is one of the important antipsoriatic effects of 
active vitamin D3. Indeed, in vitro studies have shown that proliferation of keratinocytes 
is inhibited and that the formation of the cornified envelope, transcription of involucrin 
and transglutaminase activity is enhanced by calcipotriol.2 , 3 ,7 ' 12 In vivo, inhibition of Ki-67 
expression and a reduction of PMN are early effects, whereas a reduction of suprabasal 
expression of keratin 16 and T-lymphocyte accumulation are late effects .6
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The aim of the present study was to find out the behaviour of the suprabasal 
compartment of the epidermis during treatment of the psoriatic plaque with calcipotriol.
The following questions were addressed:
i. Does calcipotriol ointment have a substantial effect on markers of epidermal
differentiation during the treatment of chronic plaque psoriasis?
ii. What is the relationship between the effect on differentiation markers and other
immunohistochemical effects of calcipotriol?
Immunohistochemistry on cryostat sections of skin biopsies with a panel of 
monoclonal antibodies during a four weeks clinical study with calcipotriol in patients with 
psoriasis was carried out to answer these questions.
2.1.3. Materials and methods
Patients
Six patients with chronic plaque psoriasis, five males and one female, participated 
in this study. Their age varied from 33 to 61 years with an average duration of their 
psoriasis of 17 ± 0.8 (mean ± SEM) years. They had used no systemic treatment for at 
least two months and no topical treatment for at least two weeks. In fact, the patients 
had hardly used any antipsoriatic treatment for periods of months or years before 
starting the present study. Patients were instructed to apply calcipotriol ointment (50 
|ig/g, Daivonex®, LEO Pharma, Denmark) twice daily on lesional skin with a maximum of 
100 grams ointment weekly. No additional topical therapy was allowed. This study was 
approved by the local ethical committee. All patients gave their written informed consent 
prior to inclusion in the study.
Clinical assessments
Before therapy and 1, 2 and 4 weeks after therapy the severity of one target 
lesion was scored for each of the following clinical signs: erythema, induration and 
scaling. Each parameter was scored using a 5-point scale: 0 = complete lack of 
cutaneous involvement, 1 = slight involvement, 2 = moderate involvement, 3 = severe 
involvement, 4 = severest possible involvement.
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Biopsy procedure
Punch biopsies of 3 mm were taken from the previously determined target lesion 
before therapy and 1, 2 and 4 weeks after therapy from all patients after local 
anaesthesia with xylocain 1 % and adrenaline.
The biopsies were embedded in Tissue Tek OCT compound (Miles Scientific, 
Naperville, USA), snap frozen in liquid nitrogen and stored at -80°C until use. Sections of 
7 urn were cut, air dried and fixed for 10 minutes in acetone/ether (60/40%) (MIB-1
°
Monoclonal antibodies
A panel of monoclonal antibodies was used.
To assess epidermal differentiation monoclonal antibodies against involucrin 
(MON-15013, 1:25), anti-human keratinocyte transglutaminase (1:100, Mouse Monoclonal 
Antibody, IgG2a Biomedical Technologies Inc.) and against filaggrin and profilaggrin 
(1:500, anti-filaggrin, BT576, Biomedical Technologies Inc.) were used.
To approximate the number of cycling epidermal cells in the basal layer an 
antibody directed against the Ki-67 antigen was used (MIB-1, 1:50, Immunotech, S.A., 
Marseilles, France).
Analysis of the inflammatory infiltrate was done by assessment of T-lymphocytes 
and Polymorphonuclear leukocytes (PMN) respectively using the monoclonal antibodies 
DAKO-T11 (1:100, Dakopatts, Copenhagen, Denmark) and DAKO-elastase (1:100, 
Dakopatts, Copenhagen, Denmark).
Staining procedure
For all monoclonal antibodies, except for T i l ,  an indirect immunoperoxidase 
technique was used. For ten minutes the slides were fixed in acetone/ether (60/40%) in 
case of MIB-1 or in acetone for the other stainings. The slides were air dried and put in a 
phosphate buffer (PB) (72 mM Na2 HP04 and 28 mM NaH2 P04). Only the slides stained 
with anti-elastase were pre-incubated with methanol/ 0.1 % H20 2 (30 %) for 20 minutes. 
All antibodies were diluted in PB. The slides were incubated with the different primary 
monoclonal antibodies for 30 minutes except for the antibody against transglutaminase 
(60 minutes). After washing with PB the slides were incubated with the secondary 
antibody, rabbit-anti-mouse immunoglobulin conjugated with peroxidase (1:50, RAM-PO, 
Dakopatts, Copenhagen, Denmark) diluted in PB containing 5% human AB-serum for
35
30 minutes. After washing with PB and demineralised water a 3-amino-9-ethylcarbazole 
(AEC) solution was used for visualisation.
Staining with T i l  was done with an indirect peroxidase-anti-peroxidase technique 
(PAP). The slides were put in PB for ten minutes and pre-incubated with 50 % Normal 
Rabbit Serum on PB for 20 minutes. After washing with PB the slides were incubated with 
the primary monoclonal antibody in a Miele Microwave at 80 Watt for 9 minutes. Then the 
slides were washed again in PB and incubated with rabbit-anti-mouse immunoglobulin 
(1:25, RAM-Ig, Dakopatts, Copenhagen, Denmark) in the microwave at 80 Watt for 9 
minutes. After washing in PB the slides were incubated with PAP-complexes (1:100, 
Peroxidase monoclonal mouse antiperoxidase complexes, Dakopatts, Copenhagen, 
Denmark) in the microwave at 80 Watt for 8  minutes. After washing, this cycle was 
repeated. Visualisation of the complexes was done by the AEC-solution.
All slides were counter-stained with Mayer's Haematoxylin (Sigma, St. Louis MO, 
USA) and mounted in glycerol-gelatine.
Histological examination
The histological examination was performed blinded.
Epidermal proliferation was measured by counting the number of MIB-1 positive 
nuclei per mm length of the section.
The involucrin and transglutaminase expression were assessed by calculation of 
the ratio positive cell layers/ total cell layers of the viable epidermis. This was done at 
two sites: above the top of the dermal papilla and between two dermal papillae. The 
filaggrin expression was assessed by measuring the percentage of the length of the 
stratum corneum and stratum granulosum which was stained.
Inflammation (PMN and T-lymphocytes) was assessed separately for dermis and 
epidermis. Dermal inflammation was semi-quantitatively enumerated by expressing the 
number of positively stained cells as a percentage of the total number of infiltrate cells14: 
0, no positive cells; 1, sporadic; 2, 1-25 %; 3, 26-50 %; 4, 51-75 %; 5, 76-99 %; 6 , 
100 %. Epidermal inflammation was assessed using a five-point scale: 0, no staining; 1, 
sporadic staining; 2, minimal staining; 3, moderate staining; 4, pronounced staining.
Statistical evaluation
For statistical analysis the t-test for paired values was used. A two-tailed 
hypothesis was employed to interpret data.
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2.1.4. Results
Clinical response
In all patients the psoriatic lesions showed improvement. The course of the clinical 
scores of the target lesion is shown in figure 1 .
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Histological response
The transglutaminase expression (Figure 2a) on the top of the dermal papilla 
showed a significant decrease in the first week of therapy (p = 0.03); in the weeks 
following no significant changes were seen. At the interpapillary epidermis the 
transglutaminase expression (Figure 2b) slightly diminished resulting in a significant 
difference after four weeks of therapy (p = 0.01). After four weeks of treatment values 
for normal were reached . 15 In the involucrin expression (Figure 2c) at the top of the 
dermal papilla a significant increase (p = 0.04) after four weeks of therapy was observed.
The involucrin expression at the interpapillary epidermis (Figure 2d) did not show 
significant changes. The filaggrin staining (Figure 2e) in the stratum corneum 
significantly increased after two weeks (p = 0.04). In the stratum granulosum a 
significant increase was already seen after one week of treatment with calcipotriol (p = 
0.01). Although 100% recovery of the stratum corneum was not reached, the recovery of 
the stratum granulosum layer was nearly complete. Pictures of the immunohistochemical 
staining for filaggrin before and after therapy are shown in Figure 3a+b.
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Fig. 2 a
Transglutaminase at the top of the dermal and during treatment with calcipotriol 
expressed as means ± SEM (values for normal human skin are represented by the 
horizontal bar as mean ± 2*SD15)
Fig. 2 b
Transglutaminase between two dermal papillae (-----) before and during treatment with
calcipotriol expressed as means ± SEM (values for normal human skin are represented by 
the horizontal bar as mean ± 2*SD15)
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Fig. 2 c I nvolucrin at the top of the dermal papilla before and during treatment with 
calcipotriol expressed as means ± SEM (values for normal human skin are 
represented by the horizontal bar as mean+ 2*SD33)
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Fig. 2 d I nvolucrin between two dermal papillae before and during treatment with 
calcipotriol expressed as means ± SEM (values for normal human skin are 
represented by the horizontal bar as mean+ 2*SD33)
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Fig. 2 e Filaggrin in stratum corneum (-----) and stratum granulosum (------ ) before and
during treatment with calcipotriol expressed as means ± SEM
The number of Ki-67 positive nuclei per mm of the section (Figure 4) significantly 
decreased in the first week of therapy (p = 0.04). In the following weeks no significant 
changes were seen in the Ki-67 count. The number of Ki-67 positive nuclei approached 
but remained above the normal range . 16
The staining of T-lymphocytes in the dermis (Figure 5a) altered significantly after 
the first week of therapy (p = 0.003), subsequently no significant changes were 
observed. T i l  staining in the epidermis (Figure 5b) showed a tendency to decrease (p = 
0.08) in the first week. In the weeks following no significant changes were seen. Anti- 
elastase staining (PMN)(Figure 5c) in the dermis significantly decreased in the first week 
of therapy (p = 0.01). No further significant changes were observed in the following 
weeks in the dermis. In the epidermis no changes in elastase binding were observed 
either. T-lymphocyte accumulation and PMN accumulation remained above the range for 
normal skin throughout the four weeks treatment period.
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Fig. 3 Anti-filaggrin staining in one patient before (a) and after 4 weeks (b) of therapy
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Fig. 4 MIB-1 staining before and during treatment with calcipotriol expressed as means± 
SEM (values for normal human skin are represented by the horizontal bar as mean +
2*SD16)
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Fig. 5 a T i l  (dermis) before and during treatment with calcipotriol expressed as means± 
SEM (values for normal human skin are represented by the shaded area as mean + 
2*SD15)
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Fig. 5 b T i l  (epidermis) before and during treatment with calcipotriol expressed as 
means ± SEM
Fig. 5 c Anti-elastase in dermis (------) and epidermis (­
with calcipotriol expressed as means + SEM
-) before and during treatment
2.1.5. Discussion
In the present study, a major clinical improvement was observed during a four 
weeks treatment period with calcipotriol. The present study comprises only the first 
phase of calcipotriol treatment since maximal reduction of severity scores is reached after 
an eight weeks treatment period . 1 7 Most studies agree that calcipotriol induces 
pronounced changes of epidermal behaviour, leaving the mononuclear infiltrate relatively
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unaffected . 6 ,1 8 "20 The present observation is in line with those studies and with the clinical 
impression of an early and relatively pronounced effect of calcipotriol on scaling, the 
clinical manifestation of epidermal differentiation.
Epidermal differentiation involves formation of cornified envelopes by cross linking 
(formation of the ^(y-glutamyl)lysine bonds) involucrin, loricrin and keratolinin by the 
calcium dependent enzyme membrane-bound transglutaminase (TGase l ) . 2 1 ' 24 In normal 
skin, staining with antibodies against TGase 1 and involucrin shows a band like pattern in 
the upper part of the epidermis representing the upper stratum spinosum and the 
stratum granulosum . 25 In situ hybridisation techniques demonstrate involucrin and TGase
1 mRNA at the transition to the stratum granulosum, being a very early event in 
differentiation .26 Activity of TGase 1 was demonstrated in vivo in mice at the transition 
zone (one or at most two cell layers) from the stratum granulosum to the stratum 
corneum . 25 At this point the actual formation of the cornified envelopes takes place 
resulting in the stratum corneum in which antigenicity of involucrin is lost.25 In psoriatic 
skin, the kératinisation process is disturbed. Large, clinically visible, histologically 
parakeratotic squames are formed in lesional skin .26 Staining with monoclonal antibodies 
against involucrin and TGase 1 demonstrates far more positive cell layers, relatively as 
well as absolutely . 2 7 Also activity of TGase 1 and the number of produced cornified 
envelopes is greatly enhanced .28 Messenger RNA of involucrin and TGase 1 is localised 
already in the lower cell layers of the suprabasal epidermis .26 This is in contrast to normal 
skin . 26 Increased expression of TGase 1 protein and mRNA in psoriasis may partly explain 
the hyperkeratosis that is characteristic for psoriasis. The formation of a more highly 
cross-linked stratum corneum may lead to a greater retention of the squames observed 
in lesional skin . 29
The present in vivo observations on epidermal differentiation during treatment 
with calcipotriol indicate that modulation of the process of kératinisation is a relatively 
early effect of this compound. However, these observations are in several respects at 
variance with in vitro observations. TGase 1 activity in cultured keratinocytes is enhanced 
by calcipotriol. 2 In the present in vivo study, however, TGase 1 positive cells decreased 
during treatment. In vivo, a similar decrease was observed during treatment of psoriatic 
plaques with the vitamin D3 analogues l,25-(OH)2-D3 and l,24-(OH)2-D3.27 Whereas 
vitamin D3 analogues in vitro enhance the transcription of involucrin11,12, only a minor 
modulation of the number of involucrin positive cell layers was observed in the present in 
vivo study. Treatment with l,25-(OH)2-D3 and l,24-(OH)2-D3 reduced the number of 
involucrin positive cell layers.4 ,5 Despite the decrease in anti-TGase 1 binding, TGase 1 as 
well as involucrin remain high during this investigation. The newly formed keratinocytes 
in the psoriatic lesion keep on expressing the TGase 1 and involucrin mRNA too
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early in their maturation process. So far, there is no convincing evidence that calcipotriol 
modulates epidermal differentiation in vivo via DNA transcription of involucrin or TGase 
1 .
A remarkable and consistent effect of calcipotriol (present study) and of 1,25- 
(OH)2-D3 and l,24-(OH)2-D34'5 is the pronounced reformation of the filaggrin positive cell 
layer. Filaggrin plays a major role in the aggregation of keratin filaments, thereby 
forming the keratin configuration as can be seen in the lower stratum corneum .30
The present study demonstrates a potent reduction of the recruitment of cycling 
epidermal cells (Ki-67 positive nuclei). This result reconfirms the antiproliferative activity 
as observed in earlier studies . 6 ,1 8 The expression of keratin 16 and keratin 17 in the 
suprabasal compartment is considered to be related to epidermal recovery. During 
treatment with calcipotriol these hyperproliferation associated keratins proved to 
reduce . 6 ,1 8 ,3 1 The antiproliferative action of calcipotriol proved to be consistent in the in 
vitro and in vivo situation.
Vitamin D3 analogues interfere with multiple parameters of cutaneous 
inflammation . 32 Modification of T-cell subpopulations and cytokine pattern and a 
reduction of PMN accumulation have been observed before .32 The present study is at 
variance with a previous study6 with respect to T-lymphocytes. In the present study the 
early reduction of the number of T-lymphocytes together with the reduction of PMN 
accumulation might be the result of the long periods (months-years) that patients had 
been untreated. In the previous study6 showing only a modest effect on T-lymphocytes, 
up to two weeks before treatment the patients had been treated with calcipotriol or 
topical steroids already.
From this study it may be concluded that inhibition of epidermal growth, recovery 
of the filaggrin positive cell layer and a decrease of TGase 1 and involucrin positive cells 
are targets for the in vivo effect of calcipotriol on epidermal differentiation.
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2.2. EPIDERMAL DIFFERENTIATION CHARACTERISTICS OF THE PSORIATIC 
PLAQUE DURING SHORT CONTACT TREATMENT WITH DITHRANOL CREAM
2.2.1. Summary
Dithranol has been used successfully in the treatment of psoriasis for more than 
75 years. Much in vitro and in vivo research has been done on the elucidation of the 
mode of action of this potent and safe antipsoriatic therapy. In vivo research revealed 
major effects of dithranol on epidermal proliferation and inflammation. Information on 
the in vivo effects on epidermal differentiation is limited. Therefore the dynamics of a set 
of differentiation markers (keratin 16, filaggrin, keratinocyte transglutaminase, 
involucrin) and markers for proliferation and inflammation (Ki-67, T-lymphocytes, 
Polymorphonuclear leukocytes) were studied in skin biopsies of six patients with psoriasis 
during four weeks of dithranol therapy. The treatment regime involved a short contact 
protocol at the unit for intensified out-patient treatment with an easily wash-off cream.
Treatment resulted in a decrease of the PASI-score of 48 % in four weeks. 
Immunohistochemically, a major decrease of keratin 16 content and virtually complete 
restoration of the filaggrin positive cell layer were seen. These changes proved to be 
significant comparing the markers in the group of six patients. Although many other 
topical treatments for psoriasis (occlusive therapy and vitamin D3 analogues) result in a 
prominent reduction of the amount of transglutaminase and involucrin positive cell 
layers, the effect of dithranol on these markers is minimal.
2.2.2. Introduction
Although dithranol has been used for many decades in the treatment of psoriasis, 
the mode of action has not been established. Various authors have demonstrated that 
dithranol inhibits epidermal proliferation . 1,2 At the molecular level, various mechanisms 
have been hypothesised to be responsible for this antiproliferative effect: interference 
with DNA and mitochondria, inhibition of metabolic pathways, modulation of protein 
kinase C (PKC) and interference with arachidonic acid metabolism and cyclic 
nucleotides . 3 ,4 Other groups have demonstrated that dithranol interferes with several 
aspects of cutaneous inflammation .5 "7 So far, our information on the effect of dithranol on 
epidermal differentiation is very limited . 1,8
The in vivo effect of dithranol on cutaneous inflammation and epidermal 
proliferation has been reported previously .1,2 The aim of the present investigation was to 
study the dynamics of
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dithranol induced changes with respect to differentiation of the psoriatic epidermis using 
a series of immunohistochemical differentiation markers (keratin 16, filaggrin, 
transglutaminase (TGase) and involucrin). These differentiation markers were related to 
the recruitment of cycling epidermal cells (Ki-67 positive nuclei) and the number of T- 
cells and polymorphonuclear leukocytes (PMN).
The differentiation characteristics and reference parameters for epidermal growth 
and inflammation were studied during a dithranol short contact regime. Dithranol was 
manufactured in a wash off cream. The treatments were carried out alternately at the 
unit for intensified out-patient treatment or at home after instruction and with twice 
weekly supervision of the patients. Punch biopsies were taken before and during 
treatment and processed for immunohistochemical analysis.
2.2.3. Materials and methods
Patients
Six patients with extensive chronic plaque psoriasis participated in this study, five 
males and one female. Their age varied from 26-61 years with an average duration of the 
psoriasis of 18 ± 8  years (mean ± SEM). They had used no systemic treatment for at least 
two months and no topical treatment for at least two weeks. No other medication was 
allowed that could influence the course of psoriasis.
Treatment protocol
Patients were treated with dithranol in a cream base using a short contact 
schedule. Dithranol creams at concentrations ranging from 0.1-5 % were manufactured 
by the hospital pharmacist according to a modified version of the protocol of Ros and Van 
der Meer.9 The ingredients of the cream base are summarised in table I.
Table I Ingredients of the dithranol cream 9
Dithranolum 1-50 gram
Cetiol V 2 0 2  gram
Cera cetomacrogolis 150 gram
Paraffinum subliquidum 150 gram
Acidum salicylicum 1 0  gram
Acidum sorbicum 1.5 gram
Acidum ascorbicum 0.5 gram
Aqua demi filtrata ad 1 0 0 0
Dithranol was applied once daily starting with a concentration of 0.1 % for 15 
minutes. The cream was removed with water and detergents. No additional topical 
therapy was allowed except for 1 0  % liquor carbonis detergens in petrolatum/cremor 
lanette I ana and 10 % salicylic acid in axungia for treatment of the scalp. Treatments
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were carried out at the department of intensified out-patient therapy. In the first week 
the patient visited the department daily and in the second and following weeks the 
patient visited the department twice a week. The dithranol concentration and/or 
application-time intervals were increased every three days if no burning or stinging was 
reported, under the supervision of a trained nurse and doctor. In the first week of this 
treatment regime, instruction and education of the patient by the nurse was intense to 
enable the patient to continue the dithranol applications at home. Treatment was 
continued until the psoriasis was cleared. The period of investigation was restricted to the 
first four weeks.
Clinical assessment
Before therapy and 1, 2 and 4 weeks after therapy the clinical response was 
monitored. Clinical monitoring was done using the PASI.
Biopsy procedure
Punch biopsies of 3 mm were taken of a representative psoriatic plaque before 
therapy and 1, 2 and 4 weeks after therapy from all patients after local anaesthesia with 
xylocain 1  % and adrenaline.
The biopsies were embedded in Tissue Tek OCT compound (Miles Scientific, 
Naperville, USA), snap frozen in liquid nitrogen and stored at -80°C until use. Sections of 
7 urn were cut, air dried and fixed for 10 minutes in acetone/ether (60/40 %) (MIB-1
°
Monoclonal antibodies
A panel of monoclonal antibodies was used.
To assess epidermal differentiation monoclonal antibodies against keratin 16 and 
13 (1:25, Ks 8.12, Sigma, St Louis, USA), anti filaggrin and profilaggrin (1:500, anti- 
filaggrin, BT576, Biomedical Technologies Inc.), anti-human keratinocyte 
transglutaminase (1:100, Mouse Monoclonal Antibody, IgQa Biomedical Technologies 
Inc.) and against involucrin, (MON-ISO10, 1:25) were used.
To approximate the number of cycling epidermal cells in the basal layer an 
antibody directed against the Ki-67 antigen was used (MIB-1, 1:50, Immunotech, S.A., 
Marseilles, France).
Analysis of the inflammatory infiltrate was done by assessment of T-lymphocytes 
and Polymorphonuclear leukocytes (PMN) respectively using the monoclonal antibodies 
DAKO-T11 (1:100, Dakopatts, Copenhagen, Denmark) and DAKO-elastase (1:100, 
Dakopatts, Copenhagen, Denmark).
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Staining procedure
For all monoclonal antibodies, except for T i l ,  an indirect immunoperoxidase 
technique was used. For ten minutes the slides were fixed in acetone/ether (60/40 %) in 
case of MIB-1 or in acetone for the other stainings. The slides were air dried and put in a 
phosphate buffer (PB) (72 mmol/l Na2 HP04 and 28 mmol/l NaH2 P04). Only the slides 
stained with anti-elastase were pre-incubated with methanol/ 0.1 % H20 2 (30 %) for 20 
minutes. All antibodies were diluted in PB. The slides were incubated with the different 
primary monoclonal antibodies for 30 minutes except for the antibody against TGase (60 
minutes). After washing with PB the slides were incubated with the secondary antibody, 
rabbit-anti-mouse immunoglobulin conjugated with peroxidase (1:50, RAM-PO, 
Dakopatts, Copenhagen, Denmark) diluted in PB containing 5 % human AB-serum for 30 
minutes. After washing with PB and demineralised water a 3-amino-9-ethylcarbazole 
(AEC) solution was used for visualisation.
Staining with T i l  was done with an indirect peroxidase-anti-peroxidase technique 
(PAP). The slides were put in PB for ten minutes and pre-incubated with 50 % Normal 
Rabbit Serum on PB for 20 minutes. After washing with PB the slides were incubated with 
the primary monoclonal antibody in a Miele Microwave at 80 Watt for 9 minutes. Then the 
slides were washed again in PB and incubated with rabbit-anti-mouse immunoglobulin 
(1:25, RAM-Ig, Dakopatts, Copenhagen, Denmark) in the microwave at 80 Watt for 9 
minutes. After washing in PB the slides were incubated with PAP-complexes (1:100, 
Peroxidase monoclonal mouse antiperoxidase complexes, Dakopatts, Copenhagen, 
Denmark) in the microwave at 80 Watt for 8  minutes. After washing, this cycle was 
repeated. Visualisation of the complexes was done by the AEC-solution.
All slides were counter-stained with Mayer's Haematoxylin (Sigma, St. Louis MO, 
USA) and mounted in glycerol-gelatine.
Histological examination
The histological examination was performed blinded; the scores for normal skin 
are shown in table II. Ks 8.12 staining in the epidermis was assessed using a semi­
quantitative scale: 0, no staining; 1, sporadic staining; 2, minimal staining; 3, moderate 
staining ;4,moderate-pronounced
52
staining; 5, pronounced staining; 6, whole epidermis stained. The filaggrin expression 
was assessed by measuring the percentage of the length of the stratum corneum and 
stratum granulosum which was stained. The involucrin and TGase expression were 
assessed by calculation of the ratio positive cell layers/total cell layers of the viable 
epidermis. This was done at two sites: above the dermal papilla and between two dermal 
papillae.
Epidermal proliferation was measured by counting the number of MIB-1 positive 
nuclei per mm length of the section throughout the whole length of the biopsy.
Inflammation (PMN and T-lymphocytes) was assessed separately for dermis and 
epidermis. Dermal inflammation was semi-quantitatively enumerated by expressing the 
number of positively stained cells as a percentage of the total number of infiltrate cells: 
0, no positive cells; 1, sporadic; 2, 1-25 %; 3, 26-50 %; 4, 51-75 %; 5, 76-99 %; 6, 
100 %. Epidermal inflammation was assessed using a five-point scale: 0, no staining; 1, 
sporadic staining; 2, minimal staining; 3, moderate staining; 4, pronounced staining.
Table II Immunohistochemical sores ± 2 x 
standard deviation (2 x SD)34"37_____________
Epitope Localisation Mean ± 2 x SD
Ks8.12
Filaggrin
suprabasal
stratum 10 < 1± 0
stratum 10 ± 0
Transglutami tip of papilla 48 ± 15
interpapillar 29 ± 14
Involucrin tip of papilla 25 ± 7
interpapillar 21 ± 15
Ki-67 stratum basale 27 ± 9
T i l dermis < 2
epidermis 0± 0
Elastase dermis 0± 0
epidermis 0± 0
Statistical evaluation
For statistical analysis the t-test for paired values was used. A two tailed 
hypothesis was employed to interpret data.
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weeks
Fig. 1 a Ks8.12 staining in the suprabasal part of the epidermis during treatment with 
dithranol; values are mean ± SEM 
(*: p< 0.05).
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Fig. 1 b Filaggrin staining in stratum granulosum (-----) and stratum corneum (------ )
during treatment with dithranol; values are mean ± SEM 
(*: p< 0.05).
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Fig. 1 c Transglutaminase staining above the dermal papilla (---- ) and between two dermal
papillae (------) during treatment with dithranol; values are mean + SEM
(*: P< 0.05).__________________________________________
weeks
Fig. 1 d Involucrin staining above the dermal papilla (---- ) and between two dermal papillae
(------) during treatment with dithranol; values are mean + SEM.
2.2.4. Results
Clinical assessment
After four weeks of treatment with dithranol the PASI-scores were reduced by 48 %.
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Fig. 2 Anti-filaggrin staining in one patient before (a) and after 4 weeks (b) of therapy.
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Immunohistochemical assessment
The results of the immunohistochemical scores are presented in figures 1-4. Ks 
8 . 1 2  staining (keratin 16, figure la )  decreased substantially during the first two weeks of 
treatment (p = 0.02 after two weeks and p = 0.02 after four weeks). The filaggrin 
staining (figure lb )  increased substantially during the first two weeks of treatment (p = 
0 . 0 1  after one week, p = 0.006 after four weeks for the stratum granulosum and p = 
0.03 for the stratum corneum). Staining with anti keratinocyte transglutaminase (figure 
lc) showed a slight and borderline significant decrease above the dermal papilla after two 
weeks (p = 0.07). TGase staining at the interpapillary epidermis did not reveal a 
significant reduction during the first two weeks; however a slight but significant decrease 
(p = 0.03) was observed after four weeks of dithranol. The involucrin staining (figure Id) 
did not show any change. Immunohistochemical slides of the staining of filaggrin before 
and during therapy are shown in figure 2 .
MIB-1 staining (Ki-67 positive nuclei, figure 3) revealed a significant decrease 
after two weeks of treatment with dithranol (p = 0.05) which became highly significant 
after four weeks (p = 0 .0 2 ).
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Fig. 3 MIB-1 staining during treatment with dithranol; values are mean+ SEM 
(* p< 0.05).
The percentage T il-pos it ive  T-lymphocytes (figure 4a) in the dermal 
inflammatory infiltrate decreased significantly (p = 0.04) in the time interval between 
one and four weeks. T i l  staining in the epidermis and anti-elastase staining (figure 4b) 
in dermis or epidermis did not reveal significant changes.
4
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Fig. 4 a T i l  staining in the dermis (-----) and epidermis (------ ) during treatment with
dithranol; values are mean ± SEM (*: p< 0.05).
w eeks
Fig. 4 b Elastase staining in the dermis (-----) and epidermis (------ ) during treatment
with dithranol; values are mean ± SEM.
2.2.5. Discussion
Classical dithranol treatment with 24 hour applications has been the gold standard 
in the treatment of psoriasis for many decades. Side-effects like staining and irritation 
often limit its use. So far, no new analogues with a more advantageous efficacy/side- 
effect profile have been registered . 11 Alternative application schedules with cream 
formulations, on the other hand, do seem to reduce the discomfort of the classical 24
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Hour dithranol applications .3 ,1 2 Short application periods (minutes-hour) of 
dithranol increase bioavailability in the psoriatic plaque whilst decreasing its effects on 
the healthy skin surrounding the lesions. 13 Cream formulations, on the other hand, are 
often thought to be less effective than the classical formulations but supply more ease in 
rinsing the skin so that it takes only about an hour for the patient to carry out this 
treatment at home . 3 ,1 2 ,1 4  After four weeks of treatment, the clinical results in the present 
study were indeed inferior compared to classical in-patient treatment since clearing 
within 4 weeks is known from in-patient studies using classical 24 hours dithranol 
applications . 3
The present study confirms earlier observations on the in vivo effects of dithranol 
on proliferation and inflammation of the psoriatic plaque1 and extends our knowledge on 
the effects on epidermal differentiation characteristics during dithranol therapy. Already 
after two weeks of treatment the recruitment of cycling epidermal cells (Ki-67 positive 
nuclei) and keratin 16 expression are reduced and the accumulation of T-lymphocytes 
only diminishes slightly and relatively late during dithranol treatment. These changes 
proved to be statistically significant, already in six patients. The early reduction of PMN 
and the more impressive reduction of the proliferation markers as reported in a previous 
study might be due to a more aggressive schedule of dosage increments .1 The changes 
proved to be statistically significant already in six patients.
The aim of this study was to determine the in vivo effects of dithranol on 
immunohistochemical markers for epidermal differentiation as previous studies have not 
addressed this issue. The pattern of interference of dithranol with these differentiation 
markers is intriguing. Whereas keratin 16 and filaggrin substantially change during 
treatment with dithranol, the number of TGase positive cell layers shows a significant but 
minimal decrease. The number of involucrin positive cell layers did not reduce at all 
during dithranol treatment. Many topical antipsoriatic therapies, for instance vitamin D3 
analogues, inhibit epidermal growth (recruitment of cycling cells and keratin 16 
expression) and enhance filaggrin expression, just like dithranol.1 5 "20 However, in their 
effect on the number of TGase and involucrin positive cell layers, dithranol and the other 
local antipsoriatic therapies differ markedly: calcipotriol, tacalcitol, calcitriol and occlusive
therapy, in contrast to dithranol, do have a substantial effect on TGase and involucrin.16'
18,20
Epidermal differentiation and kératinisation are responsible for the maintenance of 
epidermal homeostasis. These processes are disturbed in psoriatic skin .2 1 ,2 2 It has been 
suggested that terminal differentiation (forming of cross-linked envelopes) and keratin 
synthesis (and aggregation by filaggrin) are two processes that are independently 
regulated . 23 Such might explain the differential changes in the kératinisation related 
markers and terminal differentiation related markers during dithranol therapy. Multiple
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factors regulate these processes. PKC, representing a family of different isozymes, is 
decreased or downregulated in psoriatic skin. Activation of PKC and subsequent down 
modulation of the enzyme is thought to play a major role in the modelling of the psoriatic 
phenotype and the regulation of terminal epidermal differentiation .2 4 " 28 PKC has a direct 
effect on transcription of TGase, involucrin, filaggrin and keratins .2 4 ,2 8 ' 30 Dithranol 
decreases PKC activity in vitro and its therapeutic activity might at least partly be 
mediated by the inhibition of PKC .4 ,1 1 In our in vivo study, normalised keratin and 
filaggrin expression and only slightly decreased TGase staining were observed. It is 
attractive to speculate that this differential reaction pattern of psoriatic skin to dithranol 
therapy might be a result of particular up or down regulation of a specific set of PKC 
isozymes each with differential effects on different markers for differentiation .3 1 Vitamin 
D3 analogues do also have effects on PKC .3 2 ,3 3 Interference with other sets of PKC 
isozymes may probably explain the differences between dithranol and other local 
antipsoriatic therapies, such as vitamin D3 analogues, on differentiation markers. Further 
studies are required before the role of PKC in the mode of action of dithranol can be 
established.
In conclusion, dithranol treatment, using short contact applications of a cream 
formulation under intensified clinical supervision, resulted in a substantial inhibition of 
epidermal growth, a substantial increase of the filaggrin positive cell layers, whilst 
interfering only slightly with the number of TGase positive cells and not at all with the 
number of involucrin positive cell layers. This might indicate that early differentiation and 
keratinisation are important targets for the in vivo action of dithranol.
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2.3. A NOVEL DITHRANOL FORMULATION (MICANOL): THE EFFECTS OF 
MONOTHERAPY AND UVB COMBINATION THERAPY ON EPIDERMAL 
DIFFERENTIATION, PROLIFERATION AND CUTANEOUS INFLAMMATION IN 
PSORIASIS VULGARIS
2.3.1. Summary
Micanol, in which dithranol is micro-encapsulated in crystalline monoglycerides, is 
easy to wash off and staining and irritation are inconspicuous. These features make it 
appropriate to use in an out-patient setting. In this study the immunohistochemical 
effects of this new dithranol formulation were studied and compared with UVB and the 
combination of these therapies in skin biopsies of eight patients with psoriasis. Markers 
for epidermal differentiation, proliferation and cutaneous inflammation were assessed.
The present study suggests that Micanol predominantly had diminishing effects on 
inflammation markers, hardly affecting the epidermis. UVB had a broad spectrum of 
reductions. It is feasible that the combination resulted in various synergistic effects.
Previous studies, however revealed a relative persistence of the inflammatory 
infiltrate with more effects on epidermal processes following dithranol treatment. Based 
on the present study and on previous studies it is hypothesised that Micanol delivers the 
active substance more directly in the dermal infiltrate, leaving the epidermis relatively 
unaffected. This might explain the low irritancy of Micanol treatment.
2.3.2. Introduction
Topical treatment of psoriasis with dithranol, either or not combined with UVB 
phototherapy, is a safe and effective approach for those patients who do not respond to 
first line treatments like vitamin D3 analogues and topical steroids. Short contact 
schedules and new wash-off formulations have popularised the dithranol treatment of 
psoriasis vulgaris. Recently a new principle was introduced: dithranol micro-encapsulated 
in crystalline monoglycerides (Micanol) . 1 The advantage of this new dithranol formulation 
is that it is very easy to wash off. In view of the relatively high melting point of the 
formulation, the cream has to be massaged into the skin. In our centre, a three-way 
comparative study was carried out in 36 patients, showing that Micanol has substantial 
clinical efficacy without significant irritation and staining of the skin and the patients' 
environment. Further, it was shown that the efficacy of dithranol in this formulation was
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comparable with UVB phototherapy; the combination of the two therapies tended to be 
more effective than either monotherapy .2
The aim of the present study was to compare the immunohistochemical effects of 
dithranol in this new formulation with the changes due to UVB phototherapy and the 
combination of Micanol and UVB. These effects were compared and contrasted with 
studies previously carried out on the effects of dithranol in other formulations. Before and 
at the end of treatment, punch biopsies were taken from a group of eight patients who 
participated in a larger clinical study on efficacy and safety of these treatments. 
Assessments were carried out of immunohistochemical stainings with monoclonal 
antibodies against transglutaminase, involucrin, filaggrin, Ki-67, T-lymphocytes and 
polymorphonuclear leukocytes (PMN).
2.3.3. Materials and methods
Study design
Eight patients with extensive chronic plaque and/or guttate psoriasis were 
included in a partly open, partly double blind, placebo-controlled comparative study. The 
body of a patient was divided into two body-halves. Each body-half received one of the 
following treatments:
a) Micanol cream (Zyma SA, Switzerland) only.
b) Placebo cream combined with UVB.
c) Micanol cream combined with UVB.
The patients were treated during a maximum of eight weeks. The UVB treatment 
was the open part of the study. UVB was given three times a week; short contact 
dithranol therapy was given daily. Clinical assessments were carried out three times a 
week in the first two weeks and once a week during the following six weeks.
Patients
The group of eight patients consisted of two males and six females; their age 
varied from 24 to 65 years. These patients participated in a larger study on the clinical 
efficacy of Micanol, UVB phototherapy and the combination of UVB and Micanol. The 
psoriatic lesions were symmetrically distributed, chronic and in a reasonably stable 
phase. The percentage body involvement with psoriatic lesions was 5-35 %. Apart from 
psoriasis, the patients did not have other dermatological or internal diseases. 
Concomitant treatment was maintained only when it was not expected to interfere with 
the test medications. Before study initiation, no local antipsoriatic treatment had been 
administered for two weeks and the patients had not used systemic treatment for at least 
four
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weeks. Permission of the local Ethics Committee and written informed consent from all 
patients were obtained.
Treatments
Dithranol/placebo treatment
The Micanol cream (Zyma SA Switzerland) and the placebo cream were supplied in 
concentrations of 0.25 %, 0.5 %, 1 %, 2 % and 3 %. The placebo cream consisted of the 
vehiculum of the Micanol without the active substance.
Daily applications of the dithranol and/or placebo cream were carried out on one 
or both halves of the body by the patient at home. The starting concentration was 0.25 
% for 30 minutes. The cream was subsequently removed with water and detergents. 
After two days the dithranol concentration was increased if no stinging or burning 
occurred. At the highest dithranol concentration of 3 % the application period was 
lengthened at each visit with 30 min up to a maximum of 120 min.
UVB treatment
All patients received UVB treatment on one or both body-halves, three times a 
week during eight weeks. UVB exposure was carried out in a Waldman UV 1000 cabin 
(Waldman AG, Schwenningen, Germany), equipped with 26 Voltarc USA F71 T12/2072 
bulbs with an irradiance of 1.9 mW/cm2. The lamps had an emission spectrum of 285­
350 nm, maximal at 310-315 nm. Before starting the minimal erythema dose (MED) was 
assessed. Half this dose was given to start UVB treatment. The doses were individually 
adjusted to cause suberythematous to slight erythematous reactions without burning.
Assessment o f clinical efficacy
The patients were treated for eight weeks or shorter if lesions were cleared earlier. 
If only one body-half was cleared, all treatment of this side was stopped while treatment 
on the other half was continued. Clinical improvement was assessed using the PASI- 
score. The PASI-scores were calculated per body-side as half PASI-scores.
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Biopsy procedure and immunohistochemical staining
In all eight patients punch biopsies of 3 mm were taken from a representative 
lesion before and after treatment. The biopsy procedure has been described before .3 For 
immunohistochemical staining a panel of monoclonal antibodies was used.
To assess epidermal differentiation, monoclonal antibodies against involucrin 
(MON-1SO 4, 1:25), anti-human keratinocyte transglutaminase (1:100, Mouse Monoclonal 
Antibody, BT621, IgG2a Biomedical Technologies Inc.) and against filaggrin and 
profilaggrin (anti-filaggrin, 1:500, BT576, Biomedical Technologies Inc.) were used.
To approximate the number of cycling epidermal cells in the basal layer, an 
antibody directed against the Ki-67 antigen was used (MIB-1, 1:50, Immunotech, SA, 
Marseilles, France).
Analysis of the inflammatory infiltrate was made by assessment of T-lymphocytes 
and PMN respectively using the monoclonal antibodies DAKO-T11 (1:100, Dakopatts, 
Copenhagen, Denmark) and DAKO-elastase (1:100, Dakopatts, Copenhagen, Denmark).
Staining procedure
For all monoclonal antibodies, except for T i l ,  an indirect immunoperoxidase 
technique was used. Staining with T i l  was performed with an indirect peroxidase-anti- 
peroxidase technique (PAP). The staining techniques have been described previously .3 
The PAP procedure was carried out using the microwave method .5
Histological examination
The histological examination was performed blinded. These scoring methods have 
been performed and published before .3 ,6
Involucrin and transglutaminase expression was assessed by calculation of the 
ratio positive cell layers/total cell layers of the viable epidermis. This was done at two 
sites: above the dermal papilla and between two dermal papillae. Filaggrin expression 
was assessed by measuring the percentage of the length of the stratum corneum and 
stratum granulosum which was stained.
Epidermal proliferation was measured by counting the number of MIB-1 positive 
nuclei per mm length of the section.
Inflammation (PMN and T-lymphocytes) was assessed separately for dermis and 
epidermis. Dermal inflammation was semi-quantitatively enumerated by expressing the 
number of positively stained cells as a percentage of the total number of infiltrate cells: 
0, no positive cells; 1, sporadic; 2, 1-25 %; 3, 26-50 %; 4, 51-75 %; 5, 76-99 %; 6 , 
100 %. Epidermal inflammation was assessed using a five-point scale: 0, no staining; 1, 
sporadic staining; 2, minimal staining; 3, moderate staining; 4, pronounced staining.
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Statistical evaluation
Data are reported as means ± SEM. Changes in PASI and immunohistochemical 
markers, due to therapy, were evaluated with the student t-test for paired values, in 
figures shown as *: p < 0.05; **: p < 0.005. A two-tailed hypothesis was employed to 
interpret data. A synergistic effect of two treatments was defined as an effect which 
proved to significantly exceed the sum of the effects of two individual treatments. In 
order to find out whether a synergistic effect can be validated in statistical terms, we 
performed a two way analysis of variance (2-way ANOVA).
2.3.4. Results
Clinical response
All patients showed a marked improvement on both body-halves. Two patients 
cured within eight weeks on one or both body-halves. The mean total UVB dose was 20 + 
3.0 J/cm2 for the body-halves that were treated with UVB monotherapy and 18 ± 5.0 
J/cm 2 (mean ± SEM) for the combination therapy treated body-halves. No statistically 
significant difference in UVB dose was seen between the body-halves that were treated 
with UVB monotherapy or combination therapy. The PASI-score decreased significantly 
for all treatments. The relative improvement with Micanol was 69 % (p = 0.006), UVB 
therapy resulted in a relative improvement of 71 % (p = 0.04) and the combination of 
both resulted in a relative improvement of 78 % (p = 0.003). The combination of Micanol 
and UVB revealed a significantly synergistic effect on the PASI-score (p< 0.05).
Histological results
In all the biopsies taken before treatment, psoriatic histological features were 
present: hyperkeratosis, acanthosis with thinning of the suprapapillary layer, pronounced 
elongation of the rete-ridges and in the dermis a marked cellular infiltrate. After 
treatment a diminution in epidermal thickness and dermal cellular infiltrate was seen in 
all biopsies, although hyperkeratosis and acanthosis were still present, also in the 
biopsies taken from the clinically cured body-halves.
The results of the immunohistochemical stainings are shown in figures 1-3. 
Micanol had mainly decreasing effects on inflammation markers: a highly significant 
reduction of the number of PMN (p < 0.005) and on the number of T-lymphocytes (p < 
0.005) was observed. The epidermis
was not significantly affected by Micanol. UVB had an extensive profile of 
immunohistochemical reductions: highly significant reductions (p< 0.005) of the number 
of transglutaminase and involucrin positive cell layers, the number of Ki-67 positive basal 
keratinocytes and T-cells. The combination of dithranol and UVB resulted in various
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synergistic effects. Statistically significant synergy was shown for the Ki-67-staining (p<
0.05), filaggrin-staining in the stratum corneum (p < 0.05), PMN in the dermis (p < 0.05) 
and in particular, of T-cells in dermis and epidermis (p< 0.005).
1 00
d ith rano l UVB d ith rano l -+■ UVB
Fig. 1 a Transglutaminase above the dermal papilla (■) and interpapillar (□) before and 
after therapy (group comparison:
* = p < 0.05;
** = p < 0.005)._______________________________________
Fig. 1 b Involucrin above the dermal papilla (■) and interpapillar (□) before and after 
therapy (group comparison: ** = p< 0.005).
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Fig. 1 c Filaggrin in the stratum corneum (■) and stratum granulosum (□) before 
and after therapy, (group comparison:
* = p < 0.05; 
synergism:
+ = p < 0.05).
Fig. 2 Epidermal proliferation: Ki-67 staining before and after therapy, (group 
comparison:
* = p < 0.05;
** = p < 0.005; 
synergism:
+ = p < 0.05).
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Fig. 3 a PMN in the epidermis (■) and dermis ( ) before and after therapy.
Fig. 3 b T i l  in the epidermis (■) and dermis ( ) before and after therapy, (group 
comparison:
* = p < 0.05;
** = p < 0.005; synergism: + = p < 0.05; + + = p < 0.005).
2.3.5. Discussion
The design of the study was partly a left/right comparison, partly a parallel group 
study. The left/right analysis has the drawback that systemic effects of topical treatments 
might occur, resulting in a contralateral effect. Therefore it is remotely possible that the 
difference between the three regimes might have been expressed more evidently in case 
of a parallel group design. The clinical results observed in the present study are 
comparable with the results observed in the
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plenary group .2 In the present study of eight patients a statistically significant synergistic 
effect of the combination therapy was seen with respect to the PASI, indicating a more 
pronounced clinical effect of the combination therapy.
Our immunohistochemical data suggest that Micanol monotherapy had significant 
decreasing effects on dermal accumulation of PMN and dermal and epidermal 
accumulation of T-cells. In contrast, no substantial effects on epidermal growth and 
differentiation parameters were observed. These data are at variance with previous 
studies on dithranol incorporated in cream or petrolatum, which showed a relative 
persistence of the inflammatory infiltrate with more pronounced effects on epidermal 
growth and differentiation .6 ,7 During treatment with dithranol in emulsifying ointment the 
accumulation of T-lymphocytes and CD14 cells persisted up to 8  weeks whereas the 
suprabasal expression of keratin 16 as well as the number of Ki-67 positive nuclei has 
diminished considerably during treatment.6 The immunohistochemical results in this 
study were analysed using the same methodology as in the present study. It is of interest 
that the relative reduction of the PASI-score in the previous study6 was 77 %; in the 
present study the reduction of PASI was 69 %. In a histochemical study on the effect of 
dithranol in petrolatum on psoriasis by Braun-Falco ,7 besides changes in parameters for 
differentiation, the persisting inflammatory reaction was a remarkable finding .7 Although 
comparisons between different studies have their limitations, the statistical validation of 
the immunohistochemical studies demonstrates that Micanol base has a profile of 
immunohistochemical changes the is different from more traditional vehicles.
Phototherapy with UVB had substantial effects on expression of transglutaminase, 
involucrin, the recruitment of cycling cells and the accumulation of T-cells. Only a 
borderline significant effect was seen with respect to filaggrin expression. UVB 
phototherapy and dithranol treatment have markedly different profiles of effects on the 
skin compared to other local antipsoriatic therapies, for instance vitamin D^  analogues 
(calcipotriol, calcitriol and tacalcitol) . 3 ,8 ,9 These different histological changes are reflected 
in the different sequential clinical changes of the psoriatic plaque as a result of each 
therapy. UVB (X = 290-320 nm) has major effects on the epidermis, resulting in DNA 
damage by formation of pyrimidine dimers and hence interfering with macromolecule 
synthesis and cell division . 10 The in vivo effect of vitamin D3 analogues is primarily on 
epidermal proliferation and differentiation, partly via binding with the vitamin Ds 
receptor, resulting in a cascade of nuclear mechanisms, and partly via non-genomic 
mechanisms . 11 Dithranol is thought to have its effects predominantly via auto-oxidation 
and the formation of free radicals, thereby causing a cascade of effects .12 The so-called 
'minimum structure for antipsoriatic activity' is responsible for the antipsoriatic effects, 
also causing irritation and staining of the skin .13 Short
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contact application schedules constitute one method of decreasing irritation and 
discomfort for the patient. Dithranol in the formulation of the present study is another 
method of decreasing the adverse events. One could speculate that dithranol in Micanol 
delivers the active substance more directly in the dermal infiltrate, where auto-oxidation 
starts, leaving the epidermis relatively unaffected. Such might explain the low irritancy of 
Micanol treatment.
In the combination therapy, a statistically significant synergistic clinical effect was 
demonstrated. The combination therapy also revealed evident immunohistochemical 
synergistic effects on the recruitment of cycling cells, involucrin above the dermal papilla, 
filaggrin in the stratum corneum, PMN and T-cells. It is intriguing that the 
immunohistochemical effects in the combination therapy can not always directly be 
predicted from adding up the effects in either monotherapy. The present study suggests 
that the immunohistochemical effects of both therapies are mingled and amplified, 
resulting in a new profile of immunohistochemical changes.
In literature, so far, no consensus has been reached as to the synergism of the 
combination of dithranol and phototherapy . 14 " 18 Biochemical studies revealed that UVB 
increases dithranol activity . 19 But it is well-established that during optimised dithranol 
therapy with the gold standard of 24 hour applications in an in-patient setting, UVB does 
not improve the antipsoriatic efficacy .2 0 ,2 1 On the other hand, less optimised dithranol 
treatment (short contact treatment with dithranol cream at home) is enhanced by 
phototherapy as demonstrated in the present clinical study. It is a well-established fact 
that remissions last longer when UVB is added .22 It is attractive to hypothesise that 
during less optimised dithranol treatment, in which less irritation is encountered, the 
effects of the dithranol therapy are enhanced by the effects of UVB on epidermal 
processes.
In conclusion, the present study suggests that Micanol predominantly has anti­
inflammatory immunohistochemical effects. However, comparative studies with different 
dithranol formulations have to be carried out to prove this statement definitively. UVB 
had a broad spectrum of reductions in immunohistochemical parameters. The 
combination appeared to result in clinical and multiple immunohistochemical synergistic 
effects.
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2.4. CLOBETASOL-17-PROPIONATE LOTION UNDER HYDROCOLLOID DRESSING 
(DUODERM ET) ONCE WEEKLY VERSUS UNOCCLUDED CLOBETASOL-17- 
PROPIONATE OINTMENT TWICE DAILY IN PSORIASIS:
AN IMMUNOHISTOCHEMICAL STUDY ON REMISSION AND RELAPSE
2.4.1. Summary
It is well-established that the efficacy of corticosteroids under occlusion of 
hydrocolloids (HCD) is superior compared to monotherapy with topical corticosteroids. 
However, following treatment with more potent corticosteroids, increased side-effects and 
a more pronounced rebound might be expected.
In the present clinical study efficacy, relapse and safety characteristics of two 
treatment modalities were compared: clobetasol-17-propionate lotion under a 
hydrocolloid dressing once weekly versus clobetasol-17-propionate ointment without a 
hydrocolloid twice daily. Clinical assessments were recorded and skin biopsies were taken 
before therapy, at clearance and six weeks after clearance. A panel of monoclonal 
antibodies to characterise epidermal proliferation, differentiation and inflammation was 
selected. In addition, clinical and histological assessments for skin atrophy were made.
Both therapies had a major therapeutic effect, which was reflected in the clinical 
and immunohistochemical parameters. The only difference between the two therapies 
was a faster remission induction time in patients treated with corticosteroids combined 
with HCD. Six weeks after discontinuation of treatment, similar clinical and histological 
signs of relapse were observed for both therapies. Epidermal thinning was observed to 
the same extent during either therapy but proved to be reversible within six weeks after 
discontinuation of treatment.
From this study it can be concluded that the combination of HCD and 
corticosteroids is able to induce relatively fast remissions compared to corticosteroid 
monotherapy but relapse and safety characteristics are comparable to the unoccluded 
corticosteroid therapy.
2.4.2. Introduction
Topical corticosteroids have been broadly utilised in steroid responsive dermatoses 
such as psoriasis and efficacy and safety have been studied extensively. Low and medium 
potent corticosteroids are used for maintenance therapy in mild and moderate diseases. 
Rapid remissions in more severely affected skin can be obtained using potent 
corticosteroids . 1 Adverse events of topical corticosteroids can be divided in local and 
systemic effects. Local adverse events like skin-thinning are frequently observed. 
Systemic adverse events like suppression of the adrenal cortex are more serious side- 
effects . 1 " 3
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Different therapeutic schedules and modes of application have been used in 
corticosteroid therapy. The last decade the treatment with corticosteroids under occlusive 
dressings has become a popular approach. Hydrocolloid dressings (HCD), used for 
occlusive therapy, are convenient to wear and have a beneficial effect on the psoriatic 
plaque even as monotherapy without corticosteroids .4 ,5 In vivo studies show that 
monotherapy of psoriatic plaques with occlusive dressings decreases the number of 
involucrin and transglutaminase (TGase) positive cell layers,6 whereas the mitotic 
activity, keratin 16 expression and dermal T-cell accumulation tends to decrease .7 It has 
been established that the efficacy of corticosteroids combined with HCD is superior 
compared to corticosteroids without HCD occlusion but information on relapse and safety 
is sparse . 8 " 10 Recently, a multi-centre study was carried out to study clinical efficacy and 
safety of once weekly applications of clobetasol-17-propionate (clobetasol) 3 lotion under 
occlusion with the HCD Duoderm ET and to compare safety and efficacy of this approach 
with clobetasol ointment applied twice daily without occlusion .11 Compared to unoccluded 
clobetasol treatment, clobetasol under HCD induced a faster remission whereas a 6  
weeks post-treatment follow up revealed comparable relapse characteristics .11
In the patients, who participated in this study in the Nijmegen centre, skin 
biopsies for immunohistochemistry were taken before treatment, at clearance and six 
weeks after discontinuation of treatment. Immunohistochemical markers for epidermal 
proliferation, differentiation and inflammation were assessed (table I). Remission, relapse 
and safety characteristics of both treatments were compared and contrasted. In particular 
the following questions were addressed:
i. What are the differences with respect to immunohistochemical responses between 
treatment with a potent topical corticosteroid under a hydrocolloid and treatment 
with the corticoid without a hydrocolloid in chronic plaque psoriasis?
ii. In what respect do remission, relapse and safety characteristics differ between the 
two therapies used?
2.4.3. Materials and methods
Study design
Nineteen patients with chronic plaque psoriasis were included in an open, 
comparative study. One lesion of maximally 70 cm2 was treated with either:
• clobetasol lotion (Dermovate lotion, Glaxo, Zeist the Netherlands) under occlusion 
of HCD (Duoderm ET, Convatec, Woerden, the Netherlands) with a change of the 
dressing and lotion once weekly ( 1 0  patients)
•
The patients were treated during a maximum of six weeks or shorter in case of 
clearance of the lesion. Clinical assessments were carried out every two weeks. After
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clearance, no therapy was allowed and the patients visited the department every two 
weeks until the first signs of relapse of the psoriatic lesion were observed. The final 
investigation was three weeks after the first sign of relapse.
In all patients punch biopsies of 3 mm were taken from the target lesions before, 
immediately after treatment and six weeks after discontinuation of treatment. The biopsy 
procedure has been described before . 1 2 ,1 3
Table I Monoclonal antibodies used in the present study.
Antigen Antibody Source Diluti
on
Staining technique
Ki-67 MIB-1 Immunotech, France 1:50 indirect
immunoperoxidase
Involucrin Mon-15016 Dr. J van Duijnhoven, 1:25 indirect
Holland immunoperoxidase
Transglutami BT621 Biomedical 1 : 1 0 0 indirect
nase Technologies, USA immunoperoxidase
Filaggrin BT576 Biomedical 1:500 indirect
Technologies, USA immunoperoxidase
CD2 DAKO-T11 Dakopatts, Denmark 1 : 1 0 0 avidin-biotin-complex
method
Elastase DAKO- Dakopatts, Denmark 1 : 1 0 0 indirect
elastase immunoperoxidase
Patients
The group of 19 patients consisted of 16 males and 3 females, with an age 
ranging from 32 to 79 years. Apart from psoriasis, the patients did not have significant 
other dermatological or internal diseases. No treatment for psoriasis was allowed other 
than the trial medication. Concomitant treatments which did not interfere with psoriasis 
or test medications were permitted to continue. Before study initiation, no topical 
antipsoriatic treatment had been administered for two weeks and the patients had not 
used systemic treatment for at least six weeks. Permission of the local Ethics Committee 
and written informed consent were obtained from all patients.
Assessment o f clinical efficacy
Clinical efficacy was assessed using the sum-score: the sum of the three clinical 
severity parameters: erythema, induration and scaling, each of them scored on a 0-4 
point-scale (0 = no involvement, 1 = mild involvement, 2 = moderate involvement, 3 = 
marked involvement, 4 = severe involvement). Photographs were taken at each visit. 
Remission was defined as no or only a
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mild erythema without induration or scaling (sum-score < 1). Relapse was defined as any 
increase of the sum-score. The length of the remission period and the sum-score at the 
moment of relapse were also recorded.
Immunohistochemical stainings
For the immunohistochemical stainings a panel of monoclonal antibodies (table I) 
was used. All antibodies were diluted in phosphate buffered saline (PBS). This 
immunoperoxidase technique was described previously .1 2 ,1 3 Staining with DAKO-T11 was 
done with avidin-biotin complex method (ABC-kit (mouse), Vector Lab. Inc., Burlingame, 
USA). In brief, the slides were incubated with 20% normal horse serum and subsequently 
with the T i l  antibody for 60 minutes. The slides were incubated with horse-anti-mouse- 
biotinylated IgG (1:200, Vector Lab. Inc., Burlingame, USA) for 30 minutes. After 2 washes 
with PBS an incubation of 30 minutes with avidin-biotin-peroxidase complex (1:50 Vector 
Lab. Inc., Burlingame, USA) was performed. Visualisation was done using a solution of 3- 
amino-9-ethylcarbazole (AEC). All slides were counterstained with Mayer's haematoxylin 
(Sigma, St Louis, MO, USA) and mounted in glycerol-gelatine.
Histological examination
The histological examination was performed blinded. The scoring methods used 
have been performed and published before .1 2 ,1 3 Epidermal proliferation was measured by 
counting the number of Ki-67 positive nuclei per mm length of the section. The involucrin 
and transglutaminase expression were assessed by calculation of the ratio positive cell 
layers/total cell layers of the viable epidermis. This was done at two sites: above the 
dermal papilla and between the dermal papillae. In addition the total number of cell 
layers was recorded. The filaggrin expression was assessed by measuring the percentage 
of the length of the stratum corneum and stratum granulosum which was stained. 
Inflammation (PMN and T-lymphocytes) was assessed separately for dermis and 
epidermis. Dermal inflammation was semi-quantitatively enumerated by expressing the 
number of positively stained cells as a percentage of the total number of infiltrate cells: 
0, no positive cells; 1, sporadic; 2, 1-25 %; 3, 26-50 %; 4, 51-75 %; 5, 76-99 %; 6 , 
100 %. Epidermal inflammation was assessed using a 0-4 point scale: 0, no staining; 1, 
sporadic staining; 2, minimal staining; 3, moderate staining; 4, pronounced staining.
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Assessment o f skin atrophy
During the study clinical signs of atrophy were recorded. Histological atrophy was 
recorded by counting the total number of cell layers of the epidermis between the dermal 
papillae.
Statistical evaluation
Data are reported as means ± SEM. Changes in paired markers, due to therapy, 
were evaluated with the t-test for paired values. Unpaired data were analysed with a t- 
test assuming equal variances. A two-tailed hypothesis was employed to interpret data. A 
p-value < 0.05 was regarded as statistically significant.
2.4.4. Results
Clinical response
Of the 19 patients who participated in the present study, 15 patients reached a 
clearance and completed the study. One patient, treated with clobetasol lotion and 
HCD, was excluded from the study because of impétiginisation during treatment.
Three patients who were treated with clobetasol ointment did not reach a clearance 
after 6  weeks and therefore did not participate in the follow up period. The mean 
treatment time in the lotion + HCD group was 2.7 ± 0.3 weeks which was 
significantly shorter compared to the ointment group: 4.7 ± 0.7 weeks (mean ±
SEM; p=0.02). The length of the remission was equal for both therapies (clobetasol 
lotion+HCD: 5.3 + 1.1 weeks and clobetasol ointment: 5.3 ± 1.0 weeks (mean ± 
SEM)). The severity of the relapse was also similar following both treatments.
0 2 4 clearance 6 weeks after clearance
weeks
Fig. 1 The course of the sum of the clinical scores (erythema, induration and 
scaling) during treatment and after discontinuation of treatment with clobetasol 
lotion under occlusion with
hydrocolloid (-----) and monotherapy with clobetasol ointment (------ )
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The results of the clinical assessments, indicated by the sum-score, are shown in 
figure 1. During both treatments a statistically significant decrease of the sum-score 
was observed, (clobetasol lotion + HCD: p<0.001; clobetasol ointment; p<0.001)
The scores in the two treatment groups at the start of therapy did not differ 
significantly. Neither did the scores at the end of the treatment period. Clearing was 
reached in 15 patients (clobetasol lotion+HCD: 9 patients; clobetasol ointment: 6  
patients). Six weeks after discontinuation of treatment, 13 patients experienced a 
relapse with a substantial increase of the sum-scores (clobetasol lotion+HCD: 
p=0.002; clobetasol ointment: p=0.08) There was no significant difference between 
both therapies with respect to the sum-scores six weeks after discontinuation of 
treatment. The sum-score at the end of the six weeks post-treatment follow up was 
significantly lower than to the sum-score at the start of the study (clobetasol 
lotion+HCD: p = 0.02; clobetasol ointment: p=0.01).
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0 2 4 clearance 6 weeks after clearance
weeks
Fig. 2 The number of Ki-67 positive nuclei/mm of the epidermis during treatment and 
after discontinuation of treatment with clobetasol lotion under occlusion with hydrocolloid
(-----) and monotherapy
with clobetasol ointment (------ ).
Immunohistochemical assessments
With respect to all immunohistochemical stainings, both therapies induced 
significant changes during treatment (p<0.05) (table II). At the start of therapy, both 
treatment groups did not show any statistically significant differences. No significant 
differences could be demonstrated between both treatment groups at clearance either. In 
figure 2, the response to both therapies is illustrated by the number of Ki-67 positive 
nuclei in the epidermis.
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Table II Immunohistochemical sores, before clobetasol treatment, at clearance, and 6 weeks after clearance
(mean ± SEM).
Antigen Localisation Before treatment Clearance 6 Weeks after
lotion+HCD lotion+HCD clearance
ointment ointment lotion+HCD
ointment
Ki-67 basal layer 209 ± 27 243 ± 40 43 ± 28 39 ± 22 127 ± 27 141 ± 26
Involucrin interpapillar 0.59 ± 0.05 0.53 ± 0.03 0.41 ± 0.04 0.40 ± 0.04 0.52 ± 0.05 0.50 ± 0.02
above papilla 0.76 ± 0.06 0.89 ± 0.04 0.61 ± 0.03 0.66 ± 0.05 0.81 ± 0.03 0.81 ± 0.03
TGase interpapillar 0.56 ± 0.03 0.63 ± 0.03 0.38 ± 0.03 0.41 ± 0.04 0.55 ± 0.05 0.56 ± 0.04
above papilla 0.87 ± 0.02 0.90 ± 0.02 0.58 ± 0.04 0.60 ± 0.06 0.79 ± 0.04 0.78 ± 0.05
Filaggrin granular
layer
69 ± 7.3 65 ± 8.7 97 ± 1.5 94 ± 3.3 71 ± 10 82 ± 10
corneal layer 44 ± 9.0 47 ± 12 97 ± 2.4 100 ± 0 64 ± 13 76 ± 13
CD2 dermis 4.8 ± 0.32 4.9 ± 0.4 2.4 ± 0.24 2.8 ± 0.5 4.1 ± 0.4 3.8 ± 0.7
epidermis 3.3 ± 0.3 2.9 ± 0.4 0.56 ± 0.17 0.50 ± 0.34 2.7 ± 0.4 2.2 ± 0.6
Elastase dermis 1.0 ± 0.4 1.1 ± 0.4 0.22 ± 0.15 0 ± 0 1.0 ± 0.4 0.67 ± 0.3
epidermis 1.4 ± 0.4 2.2 ± 0.4 0 ± 0 0 ± 0 2.2 ± 0.5 1.2 ± 0.6
Six weeks following discontinuation of both treatments, all immunohistochemical 
markers changed substantially (table II) and these changes, indicating a relapse in 
psoriasis, were comparable for both treatment groups (table II). Six weeks after 
clearance, significant differences could be observed compared to the starting point of the 
study: a decrease of the Ki-67 count (p=0.05) and a decrease of the CD2 positive cells in 
the epidermis (p=0.05) for the patients treated with clobetasol lotion + HCD group 
compared to the pre-treatment values and a decrease of transglutaminase above the 
papilla in the patients treated with clobetasol ointment (p=0.02). The other parameters 
showed no statistically significant changes.
30
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0 2 4 c learance 6 weeks after clearance
w eeks
Fig. 3 The number of cell layers of the epidermis during treatment and after discontinuation
of treatment with clobetasol lotion under occlusion with hydrocolloid (---- )
and monotherapy 
with clobetasol 
ointment (------).
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Assessment o f epidermal atrophy
No clinical signs of atrophy were seen. The results of the counting of the number 
of cell layers are shown in figure 3. During both treatment modalities, a significant 
decrease of the number of cell layers was observed (clobetasol lotion+HCD: p<0.001; 
clobetasol ointment: p<0.001) but there was no difference between both therapies. After 
discontinuation of both therapies a similar and significant increase of the number of cell 
layers was observed (clobetasol lotion + HCD: p=0.004; clobetasol ointment: p=0.05). For 
both therapies, at the end of the six weeks follow up, the number of cell layers was not 
significantly different compared to the situation at the start of therapy.
2.4.5. Discussion
The clinical results of the present study are in line with the multi-centre 
comparative study11: a faster induction of remission in the clobetasol lotion+HCD group 
was observed compared to the clobetasol ointment group and equal clinical relapse 
characteristics were seen for both treatment groups.
In the present study, significant changes occurred during treatment with respect 
to all immunohistochemical markers which were analysed (table II). The degree of 
immunohistochemical changes did not differ significantly for both therapies. Despite of 
clinical clearance, only some of the immunohistochemical markers reached values of 
normal human skin . 14 Filaggrin, transglutaminase and elastase stainings reached the 
normal range during both treatment schedules.
Following discontinuation of corticosteroid treatment, all immunohistochemical 
markers changed substantially. These changes indicate a relapse of the psoriatic lesion 
(table II). The comparison of both therapies for the immunohistochemical markers six 
weeks after clearance, did not reveal any significant differences. This observation 
confirms and strengthens the conclusion of the clinical data of the multi-centre study11, 
that both treatments have a similar post-treatment response pattern.
Clinically, in none of the patients, signs for skin atrophy were observed. 
Histologically, the number of epidermal cell layers demonstrated a significant decrease 
during therapy. Persisting local side-effects like striae and skin thinning after topical 
corticosteroids are mainly the result of dermal atrophy, but epidermal thinning may give 
insight into atrophogenecity as well. 15 The epidermal thinning observed in the present 
study proved to be reversible after discontinuation of either treatment within the six 
weeks post-treatment observation period. Some authors suggest that corticosteroids 
under occlusion should be regarded as a potentially more atrophogenic approach
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than corticosteroids without occlusion and should therefore be avoided .2 The present 
study, however, indicates that the combination of clobetasol and a HCD does not differ 
from monotherapy with clobetasol in inducing epidermal atrophy.
In conclusion, the present study demonstrates a similar immunohistochemical 
response of the combination of clobetasol lotion under HCD compared to monotherapy 
with clobetasol ointment. No immunohistochemical indication for a faster relapse 
following discontinuation of clobetasol lotion in combination with a HCD compared to 
monotherapy with clobetasol ointment was seen. With respect to the thickness of the 
epidermis the combined approach was not more atrophogenic compared to monotherapy. 
In addition, clobetasol lotion applied once weekly under HCD induced a faster clearing 
compared to clobetasol ointment twice daily. Therefore treatment with clobetasol lotion 
under HCD reduces the duration of treatment as well as the quantity of the topical 
corticosteroid required for reaching clearing.
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3.1. THE IMMUNOHISTOCHEMICAL EFFECTS OF A SINGLE CHALLENGE WITH AN 
INTERMEDIATE DOSE ULTRAVIOLET B ON NORMAL HUMAN SKIN
3.1.1. Summary
Ultraviolet B irradiation (UVB) has extensively been advocated to investigate 
cutaneous inflammation in vivo. Mostly doses above the threshold of skin damage were 
used. Therefore it is not clear what changes were observed: specific effects of UVB or 
some extent of woundhealing?
In this study the dose-dependent effects of UVB on normal human skin were 
assessed using histology and immunohistochemistry. The dose of 1 MED was chosen as a 
dose inducing tissue changes with adequate morphology: no toxic but evident 
immunohistochemical changes. The sequential effects of this 1 MED of UVB were studied 
up to 14 days after UVB, using immunohistochemistry with a panel of monoclonal 
antibodies.
One MED of UVB resulted in substantial effects in human skin, mainly on 
proliferation and differentiation; the markers for inflammation did not reveal major 
changes. This model might provide a promising approach to evaluate the effect of drugs 
on epidermal proliferation and differentiation in vivo.
3.1.2. Introduction
To answer questions relating cutaneous inflammation, the response of normal 
human skin to ultraviolet B (UVB) has been used for decades by various groups as a 
classical approach in experimental dermatology . 1,2 Most authors evaluated the effects of 
three times the minimal erythema dose (MED) of UVB .3 ,4 Following irradiation with three 
times the MED, however, a substantial damage of the epidermis occurs with cytolysis and 
sunburn cells. Therefore, the response to such a high dose UVB can be interpreted to a 
large extent as woundhealing. An alternative approach is to study the effect of an 
intermediate dose of UVB, which does not yet induce the gross histological changes that 
were mentioned above, but on the other hand does not have a substantial effect on 
epidermal behaviour.
The aim of the present study was firstly to determine this intermediate dose of 
UVB and secondly to elucidate the sequential changes due to this UVB dose. In particular 
the following question was addressed: what are the dynamics and characteristics in 
epidermal proliferation, epidermal differentiation and inflammation due to a single 
irradiation with an intermediate dose of UVB?
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To assess these changes qualitatively and semi-quantitatively, 
immunohistochemical markers for epidermal proliferation, epidermal differentiation and 
inflammation were evaluated.
3.1.3. Materials and methods
Volunteers
Nine healthy volunteers, males and females (age 23-34 years), participated in this 
investigation. This study was approved by the local ethical committee. All volunteers 
gave their written informed consent prior to inclusion in the study.
UVB exposure
For UVB exposure a Waldman UV 7001 K light cabin, emitting broad-band UVB 
(285-310 nm) was used. In all volunteers the MED was determined on the non sun- 
exposed skin of the buttocks; MED is defined as the minimal dose yielding a sharply 
demarcated erythema after 24 hours.
Subsequently the first three volunteers were exposed to single doses of 0, Vi, 1, 2 
and 3 MED of UVB on three areas of 9 cm2 at the skin of the buttocks. A challenge of 1 
MED resulted in substantial changes with respect to epidermal differentiation without 
inducing histological damage. Therefore, the other six volunteers were exposed to 1 MED 
of UVB on three separate areas of 9 cm2 at the skin of the buttocks.
Sample procedure
Punch biopsies of 3 mm were taken from the UVB exposed areas (one biopsy per 
area) after local anaesthesia with xylocain 1% and adrenaline. In the first three 
volunteers biopsies were taken 24 hours after UVB exposure. In the six other volunteers 
biopsies were taken 1, 4 and 14 days after 1 MED of UVB exposure (three volunteers) 
and 0, 2 and 10 days after 1 MED of UVB exposure (three volunteers).
The biopsies were embedded in Tissue Tek OCT compound (Miles Scientific, 
Naperville, USA), snap frozen in liquid nitrogen and stored at -80°C until use. Sections of
7 nm were cut, air dried and fixed for 10 minutes in acetone/ether (60/40%) (Ki-67
°
Monoclonal antibodies
A panel of monoclonal antibodies was used.
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To approximate the number of cycling epidermal cells in the basal layer an 
antibody directed against the Ki-67 antigen was used (MIB-1, 1:50, Immunotech, S.A., 
Marseilles, France). Antibodies against tenascin (T2 H5, 1:2000; obtained from AA 
Verstraeten, The Netherlands Cancer Institute, Amsterdam, The Netherlands) and against 
cytokeratin 13/16 (Ks8.12, 1:20, Sigma, St. Louis, USA) were used for proliferation 
associated dermal and epidermal changes respectively.
To assess epidermal differentiation monoclonal antibodies against involucrin, 
(MON-ISO5, 1:25) and anti-human keratinocyte transglutaminase (1:100, Mouse 
Monoclonal Antibody, IgG2a Biomedical Technologies Inc.) were used.
Analysis of the inflammatory infiltrate was done by assessment of T-lymphocytes, 
Polymorphonuclear leukocytes (PMN) and Langerhans cells respectively using the 
monoclonal antibodies against the CD2 antigen (DAKO-T11, 1:100, Dakopatts, 
Copenhagen, Denmark), against elastase (DAKO-elastase, 1:100, Dakopatts, 
Copenhagen, Denmark) and against the CD la  antigen (DAKO-T6 , 1:100, Dakopatts, 
Copenhagen, Denmark).
Staining procedure
For all monoclonal antibodies, except for DAKO-T11 and DAKO-T6 , an indirect 
immunoperoxidase technique was used. For ten minutes the slides were fixed in 
acetone/ether (60/40%) in case of Ki-67 staining or in acetone for the other stainings. 
The slides were air dried and put in a phosphate buffer (PB) (72 mM Na2 HP04 and 28 mM 
NaH2 P04). Only the slides stained with anti-elastase were pre-incubated with methanol/
0.1 % H20 2 (30 %) for 20 minutes. All antibodies were diluted in PB. The slides were 
incubated with the different primary monoclonal antibodies for 30 minutes. After washing 
with PB the slides were incubated with the secondary antibody, rabbit-anti-mouse 
immunoglobulin conjugated with peroxidase diluted in PB containing 5% human AB­
serum (1:50, RAM-PO, Dakopatts, Copenhagen, Denmark) for 30 minutes. After washing 
with PB and demineralised water a 3-amino-9-ethylcarbazole (AEC) solution was used for 
visualisation.
Staining with DAKO-T11 and DAKO-T6  was done with an indirect peroxidase-anti- 
peroxidase technique (PAP). The slides were put in PB for ten minutes and pre-incubated 
with 50 % Normal Rabbit Serum on PB for 20 minutes. After washing with PB the slides 
were incubated the primary monoclonal antibody in a Miele Microwave at 80 Watt for 9 
minutes. Then the slides were washed again in PB and incubated with rabbit-anti-mouse 
immunoglobulin (1:25, RAM-Ig, Dakopatts, Copenhagen, Denmark) in the microwave at 
80 Watt for 9 minutes. After washing in PB the slides were incubated with PAP-complexes 
(1:100, Peroxidase monoclonal mouse
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antiperoxidase complexes, Dakopatts, Copenhagen, Denmark) in the microwave at 80 
Watt for 8  minutes. After washing, this cycle was repeated. Visualisation of the 
complexes was done by the AEC-solution.
All slides were counter-stained with Mayer's Haematoxylin (Sigma, St. Louis MO, 
USA) and mounted in glycerol-gelatine.
Histological examination
The histological examination was performed blinded by two investigators. These 
scoring methods have been performed and published before .6
Epidermal proliferation was measured by counting the number of Ki-67 positive 
nuclei per mm length of the section. The distribution of tenascin in the papillary dermis 
was assessed using a 6  point scale: 0 , no staining; 1 , sporadic staining; 2 , minimal 
staining; 3, moderate staining; 4, moderate-pronounced staining; 5, pronounced 
staining. In addition it was recorded whether a staining pattern continuous or 
discontinuous adjacent to the basal lamina was seen. Cytokeratin 13/16 was scored 
separately for the basal and suprabasal compartment of the epidermis using a semi­
quantitative 7 point scale: 0, no staining; 1, sporadic staining; 2, minimal staining; 3, 
moderate staining; 4, moderate-pronounced staining; 5, pronounced staining; 6 , whole 
epidermis stained.
The involucrin and transglutaminase expression were assessed by calculation of 
the ratio positive cell layers/ total cell layers of the viable epidermis. This was done at 
two sites: above the tip of the dermal papilla and between two dermal papillae.
Inflammation (PMN, T-lymphocytes and Langerhans cells) was assessed 
separately for dermis and epidermis. Dermal inflammation was semi-quantitatively 
enumerated by expressing the number of positively stained cells as a percentage of the 
total number of infiltrate cells: 0, no positive cells; 1, sporadic; 2, 1-25 %; 3, 26-50 %;
4, 51-75 %; 5, 76-99 %; 6 , 100 %. Epidermal inflammation was assessed using a five- 
point scale: 0, no staining; 1, sporadic staining; 2, minimal staining; 3, moderate 
staining; 4, pronounced staining.
Statistical evaluation
Data are reported as means ± SEM. For statistical analysis the Mann-Whitney 
ranking test for unpaired data was used; a p-value < 0.05 was supposed to be 
statistically significant. In the figures, the asterisks above the error bars indicate the first 
statistically significant changes with regard to the starting point.
90
Fig. 1 H&.E stained slides of normal human skin 1 day after UVB challenge with (a) 1 
MED, (b) 2 MED and (c) 3 MED.
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3.1.4. Results
Minimal erythema dose
The volunteers had skin types varying from 2 to 4 (Fitzpatrick-Pathak- 
classification); the MED ranged from 0.2 - 0.4 J/cm2.
Dose finding study
In each volunteer the MED was determined. Biopsies of the skin exposed to 0, V2 
,1, 2, 3 MED of UVB were assessed histologically after 1 day. H&E staining revealed 
sunburn cells, cytolysis and intracellular oedema in the biopsies taken from the skin sites 
exposed to 2 and 3 MED as presented in figure 1. No toxic changes were seen on the H&E 
slides after V2 and 1 MED. Cytokeratin 13/16 staining revealed no changes in the skin 
exposed to V2 MED but an increased staining intensity in the skin exposed to 1 MED. 
Therefore, the dose of 1 MED was selected to evaluate the dynamics of the response to 
UVB challenge.
Clinical assessment o f the time curve
At day 1 after 1 MED of UVB a sharply demarcated erythema was observed that 
faded and decreased with normalisation on day 10. Induration of the skin was visible 
after 1 day and also subsequently decreased with normalisation on day 10. Pigmentation 
was first observed on day 1 and gradually increased during the 14 days of observation. 
Scaling was first observed 2 days after UVB exposure and this increased during the 14 
days of the investigation.
Fig. 2 aThe number of Ki-67 positive cells per mm of the section in the basal layer of the 
epidermis following intermediate dose UVB challenge; data are reported as means+ SEM, 
the asterisks above the error bars indicate the first statistically significant changes (p < 
0.05) with regard to the starting point.
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Time curve o f histological changes 
H&E staining
The dermis as well as the epidermis were intact; no toxic changes, no cytolysis 
and no sunburn cells were seen in the H&E stained slides. On day 2 a slight increase of 
the dermal infiltrate cells was seen. On day 4-10 parakeratosis was observed. Acanthosis 
and elongated rete-ridges were seen on day 4 increasing up to day 14.
Fig. 2 bTenascin expression in the dermis following intermediate dose UVB challenge; data 
are reported as means + SEM, the asterisks above the error bars indicate the first statistically 
significant changes (p < 0.05) with regard to the starting point.
days after UVB exposure
Fig. 2 c Cytokeratin 13/16 expression in the suprabasal cell compartment following intermediate 
dose UVB challenge; data are reported as means + SEM, the asterisks above the error bars indicate 
the first statistically significant changes (p < 0.05) with regard to the starting point.
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Epidermal proliferation and proliferation associated changes
Ki-67 expression (figure 2a) was seen in the stratum basale of the epidermis. 
After 1 day no change was seen in the number of Ki-67 positive cell nuclei per mm of the 
histological section. After 2 days a significant increase was observed (p < 0.05). After 4 
days this increase had become more substantial. On day 10 the Ki-67 positive count 
equalled the density of day 0. However on day 14 again a tendency to increase could be 
observed.
<
which gradually increased and stayed high up to day 14 (figure 2b). At all time points 
either continuous or discontinuous tenascin expression in the dermis adjacent to the 
basal lamina was observed.
Ks8.12 staining (keratin 13/16 expression) (figure 2c) in the suprabasal epidermal
<
maximum after 2 days. Subsequently the intensity decreased and tended to normalise at 
14 days after UVB exposure. No significant changes were observed in the basal cell 
compartment with respect to cytokeratin 13/16.
Epidermal differentiation
Figure 3a illustrates the expression of involucrin. At day 2 a significant increase 
was seen (p < 0.05) that decreased significantly on day 10 (p < 0.05) tending to 
normalisation on day 14.
Transglutaminase expression (figure 3b) had a similar time course as involucrin. A
<
the expression had decreased and tended to normalisation on day 14.
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Fig. 3 a
The percentage of involucrin positive cell layers in the epidermis at the tip of the dermal papilla
(---- ) and interpapiiiary (------) following intermediate dose UVB challenge; data are reported as
means ± SEM, the asterisks above the error bars indicate the first statistically significant changes 
(p < 0.05) with regard to the starting point.
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Fig. 3 b The percentage of transglutaminase positive cell layers in the epidermis at
the tip of the dermal papilla (-----) and interpapillary (------ ) following intermediate
dose UVB challenge; data are reported as means ± SEM, the asterisks above the 
error bars indicate the first statistically significant changes (p< 0.05) with regard to 
the starting point.
Inflammation
No significant changes were observed in either dermal or epidermal CD la  
expression (figure 4a). No CD2 positive cells were seen in the epidermis in any of the 
histological slides. The percentage CD2 positive cells in the dermal infiltrate (figure 4b)
<
tendency towards a decrease and normalisation. No elastase positive cells were observed 
either in the dermis or in the epidermis following UVB challenge.
Fig. 4 a CD2 positive cells in the dermis; data are reported as means + SEM, the asterisks 
above the error bars indicate the first statistically significant changes (p < 0.05) with regard 
to the starting point.
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Fig. 4 bCDla positive cells in dermis (---- ) and epidermis (------); data are reported as means +
SEM.
3.1.5. Discussion
The present study clearly demonstrates that UVB using the maximal dose which 
did not yet induce obvious histological damage such as cytolysis and sunburn cells, 
profoundly modulates epidermal proliferation, epidermal differentiation and also 
interferes with inflammation. Many biochemical and histological changes due to high dose 
UVB have been described in literature . 1 4 , 7 , 8  The present study extends our knowledge on 
the response to intermediate dose UVB: a separation between UV damage and 
modulation of epidermal proliferation, epidermal differentiation and inflammation occurs 
following challenge with 1 MED of UVB.
The dynamics of the response to intermediate dose UVB are demonstrated in 
figures 2-4. At day 1 T-cell accumulation was observed in the dermis and the suprabasal 
epidermal compartment expressed cytokeratin 13/16. At day 2 the percentage of 
involucrin and transglutaminase positive cell layers had increased, dermal tenascin had 
increased and the recruitment of cycling cells was enhanced profoundly. No PMN 
accumulation was observed. In contrast to a study with higher doses of UVB9, the number 
of CD la  positive cells was not modulated in our study.
An intriguing observation was the pronounced expression of the Ki-67 antigen 2 
days after intermediate dose UVB. Autoradiographic studies also indicate 
hyperproliferation in response to high dose UVB . 1 But it can be argued whether 3 H- 
thymidine-incorporation always represents cell division. The mitotic index curve as shown 
by Mier et a l . 10 does represent hyperproliferation and seems to precede Ki-67 expression
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as observed in the present study. This can be explained by delayed expression of the Ki- 
67 protein . 11 In some communications the question is discussed whether it is proliferation 
or DNA repair due to DNA damage that is detected after UVB exposure. UVR causes 
formation of pyrimidine dimers . 12 The endogenous repair capacity of the DNA, also known 
as unscheduled DNA synthesis13, repairs these defects. In this way the same proteins are 
involved which also are expressed during cell proliferation. PCNA is a marker for cell 
proliferation but is also expressed in DNA repair. 14 Therefore this marker does not provide 
the possibility to differentiate between both processes. Ki-67, on the other hand, is 
expressed exclusively in proliferating cells and is therefore an adequate tool to study 
proliferation in UVB exposed skin . 15 In a previous study concerning UVR exposure, 
however, an intermediate dose UV irradiation did not induce recruitment of cycling 
epidermal cells . 14 These discrepancies might be partially explained by the use of another 
light source and dose (UVB combined with UVA; IV2 MED), by another antibody 
recognising a different epitope of the Ki-67 molecule or by a different way of processing 
the biopsy material. 15 Hyperproliferation following high dose UVB is a well-established 
event after UVB . 1 ,1 0 The present study clearly demonstrates the substantial induction of 
epidermal proliferation following intermediate dose UVB challenge, suggesting that UVB 
induces epidermal proliferation directly and not as a result of skin damage.
Tenascin is an extracellular matrix protein, induced in hyperproliferative skin1 6 ,1 7  
and during remodelling of the epidermis . 18 Some studies suggest that tenascin acts as a 
local growth factor . 19 Fourteen days after UVB, tenascin was still high. There is no 
clearness about the half life time of tenascin. The persisting presence of tenascin might 
represent remodelling of the skin. To the best of our knowledge no data are available on 
the expression of tenascin following UVB challenge.
Due to UVB the differentiation pattern of the keratinocytes was changed. Keratin 
16, a cytokeratin that is associated with hyperproliferative skin conditions like psoriasis, 
and is not expressed in normal human skin20, was one of the first immunohistochemical 
changes in our study. Staining with Ks8.12, the antibody recognising keratin 16, 15 and 
1321, was predominantly seen in the basal layer of normal skin and was upregulated in 
the suprabasal layers of UVB challenged skin. Keratin 13 is not present in adult human 
skin22 and keratin 16 is not expressed in basal keratinocytes. Therefore the staining in 
the stratum basale of the epidermis is thought to be due to keratin 15.23 Since Ki-67 
expression appeared after 2 days, cytokeratin 13/16 expression seems to precede 
proliferation and hence may not directly be related to hyperproliferation. An alternative 
explanation might be that expression of Ki-67 is delayed, so there is already proliferation 
but not yet Ki-67 expression. Indeed Gerdes et a l .11 demonstrated a specific Ki-67 
negative Gi phase for the
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cells between the G0 and S phase in peripheral mononuclear blood leukocytes. In human 
skin, tapestripping has been reported to induce a synchronised transition from Gb to Gi 
whilst Ki-67 expression is first seen after 40-48 hours .24 Such a lag phase of Ki-67 
expression might also explain the time gap between the appearance of cytokeratin 13/16 
expression and increase of Ki-67 expression which we observed after UVB in the present 
study.
Transglutaminase and involucrin are markers for terminal differentiation. 
Functionally the enzyme transglutaminase is necessary for the formation of the cornified 
envelope by enhancing the crosslinking of involucrin and other proteins .5 ,2 5 In normally 
differentiating skin these markers are only present as a band like pattern in the upper 
part of the stratum spinosum and the stratum granulosum. In hyperproliferative skin, 
terminal differentiation starts earlier and also a more substantial proportion of the 
epidermal keratinocytes expresses these markers for epidermal differentiation. UVB 
apparently initiates premature terminal differentiation in a specific cohort of the 
epidermal keratinocytes. This UVB challenged cohort moves upwards in the days after 
exposure to the upper part of the epidermis resulting in a band like expression at about
10 days after UVB.
Since exposure to 1 MED of UVB clinically results in erythema and induration, one 
might expect a pronounced inflammatory infiltrate. But after intermediate dose UVB the 
inflammatory changes are rather modest in contrast to the conspicuous epidermal 
changes. No infiltration of PMN was seen, neither in the dermis nor in the epidermis. A 
modest T-cell infiltration in the dermis occurred following UVB exposure. After 1 day 
there was a significant increase of the percentage of T-cells in the dermal infiltrate. From
2 days onwards the number of T-cells as a percentage of the total dermal infiltrate 
tended to normalise again. Langerhans cells are known to decrease due to higher doses 
of UVB .9 ,2 6 In our study no significant changes in dermal or epidermal CD la  binding were 
seen as a result of 1 MED of UVB. Murphy et a l .9 described a dose dependent decrease of 
epidermal Langerhans cells, identified by the Leu 6  monoclonal antibody; the amount of 
Langerhans cells is reduced to approximately 50 % due to UVB doses of IV2 and 3 MED. 
A dose of 0.7 MED did not induce these changes .9 The dose of 1 MED (present study) also 
failed to modulate the density of the Langerhans cell population.
A major question remains to be answered. To what extent are the changes 
described in the present study characteristic for UVB. Various models for the induction of 
cutaneous inflammation and epidermal proliferation have been characterised during the 
last decade: response to tape-stripping20, response to the epicutaneous application of 
leukotriene B4 (LTB4)27 or dithranol6.
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Whereas an intermediate dose of UVB only yields into a minimal inflammatory infiltrate, 
the other models for cutaneous inflammation show a moderate or marked accumulation 
of infiltrate cells.
In conclusion, the response to intermediate dose ultraviolet B radiation represents 
a response pattern characterised by a major induction of epidermal proliferation, 
enhanced epidermal differentiation and some T-cell accumulation without significant 
accumulation of PMN or modulation of Langerhans cells. In contrast to the in vivo models 
using high dose UVB, intermediate dose UVB challenge can be regarded as a model to 
investigate epidermal behaviour rather than inflammation. This model might provide a 
promising approach to evaluate the effect of drugs on epidermal proliferation and 
differentiation in vivo.
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3.2. THE EFFECTS OF CALCIPOTRIOL AND CLOBETASOL-17-PROPIONATE ON UVB 
IRRADIATED HUMAN SKIN, AN IMMUNOHISTOCHEMICAL STUDY
3.2.1. Summary
Corticosteroids and vitamin D3 analogues inhibit proliferation, enhance normal 
kératinisation and interfere with cutaneous inflammation in in vitro systems. Both 
treatments are effective in psoriasis, although several reports suggest that vitamin Ds is 
less effective in reducing the inflammatory changes compared to its potent effect on 
keratinocyte growth and differentiation. The aim of the present study was to compare 
and contrast the effects of the vitamin D3 analogue calcipotriol, clobetasol-17-propionate 
(clobetasol) and the placebo (ointment base of calcipotriol) on immunohistochemical 
markers for epidermal growth, kératinisation and inflammation induced by a standardised 
single challenge with ultraviolet B (UVB) radiation in normal human skin.
Clobetasol proved to inhibit UVB induced proliferation of epidermal cells, tenascin 
induction, keratin 16 induction and the accumulation of T-lymphocytes and CD la  positive 
cells. Epidermal thinning due to clobetasol was also observed. No effect of clobetasol was 
shown on the enhanced terminal differentiation following UVB challenge. In contrast, 
calcipotriol reduced the number of transglutaminase positive cells following UVB 
challenge but increased the thickness of the epidermis without a significant effect on 
other markers for kératinisation, epidermal proliferation and inflammation.
The present study reconfirms the potent effect of topical corticosteroids on various 
aspects of UVB challenged skin. In contrast, calcipotriol interfered especially with one 
differentiation pathway (transglutaminase) without modulation of other UVB induced 
changes.
3.2.2. Introduction
Phototherapy with UVB is used frequently as a potent antipsoriatic therapy but in 
the healthy human skin, UVB irradiation is also known to induce erythema, induration 
and scaling . 1 The effects of UVB are dose-dependent. Higher doses are known to damage 
the skin resulting in cytolysis and oedema. Following lower doses more minute changes 
can be observed . 1
Recently, the in vivo effects of an intermediate dose of 1 minimal erythema dose 
(MED) of UVB on normal human skin were characterised and it was demonstrated that 
such a UVB dose mainly influenced epidermal proliferation and differentiation, leaving 
markers for inflammation relatively unaffected . 1 In the present study, this UVB model 
was used to evaluate the effects of some well-established topical antipsoriatic therapies 
on UVB challenged skin: calcipotriol and
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clobetasol-17-propionate (clobetasol) . 2 ,3 Vitamin D3 analogues as well as corticosteroids 
are members of the steroid hormone superfamily and both operate mainly via genomic 
mechanisms. In vitro, both drugs inhibit proliferation and have anti-inflammatory and 
immunomodulatory functions .4 " 10 Therefore, the in vitro actions share important 
characteristics.
The aim of the present study was to investigate in what respect these antipsoriatic 
treatments were able to inhibit the UVB induced changes in normal human skin and to 
compare and contrast the in vivo actions of both compounds on UVB induced epidermal 
proliferation, kératinisation and cutaneous inflammation. In particular the following 
questions were addressed:
i. What are the effects of calcipotriol, clobetasol or the placebo on UVB irradiated
skin?
ii. What are the effects of calcipotriol versus its placebo in UVB irradiated skin?
iii. What are the effects of calcipotriol versus clobetasol in UVB irradiated skin?
An immunohistochemical investigation of skin biopsies with a panel of monoclonal 
antibodies was carried out on cryostat sections to answer these questions.
3.2.3. Materials and methods
Volunteers
Six healthy male volunteers, (age 23-28 years), participated in this investigation. 
This study was approved by the local ethical committee. All volunteers gave their written 
informed consent prior to inclusion in the study.
UVB exposure
For UVB exposure a Waldman UV 7001 K light cabin, emitting broad-band UVB 
(285-310 nm) was used. In all volunteers the MED was determined on the non sun- 
exposed skin of the buttocks; MED is defined as the minimal dose yielding a sharply 
demarcated erythema after 24 hours. Subsequently the volunteers were exposed to 
single doses of 1 MED of UVB on four areas of ± 9 cm2 of normal skin on the buttocks.
Ointment application
The volunteers were instructed to apply the three different ointments, on the 
corresponding areas, twice daily, starting one day before irradiation up to the moment of 
the biopsy, four days after irradiation. The ointments were calcipotriol ointment 
(Daivonex, Leo Pharmaceutical Products, Denmark), clobetasol-17-propionate ointment 
(Glaxo, Zeist, the
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Netherlands) and the vehicle of the calcipotriol ointment (Leo Pharmaceutical Products, 
Denmark). On the fourth irradiated area, the control area, no ointment was applied.
Clinical assessment
Erythema of the four irradiated lesions was scored using a 0-4 point scale: 0 = no 
erythema, 1 = slight erythema, 2 = moderate erythema, 3 = severe erythema, 4 = 
severest possible erythema.
Sample procedure
Punch biopsies of 3 mm diameter were taken from the UVB exposed areas (one 
biopsy per area) after local anaesthesia with xylocain 1% and adrenaline. The biopsies 
were embedded in Tissue Tek OCT compound (Miles Scientific, Naperville, USA), snap 
frozen in liquid nitrogen and stored at -80°C until use. Sections of 6  nm were cut, air 
dried and fixed for 10 minutes in acetone/ether (60/40%) (Ki-67 staining) or in acetone
°
Monoclonal antibodies
A panel of monoclonal antibodies was used. To approximate the number of cycling 
epidermal cells in the basal layer an antibody directed against the Ki-67 antigen was 
used (MIB-1, 1:50, Immunotech, S.A., Marseilles, France). Antibodies against tenascin 
(T2 H5, 1:2000; obtained from AA Verstraeten, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands) and against cytokeratin 13/16 (Ks8.12, 1:20, Sigma, St. 
Louis, USA) were used for proliferation associated dermal and epidermal changes 
respectively.
To assess epidermal differentiation monoclonal antibodies against involucrin, 
(MON-ISO11, 1:25) and anti-human keratinocyte transglutaminase (1:100, BT621, Mouse 
Monoclonal Antibody, IgG2a Biomedical Technologies Inc.) were used.
Analysis of the inflammatory infiltrate was done by assessment of T-lymphocytes, 
Polymorphonuclear leukocytes (PMN) and Langerhans cells respectively using the 
monoclonal antibodies against the CD2 antigen (DAKO-T11, 1:100, Dakopatts, 
Copenhagen, Denmark), against elastase (DAKO-elastase, 1:100, Dakopatts, 
Copenhagen, Denmark) and against the CD la  antigen (DAKO-T6 , 1:800, Dakopatts, 
Copenhagen, Denmark).
103
Staining procedure
For all monoclonal antibodies, except for DAKO-T11 and DAKO-T6 , an indirect 
immunoperoxidase technique was used. The immunoperoxidase technique has been 
described previously . 1,5
Staining with DAKO-T11 and DAKO-T6  was done with the avidin-biotin complex 
method (ABC-kit (mouse), Vector Lab. Inc., Burlingame, USA). In brief, the slides were 
incubated with 20% normal horse serum and subsequently with the T i l  or T 6  antibody for
30 minutes. The slides were incubated with horse-anti-mouse-biotinylated IgG (1:100, 
Vector Lab. Inc., Burlingame, USA) for 30 minutes. After 2 washes with PBS an incubation 
of 30 minutes with avidin-biotin-peroxidase complex (1:100 Vector Lab. Inc., Burlingame, 
USA) was performed. Visualisation was done using a solution of 3-amino-9-ethylcarbazole 
(AEC).
All slides were counter-stained with Mayer's Haematoxylin (Sigma, St. Louis MO, 
USA) and mounted in glycerol-gelatine.
Histological examination
The histological examination was performed blinded, by two investigators. These 
scoring methods have been performed and published before .1,5
Epidermal proliferation was measured by counting the number of Ki-67 positive 
nuclei per mm length of the section. The distribution of tenascin in the papillary dermis 
was assessed using a 0-5 point scale: 0, no staining; 1, sporadic staining; 2, minimal 
staining; 3, moderate staining; 4, moderate-pronounced staining; 5, pronounced 
staining. In addition it was recorded whether a staining pattern continuous or 
discontinuous adjacent to the basal lamina was seen. Cytokeratin 13/16 was scored 
separately for the basal and suprabasal compartment of the epidermis using a semi­
quantitative 0-6 point scale: 0, no staining; 1, sporadic staining; 2, minimal staining; 3, 
moderate staining; 4, moderate-pronounced staining; 5, pronounced staining; 6 , whole 
epidermis stained.
The involucrin and transglutaminase expression were assessed by calculation of 
the ratio positive cell layers/ total cell layers of the viable epidermis. Besides this 
fraction, the absolute number of cell layers of the epidermis was recorded separately. 
This was done at two sites: above the dermal papilla and between two dermal papillae.
Inflammation (T-lymphocytes, PMN and Langerhans cells) was assessed 
separately for dermis and epidermis. Dermal inflammation (T-lymphocytes and PMN) was 
semi-quantitatively enumerated by expressing the number of positively stained cells as a 
percentage of the total number
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of infiltrate cells: 0, no positive cells; 1, sporadic; 2, 1-25 %; 3, 26-50 %; 4, 51-75 %;
5, 76-99 %; 6 , 100 %. Langerhans cells in the dermis were assessed on a 0-5 point 
scale: 0, no staining; 1, sporadic staining; 2, minimal staining; 3, moderate staining; 4, 
moderate-pronounced staining; 5, pronounced staining. Epidermal inflammation was 
assessed using a 0-4 point scale: 0, no staining; 1, sporadic staining; 2, minimal 
staining; 3, moderate staining; 4, pronounced staining.
Statistical evaluation
Data are reported as means ± SEM. For statistical analysis the t-test for paired 
values was used. In principle, the statistical significance of the following comparisons 
were tested: calcipotriol, clobetasol or the placebo treated versus untreated UVB 
challenged skin (control), calcipotriol versus placebo and clobetasol versus calcipotriol. A 
two-tailed hypothesis was employed to interpret data. A regression analysis was 
performed to determine the significance of relations between different parameters.
3.2.4. Results
Clinical response
The volunteers had skin types II and III (Fitzpatrick-Pathak-classification); the MED 
ranged from 0.1 - 0.3 J/cm2. Erythema scores that were recorded four days after 
irradiation are shown in figure 1. The erythema on the UVB irradiated skin areas that 
were treated with clobetasol appeared to be significantly less compared to the erythema 
at the calcipotriol treated sites (p=0.005) and the untreated sites (control sites) 
(p=0.009). Non of the other comparisons tested was significantly 
different.
Fig. 1 Erythema at the UVB irradiated skin sites treated with calcipotriol, clobetasol, 
placebo and the untreated UVB challenged sites (control sites).
Immunohistochemical assessments
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Epidermal proliferation and proliferation related changes
The results of the Ki-67 staining are demonstrated in figure 2a. A statistically 
significant decrease of the number of Ki-67 positive nuclei was observed at the clobetasol 
treated UVB challenged sites compared to the calcipotriol treated UVB challenged sites 
(p=0.0007) and the untreated UVB challenged sites (p=0.02). Calcipotriol did not 
significantly change the UVB induced hyperproliferation.
The results of the tenascin staining are shown in figure 2b. Decreased tenascin 
expression was seen at the clobetasol treated UVB challenged sites compared to the 
calcipotriol treated UVB challenged sites (p=0.02).
ca l c i p o t r i o l  c l o b e t a s o l  p l a c e b o  c o n t ro l
Fig. 2 a Ki-67 staining at the UVB irradiated skin sites treated with calcipotriol, clobetasol, placebo 
and the untreated UVB challenged sites(control sites).
c a lc ip o t r io l  c l o b e t a s o l  p l a c e b o  c o nt ro l
Fig. 2 b Tenascin staining at the UVB irradiated skin sites treated with calcipotriol, clobetasol, 
placebo and he untreated UVB challenged sites (control sites).
106
Staining with the Ks8.12 antibody can be divided in basal and suprabasal staining (figure 2c). For 
the basal compartment no significant differences were seen in the comparisons tested. In the 
suprabasal compartment the reduction of UVB induced Ks8.12 staining by clobetasol was 
more substantial compared to the reduction by calcipotriol (p=0 .0 2 ) and compared to the 
untreated UVB challenged sites (p=0.08).
6
5
cn
calcipotrio l c lobe laso l p lacebo control
Fig. 2 c Ks8.12 staining in the basal layer (■) and suprabasal (□) at the UVB irradiated skin 
sites treated with calcipotriol, clobetasol, placebo and the untreated UVB challenged sites 
(control sites).
Epidermal differentiation
Staining for involucrin can be divided in staining between two dermal papillae and 
above the dermal papilla (figure 3a). Except for a significant reduction of involucrin 
expression at placebo treated UVB challenged sites as compared to the untreated UVB 
challenged sites (interpapillar: p=0.04; tip: p=0.006) no significant changes were 
observed comparing active drugs and placebo or control.
The transglutaminase staining is also displayed as staining between dermal 
papillae and above the dermal papilla (figure 3b). The only significant difference that was 
found was the decreased expression at the calcipotriol treated UVB challenged sites as 
compared to the placebo treated UVB challenged sites for the interpapillary region 
(p=0.06) as well as for the tip of the papilla (p=0.008).
The results of the counting of the total number of cell layers are shown in figure 
3c. A significant increase of the number of interpapillary cell layers was seen in the 
calcipotriol treated UVB challenged skin areas versus the untreated UVB challenged sites 
(p=0.04) and a significant
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decrease in the clobetasol treated UVB challenged sites versus the untreated UVB 
challenged sites (p=0.02). Above the papilla a significant difference was observed 
following UVB challenge between calcipotriol and its placebo with more cell layers at the 
calcipotriol treated site (p=0.05). Between clobetasol and calcipotriol at both UVB 
challenged sites a statistically significant difference was seen with substantially more cell 
layers following calcipotriol treatment (tip: p = 0.004 and interpapillary: p=0.003).
Fig. 3 a Involucrin staining, interpapillary (■) and above the dermal papilla (□), at the UVB 
irradiated skin sites treated with calcipotriol, clobetasol, placebo and the untreated UVB challenged 
sites (control sites).
Fig. 3 b Transglutaminase (TGase) staining, interpapillary (■) and above the dermal papilla (□), at 
the UVB irradiated skin sites treated with calcipotriol, clobetasol, placebo and the untreated UVB 
challenged sites (control sites).
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c a l c i p o t r i o l  c l o b e l a s o l  p l a c e b o  c o n t r o l
Fig. 3 c The count of the total number of cell layers, interpapillary (■) and above the dermal 
papilla (□), at the UVB irradiated skin sites treated with calcipotriol, clobetasol, placebo and 
the untreated UVB challenged sites 
(control sites).
Inflammation
Staining for T-lymphocytes (figure 4a) demonstrated significant differences between 
calcipotriol and clobetasol with respect to modulation of UVB induced inflammation for 
both dermis and epidermis (dermis: p=0.03; epidermis: p=0.04) and a significant 
difference for T-lymphocytes in the dermis between clobetasol- and the untreated UVB 
challenged sites (p=0.02). A tendency of a reduction of T-lymphocytes in the epidermis 
was seen at UVB challenged placebo treated sites as compared to untreated UVB 
challenged sites (p=0.08). In contrast to the reduction of T-cells following clobetasol 
treatment, no significant effects were seen following calcipotriol treatment.
c a l c i p o t r i o l  c l o b e t a s o l  p l a c e b o  c o n t r o l
Fig. 4 a CD2 positive cells in the dermis (■) and epidermis (□) at the UVB irradiated skin 
sites treated with calcipotriol, clobetasol, placebo and the untreated UVB challenged sites 
(control sites).
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Elastase staining, representing PMN, did not reveal any differences between the 
different treatments of the UVB irradiated areas. However, appearance of PMN following 
UVB was sparse.
Staining with the antibody against the CD la  epitope (Langerhans cells) (figure 4b) 
revealed significant differences in the dermis between calcipotriol and clobetasol treated 
UVB challenged sites (p=0.04) and between clobetasol treated and untreated UVB 
challenged sites (p=0.04). A reduction of UVB induced changes following clobetasol 
treatment and virtually no effects following calcipotriol treatment were observed.
c a l c i p o t r i o l  c l o b e t a s o l  p l a c e b o  c o n t r o l
Fig. 4 b CDla positive cells in the dermis (■) and epidermis (□) at the UVB irradiated skin sites 
treated with calcipotriol, clobetasol, placebo and the untreated UVB challenged sites 
(control sites).
Correlations
Statistically significant correlations were observed between the following 
parameters: Ki-67 and tenascin (p = 0.002), Ki-67 with Ks8.12 staining in the suprabasal 
compartment (p = 2.6-10"8), Ki-67 with erythema (p = 0.0005) and Ki-67 with the total 
amount of cell layers (p = 0.002). Correlations between erythema versus Ks8.12 staining 
in the suprabasal compartment (p=0.0003) and erythema versus T i l  staining in the 
epidermis (p=0.04) were found.
3.2.5. Discussion
Calcipotriol and clobetasol both have a potent anti-inflammatory, 
immunomodularoty and proliferation inhibiting effect in vitro .6 ,7 ,9 ,1 0 Both compounds are 
also well-established antipsoriatic treatments. However, it has been demonstrated in vivo 
during treatment of psoriatic plaques that calcipotriol has a limited effect on inflammation 
compared to its pronounced effect on epidermal
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proliferation and d ifferentiation .4 ,5 The present study demonstrates a pronounced 
difference between calcipotriol and clobetasol with respect to UVB induced effects on 
epidermal proliferation and differentiation.
The response to an intermediate dose of UVB challenge has been characterised 
before and has proven to be consistent: a marked recruitment of cycling epidermal cells 
(Ki-67 positive nuclei), expression of the extracellular matrix protein tenascin, suprabasal 
staining of Ks8.12, reflecting cytokeratin 13 and 16 expression, an increased number of 
involucrin positive and transglutam inase positive cell layers, accumulation T-lymphocytes 
and a sporadic accumulation of elastase positive cells (polymorphonuclear leukocytes ) . 1
In the present study, calcipotriol and clobetasol proved not to interfere with the 
expression of tenascin, involucrin and the number of PMN following UVB challenge. 
Clobetasol proved to inhibit the UVB induced recruitment of cycling epidermal cells (Ki-67 
positive nuclei), the total number of cell layers in the epiderm is and the suprabasal 
Ks8.12 staining, mainly reflecting keratin 16 expression. Also the UVB induced 
accumulation of T-lymphocytes and C D la  positive cells was reduced substantially by 
clobetasol. No significant effect of clobetasol was observed on UVB enhanced terminal 
differentiation (involucrin and transglutam inase positive cells). These results are 
compatible with earlier studies on the inhibition of the response to ultraviolet radiation.12'
15 The in vivo effects of corticosteroids in psoriasis are also compatible with the changes 
observed in the present m odel.8 ,1 6
Calcipotriol reduced the number of transglutam inase positive cell layers resulting 
from UVB challenge and increased the total number of cell layers in the epiderm is w ithout 
a significant effect on the number of involucrin positive cell layers. No significant effects 
could be shown with respect to the recruitment of cycling epidermal cells (Ki-67 positive 
nuclei), Ks8.12 staining of the suprabasal compartment or accumulation of infiltrate cells. 
This pattern, strikingly different from the response to clobetasol, is in line with the failure 
of calcipotriol to reduce erythema following UVB challenge in contrast to the pronounced 
reduction of erythema as reached by clobetasol. It is of practical relevance, however, that 
calcipotriol did not enhance the inflammation following UVB challenge. Indeed, in multi­
centre studies the combination of UVB and calcipotriol has been shown to be effective 
and safe without a reduction of the minimal erythema dose .1 7 ' 19 To the best of our 
knowledge, no data are available on the effect of vitam in D3 analogues on cutaneous 
inflam m ation . 20 In contrast to the failure of calcipotriol to inhibit cutaneous inflammation 
in this model, calcipotriol has a potent therapeutic effect in psoriasis and disorders of 
kératin isation . 2 ,2 1 "23
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The interpretation of the difference between calcipotriol and clobetasol in UVB 
induced inflammation is d ifficult as many factors m ight be involved in the complex in vivo 
situation. Both calcipotriol and clobetasol are members of the steroid receptor 
superfam ily and operate via genom ic mechanisms. But diversity in both compounds with 
respect to intensity and velocity of the genom ic and non-genom ic mechanisms might 
explain the differences in modulation of UVB induced inflammation.
Intriguing is the discrepancy between the potent antiproliferative effect of 
calcipotriol during antipsoriatic treatment5 and the absence of such an effect in the 
present study. In the present model, the absence of the antiproliferative effect of 
calcipotriol is reflected in an increased thickness of the epiderm is whereas clobetasol 
decreased the thickness of the epiderm is substantially. Previously it was shown that 
calcipotriol inhibits ornithine decarboxylase activity following tape-stripping, which 
demonstrates that calcipotriol interferes with growth control also in an acute model for 
cutaneous hyperproliferation . 24 The failure to inhibit recruitment of cycling cells in UVB 
induced inflammation suggests that it is not the recruitment process in itself that is the 
therapeutic target but that the reduction of epidermal hyperproliferation as reached in 
the treatment of psoriasis may result from other changes. The selective effect of 
calcipotriol on the number of transglutam inase positive cell layers and the total number 
of cell layers in UVB induced inflammation demonstrates that calcipotriol was available in 
sufficient quantities below the stratum corneum to have a cell-biological effect in the 
present study.
At the placebo treated sites UVB induced epidermal T-cell accumulation tended to 
be increased as compared to UVB induced epidermal T-cell accumulation at control sites. 
Although UVB induced erythema was not enhanced due to placebo ointment, increased 
epidermal T-cell accumulation might reflect an irritating effect of the placebo ointment, 
all the more because erythema and T-cell accumulation in the epiderm is proved to be 
significantly correlated in this study. These findings are in line with the reported irritancy 
of the placebo ointm ent in calcipotriol stud ies .2 ,2 1
The use of potent corticosteroids in clinical practice is limited by their side-effects. 
Persisting local side-effects like striae and skin thinning are mainly the result of dermal 
atrophy but epidermal thinning may give insight into atrophogenicity in general.25 In the 
present study clobetasol had a significantly decreasing effect on the total number of cell 
layers in the epidermis. This reconfirms our knowledge on the atrophogenicity of 
clobetasol. The significant increase of the number of cell layers in calcipotriol treated skin 
area versus the untreated and placebo treated skin has been documented before .26 The 
occurrence of these effects, already within four days of treatment, indicates the rapidity 
of clobetasol and calcipotriol induced modulation of epidermal thickness.
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Correlation analysis revealed that recruitment of cycling epidermal cells is a 
process that is closely associated with all parameters investigated in this model, which 
implies that recruitment of cycling epidermal cells is a general reflection of the response 
of the skin to UVB.
The present study reconfirms the potent effect of topical corticosteroids on UVB 
challenged skin and the failure of calcipotriol to modulate the cutaneous response to UVB.
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4.1. THERAPEUTIC APPROACH TO ERYTHRODERMIC PSORIASIS; THE REPORT OF 
A CASE AND A DISCUSSION OF THERAPEUTIC OPTIONS
4.1.1. Summary
In this case report a patient with therapeutically recalcitrant erythroderm ic 
psoriasis is presented. After various attempts with several major therapies in this patient, 
the first substantial improvement was achieved using the combination of cyclosporin and 
calcipotriol, followed by the combination of UVB and calcipotriol.
In this paper the therapeutic options for severe psoriasis are discussed and since 
combined approaches seem to be an attractive alternative for severe psoriasis 
mechanisms of synergy of combined therapeutic approaches are hypothesised.
4.1.2. Introduction
Erythroderm ic psoriasis is a rare but dramatic condition. As a result of a trigger of 
any kind, psoriasis can become unstable and can extend until the whole skin is 
erythematous and scaly. In general, system ic treatment of erythroderm ic psoriasis is 
inevitable and patients should be admitted at the inpatient department.
Well-established therapeutic options for severe psoriasis, including erythroderm ic 
psoriasis, are methotrexate, acitretin and cyclosporin. However, the therapeutic response 
in patients with the erythroderm ic psoriasis may be variable and sometimes 
disappointing. The search for the appropriate therapy is time-consum ing. Often a 
combination of system ic and local therapies will provide the eventual remedy for the 
patient after several weeks of intensified supervision.
The aim of this report is to present a case, indicating the therapeutic problems 
during treatment of erythroderm ic psoriasis.
4.1.3. Case report
An 83-year-old erythroderm ic man was admitted to our hospital. A t dermatological 
investigation generalised erythema and extensive scaling was observed all over the body 
(figure 1), face, scalp, palms and soles. Histopathological investigation of the skin 
showed a chronic, non-specific dermatitis w ithout signs of lymphoma or psoriasis. At 
general investigation we saw a dyspnoeic man with oedema on both lower legs. The body 
weight was 63 kg. No enlarged lymphnodes were palpable. No additional abnormalities 
were observed except for pre-existent gal-stones. Blood-tests, X-thorax, ECG, CT-scan of 
thorax and abdomen, X-colon did not reveal any internal pathology. Especially no 
evidence existed for malignancy. Serum l,25(O H)2 vitam in D3 and 25 OH vitam in D3 
were 70 pmol/l and 50 nmol/l respectively which were in the normal range.
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Fig. lE ryth roderm ic skin and extensive scaling all over the body, at the moment of 
admission to hospital.
The patient had had psoriasis vulgaris for five years. The condition could be 
controlled up to six months prior to admission. A first exacerbation was treated with tar- 
UVB and calcipotriol but four months later, the psoriasis flared again resulting in 
erythroderma. The patient was admitted to a hospital elsewhere and was treated with 
potent topical corticosteroids such as clobetasol 17-propionate and different systemic 
therapies; each of these only for a short period. Acitretin had been given for three weeks, 
methotrexate for two weeks and oral corticosteroids also
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for two weeks without any substantial improvement. No factors were found that could 
have triggered this exacerbation of psoriasis. There was no history of infections or 
malignancy.
As the expression of psoriasis was extremely severe and unresponsive to various 
treatments, the patient was transferred to the university hospital. We started therapy 
with acitretin (20mg/day) and hydrocortisone (1% in petrolatum) topically. Water-salt- 
balance normalised; furosemide 40 mg daily was given to control oedema and dyspnoe. 
Protein loss due to scaling was compensated with the appropriate diet. After four days 
the dose of acitretin was increased to 30mg/day. Because of no improvement after 
another four days cyclosporin (3mg/kg/day) was added. This resulted only in a minor 
improvement after three weeks, subsequently the dose of cyclosporin was increased to 
4mg/kg/day. After another week acitretin was stopped and cyclosporin was again 
increased to 5mg/kg/day. The skin condition in the patient still did not improve. Then it 
was decided to start local calcipotriol on the right side of the body whilst continuing 
cyclosporin. The calcipotriol-treated side showed a remarkable improvement compared to 
the other side which was treated with bland emollients (figure 2). After one week the 
whole body was treated on alternate days with calcipotriol twice daily up to 1 0 0  grams 
per week. On the remaining days of the week bland emollients were applied. As the 
quantity of calcipotriol ointment approximated 1 0 0  grams per week calcium and 
phosphate in the serum were measured at weekly intervals.
Fig. 2 Remarkable improvement on the right side of the body due to calcipotriol on this side 
combined with systemic cyclosporin.
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The condition of the skin improved markedly within four weeks. Meanwhile, after 
treatment with cyclosporin for two months, the serum creatinin increased and the patient 
developed a tremor of an unknown origin that could have been a side-effect of 
cyclosporin. These symptoms necessitated discontinuation of cyclosporin. As an 
alternative to cyclosporin, phototherapy with a low dose UVB in combination with local 
calcipotriol was started. The patient responded well to this treatment and was discharged 
from hospital in a reasonable condition after one month phototherapy. Phototherapy in 
combination with local calcipotriol was continued at the out-patient department for about 
four months. So far the condition of the patient remains excellent w ithout any psoriatic 
lesion up till six months after discharge from hospital.
During the various treatments, apart from the transient increase of serum 
creatinin and the temporary tremor during cyclosporin, no side-effects occurred. Serum 
calcium and phosphate remained in the normal range.
4.1.4. Discussion
Before deciding on the strategy of the treatment the underlying cause of the 
erythroderma has to be established. Histopathological investigation is not always 
specific . 1 The history of a previous skin disease is an important lead to the diagnosis; 
25% of the cases is associated with psoriasis. Drugs, neoplasm and eczema account for 
the majority of the other known causes. In a substantial part of the cases no obvious 
cause is found . 2 In case the nosological identity of the erythroderma remains unknown, 
further internal investigation is required to exclude paraneoplasm .3
As erythroderma is a serious condition, fast improvement is urgently wanted. 
Topical treatments with potent corticosteroids may be useful, however, as the patient 
described in this report had been treated elsewhere already with potent corticosteroids 
(clobetasol 17-propionate), a weak steroid preparation was prescribed in order to prevent 
system ic complications. System ic treatment is often necessary but is sometimes already 
changed if no response is observed after a few days. Also in the present case, various 
short treatments were initiated without allowing a sufficient treatment period for an 
antipsoriatic result. One may argue that the period of one week acitretin monotherapy 
might have been too short to induce a significant improvement. However the severity of 
the erythroderma required a fast therapeutic effect, hence the combined approach.
Combinations of the major therapies for psoriasis are an attractive option since 
some combinations allow a lower dose than used in monotherapy which reduces side- 
effects. The combination of methotrexate and etretinate is controversial in view of 
hepatotoxity ; 4 ,5 the
120
combination of etretinate and cyclosporin has been used with success in psoriasis .6 ,7  
From a theoretical point of view the immunosuppressive effect of cyclosporin and the 
differentiation modulating effect of retinoids is a promising combination. Oral retinoids 
have also been combined successfully with UVB or PUVA (re-PUVA ) . 8 ,9 Combination of 
two immunosuppressive therapies like methotrexate and cyclosporin is not 
recommended . 10
Another, practical approach is the combination of system ic and topical therapy. 
After various attempts with several major therapies in this patient including the 
combination of cyclosporin and acitretin, the first substantial improvement was achieved 
using the combination of calcipotriol and cyclosporin. In the past emollients, tars and 
topical steroids have been used in combination with system ic therap ies .11 Nowadays, the 
vitam in D3 analogue calcipotriol is available. Its beneficial effect as a monotherapy in 
mild to moderate chronic plaque psoriasis has been well-established .12 However, 
calcipotriol m ight irritate the skin in about 20% of the patients .13 In particular patients 
with erythroderm ic psoriasis are susceptible to low doses of irritants. On the other hand, 
patients with unstable and erythroderm ic psoriasis have been reported to respond well to 
calcipotrio l . 1 4 ,1 5 In the present case the maximum quantity of 100 gram calcipotriol 
ointment per week was not exceeded. As serum vitam in D3 levels were normal it was 
excluded that this patient m ight have had a vitam in D3 deficiency.
The skin is site of production of vitam in D3 and target of its active metabolite: 
la,25-dihydroxyvitam in D3 . 16 Vitam in D3 receptors, member of the steroid-hormone- 
receptor super-fam ily, are found in the epiderm is .1 7 The therapeutic mode of action of 
vitam in D3 and its analogues in psoriasis is partly via these receptors which regulate gene 
transcription and partly through non-genom ic m echanisms .18 Calcipotriol inhibits 
proliferation and induces term inal differentiation in cultured human keratinocytes .19 In 
vivo these effects are observed as w ell .20 Immunomodulating effects of calcipotriol are 
also described; inhibition of T-cell proliferation in response to interleukin 1 in vitro21 and 
reduction of interleukin 6  in a psoriatic plaque in vivo in response to calcipotrio l .22
In literature both cyclosporin2 3 and UVB2 4 ,2 5 have been combined successfully with 
calcipotriol in psoriatic patients. In particular low dose cyclosporin (2mg/kg/day) in 
combination with calcipotriol proved to be an effective and safe approach .23 From a 
theoretical point of view it is attractive to speculate that calcipotriol-cyclosporin is a 
useful combination. The modes of action of cyclosporin and la,25-dihydroxyvitam in D3 
and its analogues are thought to be com plem entary .26 " 28 Recently several investigators 
have demonstrated the synergistic effects of both antipsoriatic therapies. Calcipotriol can 
potentiate the immunosuppressive effect of cyclosporin in mixtures of human lymphatic 
and epidermal ce lls . 29 The effect of cyclosporin on interleukin 2 is increased by 
ca lc itrio l . 26 -2 8 On the other hand the differential effect of both treatments on epiderm is
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and immune system might explain the synergistic effect .3 0 ,3 1 When cyclosporin treatment 
was not possible anymore in our patient due to increase of serum creatinin, UVB in 
combination with calcipotriol was applied successfully. In literature there is still no 
clearness about synergy of UVB and calcipotriol in psoriasis .2 4 ,2 5 But the remarkable effect 
of the combination in this patient suggests that in some cases synergism might occur.
In case of erythroderm ic psoriasis, the therapeutic strategy often includes 
system ic treatment. Options are monotherapy with acitretin, cyclosporin or methotrexate. 
The choice depends on indications and contraindications in the individual patient. In the 
present case of persisting erythroderma, combination therapy of cyclosporin plus 
calcipotriol and subsequently UVB plus calcipotriol proved to be a successful approach.
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4.2. IN-PATIENT TREATMENT WITH CALCIPOTRIOL VERSUS DITHRANOL IN 
REFRACTORY PSORIASIS
4.2.1. Summary
Calcipotriol (50 i-ig/g) ointment recently became available for the treatment of 
psoriasis. Calcipotriol has been shown to be superior to home treatment with dithranol. 
The time-honoured regime of topical treatment with dithranol in paste or petrolatum for
24 hours at the in-patient department is the golden standard of optimal efficacy of 
antipsoriatic therapy. This treatment regime is adopted in case of insufficient control of 
psoriasis by out-patient treatments.
The aim of the present study was to challenge the position of in-patient dithranol 
treatment. A  left-right comparative case-control study was designed in ten patients with 
refractory psoriasis, comparing classical dithranol treatment and calcipotriol treatment at 
the in-patient department.
In contrast to what was expected, six of the ten patients showed a more 
pronounced improvement after two weeks at the calcipotriol treated sides. Irritation from 
calcipotriol was observed in four patients after one week and in two after two weeks 
treatment. At the dithranol treated sides three of the ten patients showed a better 
improvement. Four patients experienced irritation after one week and eight patients after 
two weeks. Irritation due to calcipotriol was not associated with an increased irritation 
due to dithranol, which implies that both treatments have a different mechanism of 
irritation.
The present case-control study indicates that calcipotriol has challenged the 
untouchable superiority of classical in-patient treatment with dithranol. Further studies 
are indicated to improve compliance of out-patient calcipotriol treatment by cream 
formulations and once a day schedules.
4.2.2. Introduction
Chronic plaque psoriasis can be treated with various out-patient therap ies .1 
However, in patients with extensive, therapy resistant and severely disabling psoriasis it 
is our policy to adm it the patient to the in-patient department. For this group of patients 
with refractory psoriasis dithranol so far has been the therapy of first choice at our in­
patient department. In case lesions prove to be resistant against this treatment or in case 
new lesions continue to appear or in case of severely itching psoriasis various 
combination approaches are indicated.
Dithranol is a very safe and effective therapy .2 Previously, dithranol has been used 
in petrolatum 3 ,4 and Lassar's paste . 5 B ioavailability varies significantly with its 
vehicu lum . 6 Irritation
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of the skin and discoloration of the skin and textiles have always been lim iting its use .7  
For home treatment dithranol in a cream base has been developed which is easier to 
apply and wash off and therefore proved to be more acceptable for the patient to use at 
hom e . 8 A  disadvantage is the lower efficacy of this mode of dithranol treatm ent .2,8 In­
patient treatment with dithranol in paste or petrolatum, however, is the golden standard 
of this time-honoured therapeutic approach, resulting in clearing of psoriasis in more 
than 90 % of the patients within three to five weeks tim e .2 Dithranol in a cream base at 
the out-patient department only results in clearing in 10-35 % of the patients in seven to 
eight weeks tim e . 2
The last decade vitam in D3 analogues have been shown to have an important 
antipsoriatic effect .9 " 12 Recently calcipotriol 50ng/g in ointment (DaivonexR, LEO 
Pharmaceutical Products) became available as a routine treatm ent .13 Several comparative 
studies on the efficacy of calcipotriol and the classical antipsoriatic therapies have been 
carried out to elucidate and establish the position of calcipotriol in dermatology. 
Betamethasone 17-valerate14 and short contact dithranol treatment15 have been 
compared to calcipotriol for its efficacy and safety. Calcipotriol proved to be equally 
effective compared to betamethasone 17-valerate. Remarkably, home treatment with 
calcipotriol appeared to be more effective compared to home treatment with short 
contact dithranol in a cream base.
In the present study the efficacy of treatment with dithranol and calcipotriol was 
compared in a group of patients with severe, therapy resistant and disabling psoriasis 
who were, for this reason, admitted to our in-patient department.
The aim of the present orientation is to challenge the common believe that 
dithranol is the treatment of first choice in severe psoriasis. In particular we addressed 
the follow ing questions:
i) Does calcipotriol have a beneficial effect in severe psoriasis to the extent that
dithranol is effective?
ii) Which aspects lim it the use of calcipotriol in severe psoriasis?
As this study involves patients with severe psoriasis we set out a two week left- 
right comparative case-control study to explore the first two weeks of the in-patient 
treatment phase with calcipotriol and dithranol in Lassar's paste or in petrolatum.
4.2.3. Materials and methods
Patients
The investigation was carried out at the in-patient department. Patients with 
extensive and disabling plaque psoriasis, resistant to topical therapy, were admitted and 
included in the study.
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Four males and six females were included with an age ranging from 20-72 years and with 
a duration of their psoriasis ranging from 3-53 years. The patients had used no oral 
treatment for psoriasis within six weeks prior to the study except for one patient who had 
used fumaric acid. Topical treatment was allowed until the date of submission to the 
hospital. Table I summarises the treatments for psoriasis of the patients during six weeks 
prior to admission. No oral medication was allowed that could influence the course of 
psoriasis. Hydroxyzine was allowed for those patients with severe pruritus. No additional 
topical nor system ic treatment for psoriasis was permitted during the trial except for 
corticosteroids at the scalp and the face.
Table I Previous therapy
Therapy 6 weeks prior to # 
study
No therapy 1
Topical steroids 5
Calcipotriol 4
Tar 1
Fumaric acid 1
Phototherapy 1
Dithranol 1
Approach
Patients were treated during two weeks using a left-right w ithin-subject 
comparison. One side of the body was treated with dithranol paste or petrolatum and the 
other side with calcipotriol. Which side of the body was treated with what therapy was 
randomly chosen. The regimen for dithranol consisted of 24 hour application of dithranol 
paste or petrolatum in increasing concentrations ranging from 0.05-4%. The 
concentration of dithranol was increased at alternate days. Calcipotriol was applied twice 
daily on lesional skin with a maximum of 100 grams per week. Individualisation of the 
treatment by adjunct therapies was postponed till after the two week's evaluation. The 
clinical scores were recorded before and after one and two weeks of therapy. Extent and 
severity of the disease were recorded as shown in table II.
Table II Scoring for extent and severity of disease
i) Extent of disease ii) Severity
0  - no involvement 0  - no involvement
1  - < 1 0  % 1  - slight
2 - 10-29 % 2 - moderate
3 - 30-49 % 3 - severe
4 - 50-69 % 4 - severest
possible
5 - 70-89 %
6  - 90-100 %
127
The extent of the disease was scored in percentage of involvement of the skin. 
This percentage was transposed into an area score. Arms, trunk and legs were scored 
separately. The severity of erythema, induration, scaling and pruritus was assessed using 
a 5 point-scale (table II). After one and two weeks of treatment the skin-irritation as a 
result of therapy was recorded using the 5 point scale. PASI-scores were calculated 
according the formula in table III.
Table III PASI-score
Calculation of the PASI-score__________________________________
PASI = 0.2 x A arms x X(E+I+S) + 0.3 x A trunk x X(E+I+S) + 0.4 x A legs x
X(E+I+S)
A = Area score
X(E+I+S) = Sum of scores for Erythema, Induration and Scaling
Statistical analysis
Changes in clinical scores and comparisons between the two body-sides of the 
same patients were analysed using the Student t-test for paired values.
To obtain insight in correlation between different parameters which characterise 
the disease a regression analysis was performed (Pearson-r).
4.2.4. Results
At the start of the study severity-scores of both body-sides were comparable; the 
average PASI-score was 17.1 ± 2.1 (mean ± SEM) for the whole body. Both treatment 
regimens induced a statistically significant decrease in PASI-scores after one week of 
treatment (p = 0.0005 for calcipotriol and p = 0.0003 for dithranol). In the second week 
of treatment there was a significant further decrease of the PASI-score (p = 0.03 for 
calcipotriol and p = 0.03 for dithranol) compared to scores after one week. The 
calcipotriol treated side tended to respond slightly better to therapy than the dithranol 
treated side but this difference is not statistically significant (p = 0.08).
Figure 1 illustrates the difference (A) between the PASI-score before and after one 
and two weeks treatment of the calcipotriol and dithranol treated body-sides of the 
individual patients. Before treatment the PASI-scores at both body-sides were equal 
except in one patient (patient 8 ). After one week of therapy, however, three patients 
showed a therapy response in favour of dithranol and five patients showed a therapy 
response in favour of calcipotriol. Two patients showed no difference between the two 
therapies. After two weeks of therapy six patients responded better to the calcipotriol 
therapy and three patients responded better to the dithranol therapy. In one patient 
there was no difference in response to both therapies.
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Pruritus was experienced in eight out of ten patients before treatment. Prior to 
therapy there was no difference between the two body-sides. The scores for pruritus are 
relatively high for psoriasis (2.0 ± 0.4)(mean ± SEM). After one week of therapy a 
significant decrease of pruritus was experienced at the calcipotriol treated sides (p =
0.003) as well as at the dithranol treated sides ( p = 0.005). In the second week of 
treatment the scores for pruritus still tended to decrease. Calcipotriol was significantly 
better than dithranol in reducing pruritus (p = 0.04 after one week of treatment and p =
0.04 after the second week of treatment).
Fig. IDe lta  PASI-score (calcipotriol minus dithranol) before (£|, after one ( )
and two (□ ) weeks
treatment.
After one week of therapy irritation was seen on both body-sides due to both 
therapies, but there is no significant difference between the two therapies. The initial 
irritation of calcipotriol tended to decrease in the period between one and two weeks. 
Two out of four patients indicated that irritation had decreased during continued 
treatment with calcipotriol: the irritation as a result of dithranol treatment increased 
significantly in the second the week of therapy (p = 0.01). After two weeks of treatment 
the mean score for irritation due to dithranol was significantly higher than the score for 
treatment with calcipotriol (p = 0.006). There was no correlation between the scores for 
irritation on both body-sides in each patient after either one or two weeks of treatment. 
Regression analysis revealed that there was no association between pruritus before 
therapy and irritation as a result of two weeks of therapy for either calcipotriol or 
dithranol.
129
The mean duration of the in-patients treatment was 5.5 ± 0.7 (mean ± SEM) 
weeks. After the two weeks comparative study coal tar treatment was added in five 
patients, phototherapy with ultraviolet B was added in five patients and 
photochemotherapy in one patient. In three patients oral treatment with acitretin had to 
be added in order to enhance clearing. Out of these patients with difficult psoriasis four 
patients reached total clearing and the other six patients a substantial improvement.
4.2.5. Discussion
Most of the investigations on the efficacy and side-effects of calcipotriol deal with 
mild to moderate chronic plaque psoriasis . 1 However Beth-Jones et al.16 reported a group 
of patients with extensive psoriasis; PASI: 18 ± 8 . 8  (mean ± SEM). A  four week 
treatment period with calcipotriol ointment at home had resulted in a reduction of the 
PASI-score to 7.0 ± 2.0 (mean ± SEM)(61% reduction). Dubertret et a l .1 7 reported a 
reduction of the PASI-score from 14.2 ± 7.5 (mean ± SEM) to 8 . 6  ± 7.5 (mean ± 
SEM)(39% reduction) after two weeks treatment at home with calcipotriol ointment. In 
the present study the PASI-scores at the calcipotriol treated sides dropped from 8.3 ± 1.0 
(mean ± SEM) to 2.9 ± 0.4 (mean ± SEM)(6 6 % reduction). The difference between the 
present study and the other studies in extensive psoriasis1 6 ,1 7 is the setting at the in­
patient department in the present study and the setting of home treatment in the latter 
studies. Our figures are indeed analogous to another in-patient study on calcipotriol in 
which patients were treated during two weeks with a high dose calcipotriol and decrease 
in PASI-score of 71% was seen . 18
Even a more pronounced discrepancy has been observed as to the efficacy of 
dithranol treatment carried out at in-patient departments and home treatm ent .2 Dithranol 
treatment at the in-patient department has been shown to result into a clearing in 80­
1 0 0 % of the patients19, whereas dithranol treatment at home resulted into a clearing in 
6-56% of the patients . 2 0 ,2 1
Four out of ten patients in the present study had been treated with calcipotriol 
before at home without a satisfactory improvement. In these patients in-patient 
treatment with calcipotriol resulted in a substantial improvement. The most feasible 
explanation for the pronounced discrepancy between the in-patient and out-patient 
setting is compliance.
A  comparison between home treatment with short contact dithranol and 
calcipotriol revealed that calcipotriol is superior with respect to clinical efficacy compared 
to d ithranol . 15 Comparing dithranol treatment at the in-patient department with 
calcipotriol at the in-patient department a tendency for superiority of calcipotriol above 
dithranol was observed in the majority of the patients in this case-control study. A 
statistically significant superiority of calcipotriol was
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shown with respect to pruritus. These observations challenge the common believe that 24 
hour application of dithranol in Lassar's paste or petrolatum is superior to any other 
topical treatment.
Irritation of lesional and perilesional skin was observed in four patients at the 
calcipotriol treated sides after one week's treatment. The irritation tended to decrease 
after two weeks treatment. In contrast to the habituation to calcipotriol17, dithranol 
irritation tended to increase after two weeks of treatment. Irritation as a result of 
dithranol is supposed to be essential for its antipsoriatic effect but is also a less 
appreciated adverse event. The concentration of dithranol is increased by the tolerance of 
the individual patient. No correlation could be shown between dithranol irritation and 
calcipotriol irritation which suggest that the mechanism of irritation is different. It is of 
interest that those patients who experienced pruritus before treatment were not 
predisposed to develop irritation to calcipotriol or dithranol. It is striking to see that 
calcipotriol had a better effect on pruritus than dithranol in this group of patients.
In the present study the second phase of the in-patient treatment after the two- 
week investigation was difficult to evaluate as the strategy was to individualise treatment 
using combinations which were most fit for the individual patient.
From this study it may be concluded that calcipotriol treatment at the in-patient 
department, carried out with care and precision is highly effective to the extent that it 
challenges the time-honoured 24 hour applications of dithranol. It is attractive to 
hypothesise that the development of cream formulations and once a day schedules to 
improve compliance for calcipotriol m ight dim inish the gap between efficacy of home 
treatment and treatment at the in-patient department.
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4.3. LONG-TERM EFFICACY AND SAFETY OF ONCE DAILY TREATMENT WITH 
TACALCITOL OINTMENT IN CHRONIC PLAQUE PSORIASIS
4.3.1. Summary
Tacalcitol (Curatoderm 4 ng/g ointment, once daily) has been shown to be effective 
and safe in the treatment of patients with chronic plaque psoriasis in a double-blind placebo 
controlled study. A group of 58 patients who had previously responded to tacalcitol, 
continued therapy with tacalcitol ointment. In the present communication, efficacy, safety 
and tolerance of this drug are reported during long-term application.
During a continuous treatment period of half a year (22 patients), during a 
treatment of one year (9 patients) and during a treatment of 60 weeks (3 patients) the 
degree of clinical improvement maintained comparable to the efficacy confirmed at the end 
of the double-blind short-term study. By 8  out of the 58 patients irritation of the skin or a 
burning, itchy sensation was experienced. However, no single patient had to discontinue 
treatment for this reason.
Safety parameters did not show clinically relevant changes. In particular serum 
calcium and phosphate and nocturnal urine alpha-l-m icroglobulin remained unaffected by 
prolonged treatment.
In conclusion, tacalcitol is a well-tolerated and effective antipsoriatic treatment for 
long-term control of psoriasis. It is indicated that further long-term efficacy and safety 
studies are carried out in patients with extensive psoriasis beyond the treatment period of
2 0  weeks.
4.3.2. Introduction
Vitamin D3 analogues represent a major innovation of the treatment of psoriasis 
today . 1"4 During the last 5 years, the analogue calcipotriol (SQig/g) ointment has become a 
first line therapy for this indication. Calcipotriol treatment is well-appreciated, also for long­
term management of psoriasis, although irritation of the skin has been experienced by 25% 
of the patients and required discontinuation of treatment in approximately 6 % of the 
patients . 5,6
In Japan, tacalcitol (2ng/g, twice daily) ointment is a vitamin D3 analogue which has 
become the mainstay in the routine treatment of psoriasis .7 ' 10 Irritation following tacalcitol 
application was recorded in less than 1% . 7 " 10 The clinical efficacy of this formulation proved 
to be comparable to twice daily treatment with betamethason valerate lm g/g  ointm ent .11
Recently, an European dose-finding study was carried out to assess the optimal 
concentration and the clinical efficacy of a once daily application of tacalcitol (0.25-16ng/g 
ointment ) . 12 Concentrations above 4 ng/g did not enhance the antipsoriatic efficacy, 
whereas lower concentrations
133
than the optimum 4 ng/g were significantly less effective. A multi-centre placebo-controlled 
within patient left-right comparative study was performed in 1 2 2  patients to investigate 
clinical efficacy, side-effects and tolerance of this dosage regimen in Caucasian patients 
with chronic plaque psoriasis . 13 The once daily application of tacalcitol ointment (4ng/g) for
8  weeks proved to be an effective, safe and well-appreciated antipsoriatic principle.
The objective of the present study was to assess efficacy, safety and local tolerance 
of tacalcitol ointment 4 ng/g, applied once daily, in the long-term treatment. This study was 
carried out in patients who had previously participated in the placebo controlled study. In 
particular the following questions were addressed:
i. Can the clinical efficacy of tacalcitol ointment, as confirmed by the 8 -week placebo 
controlled study, be maintained during a long-term study?
ii. Does long-term use of this vitamin D3 analogue affect systemic safety parameters?
iii. What is the frequency and severity of irritation of the skin during long-term 
tacalcitol therapy?
iv. What is the overall judgement of patients and investigators regarding global 
improvement and usefulness of this treatment?
4.3.3. Materials and methods
An open, multi-centre prospective study was performed to assess efficacy, safety 
and local tolerance of tacalcitol (4ng/g ointment, once daily) in the long-term treatment of 
psoriasis. All patients had been included before in a w ithin-patient left-right placebo 
controlled study on efficacy and safety of a short-term treatment with the same tacalcitol 
formulation . 13 Upon completion of the double-blind phase and a follow up period of 4 
weeks, each patient, who had responded to tacalcitol before was invited to enter the long­
term phase.
Patient selection
Patients with chronic plaque psoriasis were enrolled at 3 academic centres. All 
subjects had already fulfilled the inclusion and exclusion criteria which were the same as for 
the 8 -weeks placebo controlled study . 13 In brief, patients of either sex, aged between 15 
and 80 years, females of childbearing age if they were using adequate contraception and 
patients with normal serum calcium or phosphate were included. Systemic or topical 
antipsoriatic therapy, other than tacalcitol treatment, over 2 months respectively 4 weeks 
prior to the start of the study, was an exclusion criterion. Other exclusion criteria were: 
serious diseases, known allergy for study medication, medication interfering
134
with the course of psoriasis or systemic calcium metabolism. All patients gave their written 
informed consent, prior to the study. Inclusion criteria for the long-term evaluation were: 
location of psoriatic lesions anywhere except the scalp for test-area, male and female, only 
post-menopausal females or females in fertile age giving written consent not to become 
pregnant during this study, patients who have given informed consent, patients who 
finished the right-left comparison on tacalcitol with a satisfactorily therapeutic result and 
who are interested in treating their psoriatic lesions with tacalcitol furthermore. Patients 
were permitted to treat the psoriatic lesions with a maximum of 2 0  tubes a 1 0 0  gr. per 
patient. The patients were permitted to discontinue treatment after a minimum of 12 weeks 
treatment. The maximum treatment period was 60 weeks. The patients had to be treated 
for at least 12 weeks; otherwise they were regarded as drop out. Patients discontinued 
treatment for reason of clearing, side-effects or on their own initiative.
Treatment
During the long-term phase all psoriatic plaques (except on the scalp) could be 
chosen as test areas. A maximum of 20 g tacalcitol ointment was allowed once daily.
Study Medication
The test drug tacalcitol ointment contains the active ingredient 1,24-dihydroxy- 
cholecalciferol (tacalcitol) at a 4^g/g concentration and the inactive ingredients paraffin oil, 
di-isopropyl adipat and white petrolatum. The preparations were filled in 100 g-tubes. 
Patients received a 4-weeks supply of study medication at start of the long-term period and 
again every four weeks
Efficacy assessments
At the start of the study (week 0) and subsequently every fourth week, clinical 
severity parameters were assessed by the investigator. The extent of the psoriatic test area 
was recorded as percentage of the total body surface and assessed at the baseline-visit and 
at regular visits. The symptoms: erythema, infiltration and scaling were recorded using a 5- 
point scale from 0 = 'none' to 4 = 'extremely severe'. At each visit, the symptoms 
erythema and scaling were compared to their initial severity. This condition was rated as 
'deteriorated', 'unchanged', 'slightly improved', 'moderately improved', 'markedly improved' 
or 'cured'. At the end of the study, a global assessment of efficacy was made by the 
investigator and by the patient. The assessment of efficacy was rated as 'very good', 'good', 
'moderate' or 'insufficient'. An assessment of usefulness was given by the patients at the 
end of the treatment on a 1 0 -point scale from the 1  = 'not useful at all' up to 1 0  = 
'extremely useful'.
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Safety assessment
The occurrence of any adverse event was recorded at each visit. These events were 
evaluated for duration, severity (slight, moderate or severe) and a possible relation to 
disease or drug. In particular, the investigator had to pay attention to any signs of 
irritation, skin rashes and their location, extent and severity.
A  global assessment of tolerance was given at the end of the treatment by the 
investigator and by the patient, rated as 'very good', 'good', 'moderate' or 'insufficient'. The 
patient's general condition was recorded at start of and at each visit during the long-term 
study. The assessment was rated as 'very good', 'good', 'moderate' or 'insufficient'. Clinical 
laboratory evaluation was carried out at baseline and at each visit. The haematology 
comprised counts of erythrocytes, leukocytes, platelets, haemoglobin, haematocrit, the 
biochemistry, serum calcium, inorganic phosphate, creatinin, ASAT, alkaline phosphatase 
and LDH. In one centre nocturnal urine alpha-l-m icroglobulin was assessed additionally.
Statistical analysis
Changes from the beginning of the long-term study were given by P-values of the 
Sign Test and by the Mann-Whitney statistics. The Mann-Whitney statistics was used to 
measure the size of the magnitude of this change:
P (during treatment > before treatment) = 0.50 indicates equality of the two series, 
P (during treatment > before treatment) = 0.56 implies a small effect, P (during treatment 
> before treatment) = 0.64 a medium sized effect and P (during treatment > before 
treatment) = 0.71 indicates a large effect . 14
4.3.4. Results
Demographic data
In total 58 patients, 18 women and 40 men, entered the long-term efficacy and 
safety study. The average age was 45 years, ranging between 19 and 78 years. Table I 
summarises demographic details in each of the centres.
Table I Demographic data
Number of 
patients
male/fem
ale
Age 
(mean ± SD)
Weight (kg) 
(Mean ± SD)
Height (cm) 
(Mean ± 
SD)
Centre
1
42 29/13 45+ 10.9 80.8+13.4 176.3 + 7.8
1
Centre 7 4/3 36.4+13.9 76.1 ± 16.3 174.1 ± 12.4
Z
Centre
3
9 7/2 47.1 ± 8 . 6 80.1 ± 13.4 177.1 ± 9.2
Total 58 40/18 44.5+11.2 80.1 ± 13.6 176.1 ± 8 . 6
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Patients details
All patients suffered from chronic plaque psoriasis. At the beginning of the previous 
double blind phase, the duration of psoriasis since the first outbreak was 225 ± 157 months 
(mean ± SD) and since the last attack 130 ± 80.4 months (mean ± SD). The time interval 
between the end of the double-blind phase and start of the long-term study was 4.4 ± 2.6 
weeks (mean ± SD). The extent of the psoriatic lesions at the beginning of the double-blind 
phase was 9.7% ± 3.3 (mean ± SD) and at the beginning of the long-term study 8 .6 % ± 
3.9 (mean ± SD). At the beginning of the double-blind phase the sumscore was 8.9 ± 1.5 
(mean ± SD) and at the beginning of the long-term study 7.9 ±2.1 (mean ± SD).
Disposition of patients
Out of the patients, who had been included in 14 centres during the double-blind 
phase, in total 58 were enrolled at the three centres for the long-term efficacy and safety 
evaluation.
Reason for termination Number of patients
(%)
According protocol 43 (74%)
Insufficient efficacy 7 (12%)
Prohibited concomitant 3 (5%)
therapy*
Non-compliance 2 (3%)
Other 3 (5%)
♦Topical corticosteroids (n=2)
and non-steroidal anti-inflammatory drugs (n=l)
The duration of the long-term efficacy study for all patients was 24.8 ± 17 weeks 
(mean ± SD). Table II summarises reasons for termination of the long-term treatment. In 
no single patient, clearing was the reason for termination. In 5 patients the test drug was 
not applied permanently throughout the study and in 6  patients the last examination was 
1-4 weeks following the discontinuation of the treatment. No correlation was observed 
between the severity scores before start and the subsequent duration of the long-term 
treatment.
Patients who had a more extensive involvement of body surface were treated 
relatively shorter compared to patients with a more moderate involvement (figure 1). The 
correlation was statistically significant (r = 0.32; p < 0.01).
Clinical efficacy
The percentage of bodysurface involved with psoriasis decreased during the first 36 weeks 
of the long-term treatment. Already after 4 weeks a highly significant reduction of the 
affected test areas
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was reached compared to the baseline (p = 0.0013). It should be noted that the extent of 
psoriatic lesions at start of the long-term study was lower compared to the extent of lesions 
before start of the double blind phase. Figure 1 illustrates the reduction of the extent of 
lesions during treatment compared to the pre-treatment values for each subpopulation still 
on active treatment at the time of each visit.
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Fig. 1 The extent of psoriatic lesions before treatment (-0-), during treatment (- -) and before 
the previous double blind phase (-A -) * P < 0.005, ** P < 0.0001, *** P < 0.00001.
The sumscore defined as the sum of the scores for erythema, infiltration and scaling 
decreased throughout the long-term study by 2 score points. The reduction of the sumscore 
compared to the baseline sumscore at the start of the placebo-controlled study (8.9 ± 1.5) 
was 3 score points. After 8  weeks treatment the maximum improvement of the sumscore 
was reached and maintained during subsequent treatment. According to the Mann-Whitney 
statistics, this reduction of the sumscore can be considered as a large effect (p< 0.0001; P 
(during treatment > before treatment) > 0.84). Erythema, induration and scaling all 
decreased during the treatment period.
Ì
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Global assessment of efficacy by investigators and patients is summarised in table 
III. In 84% the assessments of investigator and patient were conform. The usefulness of 
the therapy, as assessed by the patients on an analogue 1 0 -point scale (0 - 1 0 ) was 
assessed as 7 (median).
Efficacy
Assessment
Assessment of efficacy by
Investigai
or
% Patient %
very good 6 10.3 9 15.5
good 28 48.3 24 41.4
moderate 2 1 36.2 19 32.8
insufficient 3 5.2 6 10.3
valid number 58 1 0 0 58 1 0 0
Adverse events/unwanted events
For 15 out of the 58 patients adverse events were reported. Table IV summarises 
these events. All extracutaneous adverse events were considered to be unrelated to 
psoriasis or study medication.
Table IV Adverse events in 58 patients (n.s. = not specified)
Unwanted event Number of patients Severity
Headache 2
mild moderate severe 
2
n.s.
Abdominal pain 1 - - 1 -
Myalgia 1 - 1 - -
Costal confusion 1 - 1 - -
Pain left hip 1 - 1 - -
Common cold 1 1 - - -
Flu, sinusitis 1 - - 1 -
Erysipelas 1 - - 1 -
Burning sensation 3 - 3 - -
Itching, pain 3 1 - 2 -
Irritation 2 1 1 - -
Urticaria 1 - - - 1
Burning sensation (3), itching/pain (3) and irritation (2) were considered to be due 
to either psoriasis or the study medication. These symptoms did not increase in severity 
during treatment. In 2 patients these cutaneous adverse events were considered as severe, 
in 4 as moderate and in 2 patients as mild. In none of the patients treatment was 
discontinued for reason of these events.
Table V Global assessment of tolerance by investigator and patient (Total N = 58)
Tolerance Assessment Assessment of tolerance by
Investigato % Patient %
very good 36 62.1 34 58.6
good 21 36.2 22 38.0
moderate 1 1.7 1 1.7
insufficient - - 1 1.7
valid number 58 1 0 0 58 1 0 0
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The global assessment of tolerance by the investigators and patients is summarised 
in table V. The investigators and patients considered tolerance as good or very good in 98% 
and 96% of the patients respectively. The general condition of the patients was considered 
as good throughout the long-term study.
Laboratory assessments
Laboratory investigations did not reveal any change of clinical importance. The sign 
test did not show a significant change of the haematology values compared to baseline 
except for a transient increase of platelets after 12 weeks (p = 0.004) and after 52 weeks 
(p = 0.04). With respect to biochemistry values, the sign test indicated no abnormalities 
except for an increase of ASAT after 20 weeks (p = 0.03). The levels of serum calcium, 
phosphate, creatinin and nocturnal urine alpha-l-m icroglobulin are illustrated in figure 2 a- 
d. In no single patient hypercalcaemia was observed. Except for serum calcium after 8  and
2 0  weeks of treatment, no statistically significant change in serum calcium levels was 
demonstrated. The Mann-Whitney statistics indicated positive effects, i.e. a decrease of 
serum calcium during treatment compared to the levels at the beginning of the long-term 
study.
In one patient serum phosphate had increased up to 1.5 mmol/l. After 36 weeks, 
serum creatinin increased above baseline according to the sign test. In 8  patients, serum 
creatinin levels had been above normal between start and study week 12. The sign test had 
not revealed any change from baseline at any time of the long-term investigation with 
respect to nocturnal urine alpha-l-m icro-globulin. In one patient, who suffered from 
hypertension since 1980, values above normal were seen throughout the long-term study, 
except at weeks 12 and 24.
Fig. 2 a Serum calcium during treatment with tacalcitol.
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Fig. 2 b Serum phosphate during treatment with tacalcitol.
Fig. 2 c Serum creatinin during treatment with tacalcitol.
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Fig. 2 d Nocturnal urine alpha-l-m icroglobulin during treatment with tacalcitol.
4.3.5. Discussion
The present study demonstrates that tacalcitol has a maintained efficacy 
antipsoriatic during long-term treatment and is well-tolerated.
Out of 14 centres which participated in the initial placebo controlled study, 3 centres 
carried out the long-term efficacy and safety study. Out of the patients who had previously 
been included in these three centres, 58 patients wanted to continue the treatment with 
tacalcitol. Such a desire is in line with the facts that 60% of the patients indicated that the 
efficacy was good to very good and that 95% of the patients indicated the tolerance as 
good or very good. Nearly half of the patients (n = 26) remained on continuous treatment 
for more than 20 weeks with a maximum treatment period of 62 weeks (n = 3). All but 5 
patients were on continuous treatment without intermissions. A statistically significant 
correlation, was observed between the extent of psoriatic lesions before treatment and the 
duration of the treatment.
At week 28, the most pronounced reduction of the extent of psoriatic lesions was 
observed. However, the reduction of psoriatic lesions was statistically significantly less in 
those patients with a more extensive involvement. A possible explanation might be that 
accurate ointment applications in extensive psoriasis are more difficult and that the 
intensity of ointment applications is critical during treatment with tacalcitol.
The efficacy assessment during the present long-term study is uncontrolled. The 
placebo controlled efficacy assessment has been reported before .13 The percentage of 
bodysurface involved
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with psoriasis reduced by only 1% during the placebo controlled study. In the present 
study, however, the area of involvement reduced substantially, which reached statistical 
significance from week 4 onward (p < 0 .0 0 1 ) and became more apparent after 1 2  weeks of 
treatment (p < 0.00001). The reduction of the sumscore compared to the baseline score 
before starting the double blind phase was on average 4 score points during the 8  weeks 
short-term study, whereas the reduction during the long-term study in comparison to the 
score at the start of the double blind phase was 3 score points. Therefore, prolonged 
treatment does not improve the sumscore of the individual beyond the reduction as 
reached during an 8  weeks' treatment. However, prolonged treatment causes a significant 
reduction of the body surface of psoriatic involvement. The maintained antipsoriatic efficacy 
without signs of habituation is in line with the efficacy characteristics of long-term 
administration of the vitamin D3 analogue calcipotriol.5,6 So far, a quantitative comparison 
of clinical efficacy and safety between different vitamin D3 analogues is not possible as data 
are not available. Long-term treatment with tacalcitol ointment was judged by investigator 
and patients as good or very good in 58% and 57% of the patients respectively. Long-term 
treatment with this drug in the present series of patients can be regarded as a safe 
approach. There proved to be no interference with the general condition. Extra-cutaneous 
side-effects (table IV) were not considered to be drug related. Haematological and clinical 
biochemistry investigation did not reveal any clinically significant changes. In particular, 
serum calcium, phosphate and creatinin remained in the normal range. Recently nocturnal 
urine a-microglobulin (protein HC) proved to be a valuable marker for tubular 
dysfunction . 15 ,16 Tubular dysfunction is an early feature of calcium deposition in the 
parenchyma of the kidney. This parameter remained unaffected during the study. In 
conclusion, tacalcitol treatment in the present study was free of systemic side-effects.
Irritation of the skin has been reported regularly for various vitamin analogues.17"
19 However, irritation during treatment with low dose tacalcitol in psoriasis has been 
reported to be extremely rare in the Japanese psoriatic patients .7 ' 11 In the present study in 
Caucasian patients, irritation of the skin was observed in 12% of the patients. In no single 
patient, however, the irritation required discontinuation. No single patient experienced 
aggravation of irritation during continuation of tacalcitol treatment. The global tolerance of 
tacalcitol was judged as very good or good by 96% and 98% of the investigators and 
patients respectively. The convincing tolerance of tacalcitol ointment is in line with the 
Japanese experience.
The usefulness of tacalcitol ointment was judged to be 7 on a 10 point scale. This 
implies that tacalcitol is not the panacea of a highly effective antipsoriatic approach but 
rather represents a well-appreciated once daily treatment with a medium, for long-term 
control maintained, antipsoriatic
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efficacy. The excellent local tolerance suggests that tacalcitol treatment might be indicated 
for the treatment of the face and flexures. Further studies are indicated to compare and 
contrast the clinical efficacy and safety profile of tacalcitol with other vitamin Ds analogues 
and to study the safety in patients with extensive psoriasis during a long-term study.
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Chapter 5
General discussion
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5.1. INTRODUCTION TO DISCUSSION
In the general introduction, three aims were defined in order to further develop 
our knowledge on the in vivo mode of action and clinical efficacy and safety of topical 
treatment of psoriasis. These aims were:
I. To study the in vivo effects of established topical antipsoriatic treatments on 
epidermal proliferation and differentiation in the psoriatic plaque.
II. To develop a new model to study the induction of recruitment of cycling cells and 
proliferation associated epidermal differentiation in human skin in vivo and to 
study the effect of topical antipsoriatic treatment on such a model.
III.To study efficacy and safety aspects of new and existing topical treatments for 
psoriasis.
The various questions were dealt with in the individual chapters. Here we will 
integrate these findings with the knowledge available in literature.
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5.2. IN VIVO EFFECTS OF TOPICAL THERAPY ON THE PSORIATIC PLAQUE
Various studies have been undertaken to study cell-biological changes in the 
psoriatic lesion during treatment. In a previous thesis, epidermal growth (Ki-67 staining 
and keratin 16 expression) and inflammation characteristics (T-lymphocytes, elastase 
positive cells, Langerhans cells and monocytes/macrophages) were assessed during 
treatment with the vitamin D3 analogue calcipotriol, the corticosteroid budesonide and 
dithranol in an emulsifying ointment . 1 The thesis 'Dynamics of epidermal growth and 
keratinization in psoriasis' comprised the study of differentiation markers filaggrin, 
involucrin and transglutaminase during monotherapy with hydrocolloids and experimental 
vitamin D3 analogues . 2
The present thesis comprises the effects of available and some new topical 
treatments and combinations of treatments on differentiation markers and in addition, the 
proliferation marker Ki-67, T-lymphocytes and polymorphonuclear leukocytes (PMN). The 
results of these and previous studies are summarised in table I.
Table I  Simplified presentation of the in vivo effects of topical antipsoriatic treatments (I 
or T: < 10 % change; 11 or TT: 10-50 % change; TTT or TTT: > 50% change; S: 
synergistic response (more than the sum of the individual treatments); =: no effect; nd:
nnh H n n o 1 W iT V  hx/H rnrnlIniH  H r o c c in n  1-3,present thesis
Ki-67 Ks8.1
2
involuc
rin
filagg
rin
TGa
se
T-cells PMN
dithranol TT TTT ttt T
derm
is
T
epider
mis
TT
derm
is
TT
epider
mis
TTT
(classic)
dithranol _ nd __ _ _ TTT TTT TTT TTT
(Micanol)
calcipotriol TTT — T TTT T T TT TT TTT
calcitriol TTT nd T TTT T TT TT TTT TTT
tacalcitol TTT TTT TT TTT TT T TT TTT TTT
HCD = T T TTT nd T = = =
corticosteroids TTT u T TT TT TTT TTT TTT TTT
UVB TTT nd T TTT TT TTT TTT = =
Micanol+UVB TTT~ nd T TT-S = TTT- TTT-S TTT- =
s s s
Most topical treatments proved to decrease the number of Ki-67 positive 
keratinocytes, indicating a decreased proliferation rate. A consistent change in the 
differentiation pattern was seen during all treatments: an increased filaggrin content, a 
decrease of the percentage of transglutaminase positive cell layers and a decrease of the 
number of keratin 16 positive cells. Differences between different therapies were 
predominantly observed with respect to the reduction of the percentage of T-lymphocytes 
and PMN in the dermal infiltrate and in the epidermis.
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Dithranol
Treatment with dithranol in the classical vehicles had major effects on epidermal 
proliferation and differentiation and only minimal effects on inflammation markers. 
Therefore dithranol can be regarded as a treatment that affects the epidermis more 
selectively. However, the anti-inflammatory potential seems to be influenced by the 
formulation of the dithranol preparation to a large extent. The classical vehicle of 
petrolatum , 4 the Dithranol Hermal-AW ointment5  and the cream base used in the 
department for intensified out-patient therapy (chapter 2 .2 ) proved to have minimal anti­
inflammatory effects, whereas dithranol in the monoglyceride formulation had a profile of 
changes with a predominantly anti-inflammatory effect (chapter 2.3).
Vitamin D3 treatments
Treatment with calcipotriol (chapter 2.1) and other vitamin D3 analogues2 had 
prominent effects on epidermal proliferation and differentiation. With respect to cutaneous 
inflammation, an important reduction of the number of PMN was observed during treatment 
with only minimal effects on the percentage of T-lymphocytes in the dermal infiltrate. This 
therapeutic response pattern suggests that a reduction of the number of T-lymphocytes is 
not a 'conditio sine qua non' for a therapeutic effect in psoriasis.
Hydrocolloid dressings
Hydrocolloid dressings as a monotherapy have a modest effect on cell-biological 
parameters of the psoriatic plaque: a reduction of keratin 16 expression and involucrin and 
an increase of filaggrin, although clinical parameters hardly indicate any clinical 
improvement . 3 ,6 ,7 Therefore, hydrocolloids are not suitable as a monotherapy. In 
combination with topical antipsoriatics, however, weekly dressing changes with a topical 
antipsoriatic under occlusion of a hydrocolloid dressing provide a new pharmacological 
principle with an intensified action of the topical antipsoriatic, increasing its bioavailability, 
decreasing its dose and providing optimal patient compliance (chapter 2.4)7
Topical corticosteroids
Topical corticosteroids (clobetasol (chapter 2.4) and budesonide8), on the whole, 
had a broad effect on all aspects of epidermal growth, differentiation and inflammation. 
Topical corticosteroids can therefore be regarded as a broad spectrum antipsoriatic 
treatment. In addition, the effects of topical corticosteroids proved to be rapid. Treatment 
by clobetasol-17-propionate lotion under hydrocolloid occlusion had even a faster clearing 
capacity and the same relapse characteristics compared to conventional twice daily 
application of clobetasol-17-propionate ointment without occlusion (chapter 2.4).
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Phototherapy
Phototherapy (UVB) had a broad effect on all aspects of epidermal growth, 
differentiation and inflammation, except for PMN accumulation (chapter 2.3). Phototherapy 
therefore can be regarded as therapy that interferes with both epidermal processes and 
immune mechanisms .9 Combination of dithranol and phototherapy (UVB) can be regarded 
as a synergistic treatment. The combination resulted in an improvement which was 
significantly more than the sum of the improvements of the individual treatments.
Conclusions
Based on the immunohistochemical observations it can be concluded that:
I. Topical corticosteroids and phototherapy (UVB) are both immunosuppressive 
treatments and also modulators of epidermal growth and differentiation.
II. Calcipotriol treatment is a more selective treatment with prominent effects on 
epidermal growth, differentiation and epidermal PMN accumulation, but with 
minimal effect on T-cell accumulation.
III.Dithranol is a selective antipsoriatic therapy with only minimal anti-inflammatory 
capacity. However, Micanol, dithranol micro-encapsulated in crystalline 
monoglycerides, proved to have a substantial anti-inflammatory effect.
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5.3. IN VIVO MODELS FOR PSORIASIS
In vivo models for epidermal proliferation permit studies on the induction of the 
recruitment of cycling epidermal cells and the associated changes in the process of 
keratinocyte differentiation in vivo. The increased recruitment of cycling epidermal cells is 
the key-feature of psoriatic hyperproliferation of the epiderm is .10 " 12 In addition, in vivo 
models provide a 'standardised lesion' in contrast to the heterogeneity that characterises a 
genuine psoriatic lesion.
The effect of tape-stripping has often been used as a model to mimic certain aspects 
of the psoriatic lesion. This technique involves the removal of the stratum corneum by 
repeated applications of adhesive tape. The tape-stripping model is well-reproducible and 
non-invasive and results in a hyperproliferative response, slight cutaneous inflammation 
and a psoriasis-like epidermal differentiation pattern .13 The model is adequate for studies 
on the in vivo effect of systemic drugs on epidermal growth and differentiation. A specific 
effect of systemic antipsoriatics could be shown by acitretin, in contrast to absence of such 
interference by cyclosporin . 14,15
Previously, various experiments have been carried out to study the effect of topical 
antipsoriatic treatments on epidermal proliferation following tape-stripping. Calcipotriol 
proved to inhibit ornithine decarboxylase activity following tape-stripping .16 Ornithine 
decarboxylase is the rate limiting enzyme of the polyamine synthesis which is pivotal in 
epidermal proliferation . 1 7 Other experiments showed that topical corticosteroids delay the 
wave of hyperproliferation following tape-stripping .18,19 In these experiments, proliferation 
was assessed by measuring the percentage of cells in SQ M  phase using flowcytometry.
One could speculate that, from a pharmacological point of view, the tape-stripping 
model is less appropriate for topical drugs because of the vehicle effect. The vehicle will to 
some extent compensate for the removal of the stratum corneum (skin barrier) in tape­
stripping and as such influence the process of regeneration. Another problem is that the 
removal of the skin barrier will provide a totally different bioavailability of topical drugs as 
compared to the unstripped skin. Therefore the search for alternative models to study the 
effect of topical treatments is indicated.
In the present thesis, a new in vivo skin model was developed (chapter 3.1). This 
model was obtained by irradiation of normal human skin with an intermediate dose of one 
MED (minimal erythema dose) UVB which resulted in a response pattern that is comparable 
with a psoriasis-like epidermal hyperproliferation and differentiation and did not result in a 
major inflammatory infiltrate or epidermal cell destruction. The UVB model was used to 
study the effect of topical antipsoriatic
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treatments. A  study was carried out on the interference of topical antipsoriatics with 
epidermal proliferation and differentiation using an UVB skin challenge (chapter 3.2). 
Clobetasol-17-propionate proved to inhibit recruitment of cycling epidermal cells, involucrin 
expression, transglutaminase expression and keratin 16 expression following UVB 
challenge. In contrast, calcipotriol did not modulate the induction of these aspects of 
proliferation and epidermal differentiation, apart from the inhibition of the number of 
transglutaminase positive cell layers. So far, no information is available on the effect of 
systemic treatments on UVB induced hyperproliferation.
From the interference of antipsoriatic treatments -topical and systemic- with trauma 
(tape-stripping) or UVB induced hyperproliferation, it can be concluded that acitretin and 
topical corticosteroids inhibit the recruitment of cycling cells and associated epidermal 
differentiation in vivo. Cyclosporin treatment has no effect on the induction of epidermal 
hyperproliferation in vivo in the tape-stripping model, in contrast to its growth inhibitory 
effect in vitro . 20 "22 No information on the modulation of the induction of epidermal 
hyperproliferation is available so far for dithranol, photo(chemo)therapy and methotrexate.
Calcipotriol inhibits trauma induced hyperproliferation .18,19 However, in UVB induced 
proliferation, calcipotriol was not effective in this respect. It is my own experience that 
unstable psoriasis, that is characterised by spreading lesions and pin-point papules, 
responds less to calcipotriol compared to chronic plaque psoriasis. This might explain the 
disability of calcipotriol to modulate the 'new lesion' induced by UVB radiation. An 
alternative explanation for the absence of an effect of calcipotriol an UVB inflammation is 
the relatively short application period of calcipotriol in the experimental model.
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5.4. THE TOPICAL THERAPY OF PSORIASIS: AN UPDATE
5.4.1. Dithranol based therapies
Dithranol, introduced by Galewski and Unna more than 80 years ago, remains to 
be a very important treatment for psoriasis .23 An important development is the short 
contact principle. Short contact applications enable a decreased penetration in the 
uninvolved skin of the psoriatic patient whilst having an adequate bioavailability in the 
psoriatic p laques . 24 The short contact treatment using dithranol in a cream that can easily 
be washed off, has increased the possibilities of the use of dithranol at home.
Dithranol m icro-encapsulated in crystalline monoglycerides (Micanol) is a new 
developm ent . 25 In a comparative study over eight weeks between Micanol monotherapy, 
Micanol combined with UVB phototherapy and UVB combined with the placebo of Micanol, 
a complete clearance of psoriasis was seen in respectively 29%, 54%, and 46% of the 
patients . 26
The results of the dithranol short contact therapy depend on the intensity of the 
treatment and compliance of the patient. Table II shows that a complete clearance in 
62% of the patients is reached by short contact applications of dithranol at the in-patient 
department. At the out-patient department, only 10% of the patients reached a complete 
clearance if the control visits were carried out at 1-3 weeks intervals.
Table II Clearance during short contact therapy with dithranol
Number of visits Base Literature % of cleared 
patients
In-patient Emulsifying ointment Paramsothy et 62
treatment al.27
Three times Micanol Gerritsen et al.26 53
weekly
Three times Psoricreme® or petrolatum with salicylic de Mare et al.28 50
weekly acid
Once weekly Psoricreme® or petrolatum with salicylic de Mare et al.28 33
acid
Once weekly Micanol Gerritsen et al.26 29
Once per 1-3 Petrolatum with salicylic acid Hindrycks et al.29 10
weeks
A new concept is the intensified out-patient treatment in which patients are 
treated and instructed by specially trained nurses with short contact dithranol cream 
applications in order to carry out this treatment at hom e .30 One study showed that in 
intensified out-patient treatment, a 70% -reduction of the PASI-score takes more time 
compared to in-patient treatment with 24 hour applications of dithranol but takes 
significantly less time compared to UVB phototherapy .30 At the moment an extensive, 
comparative, multi-centre study is being carried out on the cost-effectiveness and patient 
satisfaction of these three treatment possibilities.
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In the present thesis, it was shown that the cream base (chapter 2.2) and the 
monoglyceride suspension (chapter 2.3) proved to be we 11-tolerated, proved to have a 
substantial antipsoriatic effect and could be washed off easily. The cream formulation, as 
monotherapy, approached the efficacy of classical in-patient treatment, although a 
prolonged treatment period was required to reach this result .30 Dithranol in the 
monoglyceride formulation, however, proved to be more adequate as an adjunct 
treatment to UVB . 26
5.4.2. Vitamin D* treatments
The last decade, vitam in D3 analogues have been shown to have an important 
antipsoriatic effect. Recently, vitam in D3 analogues were introduced as a routine 
treatment in dermatology. The mode of action of these derivatives is pluriform and 
comprises inhibition of cellu lar proliferation, enhancement of normal epidermal 
differentiation (formation of cornified envelopes, enhancement of transglutam inase 
activity and transcription of involucrin) and modulation of inflammatory events .3 1
Calcipotriol
Calcipotriol was introduced in the Netherlands in 1992. In comparison to calcitriol, 
the naturally occurring hormone (1,25-dihydroxy vitam in D3), calcipotriol has 100-200 
times less effect on the calcium metabolism after system ic adm inistration in animals. 
Calcipotriol has become the therapy of first choice in mild to moderate psoriasis.
Calcipotriol ointm ent (SO^g/g ointment), applied tw ice daily, has a marked effect 
in 80% of the patients. Irritation of the skin is seen in approximately 25% of the 
patients; 5% of the patients has to discontinue treatment because of skin irritation .3 2 " 34 
During a large long-term study, a clinically relevant increase of serum calcium and 
phosphate was not seen; the amount of ointment applied in these studies did not exceed 
the maximal dose of 100 grams per week .3 4 From this study it can be concluded that the 
long-term treatment with calcipotriol is a safe and effective therapeutic principle.
Calcipotriol is a topical treatment with important possibilities for combination 
therapy and the combination of calcipotriol with other antipsoriatic therapies is a major 
step forward in the treatment of psoriasis. The effects of calcipotriol in vivo are mainly on 
epidermal proliferation, differentiation and accumulation of PMN. Cyclosporin, on the 
other hand, mainly has immunosuppressive effects. In a group of 69 patients, treated in 
a multi-centre study, with a low dose of cyclosporin ( 2  mg/kg/day) either or not 
combined with topical calcipotriol, an
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improvement of the PASI-score of more than 90% was experienced in 50% of the 
patients treated with the combination of cyclosporin and topical calcipotriol ointment 
twice daily. Only 12% of the patients reached such an improvement using cyclosporin 
monotherapy without calcipotrio l .3 5 At the moment no comparable studies concerning 
methotrexate or acitretin are available.
The combination of calcipotriol and UVB phototherapy is more effective compared 
to calcipotriol m onotherapy . 3 6 "3 8 Calcipotriol enables a marked reduction of the UVA dose 
in PUVA therapy . 39 The therapeutic effect of the combination of calcipotriol and medium 
strength topical corticosteroids does not differ substantially from both m onotherapies .12,40 
However the combination of calcipotriol and betamethasone dipropionate has been 
demonstrated to be more effective compared to each treatment as m onotherapy .41
On the whole, 80% of the patients has a satisfactory response to calcipotrio l .3 2 ' 34 
Not only patients with psoriasis of limited extent benefit from calcipotriol. It was shown in 
chapter 4.2 that calcipotriol can also be effective in patients with extensive psoriasis, 
provided that optimal compliance is realised. In combination with cyclosporin, calcipotriol 
proved to be very effective as adjuvans in the management of erythroderm ic psoriasis 
(chapter 4.1).
Tacalcitol
A lim itation of the current calcipotriol therapy is irritancy which, in principal, 
excludes treatment of the face. Low irritancy was claimed by Japanese investigations for 
an alternative vitam in D3 derivative: tacalcitol (l,24(R)-d ihydroxy vitam in D3). Tacalcitol 
( 2  ng/g ointment; applied twice daily) has been reported to be effective in 80% of the 
patients resulting in a marked improvement .42 In a left-right comparative study, it was 
established that tacalcitol is more effective compared to treatment with betamethason- 
17-valerate ointment and tacalcitol proved to have only a minor irritating potential in less 
than 1 % of the patients .43
Recently, efficacy and safety of tacalcitol were investigated in Europe .44 A  dose- 
finding study on tacalcitol ointment was carried out, using once daily applications. This 
study revealed sim ilar antipsoriatic effects of treatment with ointment containing 4^g/g 
tacalcitol compared to ointment containing 16 ng/g tacalcitol. O intment with less than 4 
ng/g of the active substance demonstrated a substantially decreased therapeutic 
efficacy . 44
In a multi-centre study, the therapeutic efficacy, safety and tolerability of 
tacalcitol ointment (4 ng/g) compared to placebo ointment were investigated. The 
ointment was applied once daily in Caucasian patients with psoriasis during eight weeks 
in a left-right comparative study .40
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Hundred-twenty-two patients from different centres were included in the study. Already 
after a treatment period of two weeks, a highly significant difference in the clinical scores 
was observed between patients treated with tacalcitol ointment compared to patients 
treated with the vehicle. The clinical relevance was also apparent: 60% of the patients 
judged the treatment as good or very good. During the eight weeks of treatment, no 
changes were seen in the serum calcium concentration. Signs of skin irritation were seen 
in 12% of the patients. Only in one patient, the therapy was discontinued due to 
irritation. This considerable difference in irritating potential between the European and 
Japanese study can be explained by the difference in concentration of the tacalcitol 
ointment but also by the fact that far more emphasis is laid in Europe on the irritating 
potential of vitam in D3 analogues. The European multi-centre study indicates that 
tacalcitol ointment in a concentration of 4 ng/g applied once daily is an effective therapy 
with only a relatively small irritation potentia l.40
In the present thesis, it was shown that tacalcitol was well-tolerated and safe, also 
during prolonged treatment (chapter 4.3). It is feasible that tacalcitol will broaden the 
vitam in D3 principle to the treatment of the face and flexures.
5.4.3. Hvdrocolloid dressings
Since the seventies, it has been known that occlusive dressings have an 
antipsoriatic potentia l.45 Plastic foil as an occlusive dressing proved to have an irritating 
and macerating effect during prolonged applications. A hydrocolloid dressing, however, 
can be worn for a whole week w ithout having such side-effects. In contrast to daily 
dressing changes or daily ointment or cream applications, an optimal compliance is 
guaranteed using occlusive therapy with once weekly dressing changes. Although 
monotherapy with hydrocolloid dressings has been proven to be beneficial in psoriasis, 
this effect is only m inor .7 The combination of a hydrocolloid dressing with a topical 
corticosteroid, on the other hand, is very effective, particularly in localised, recalcitrant 
psoriasis .4 6 ,4 7 The hydrocolloid dressing represents an interesting pharmacological 
principle because of the prolonged effect of a single once weekly application of a topical 
corticosteroid. Calcipotriol under occlusion of a hydrocolloid dressing has also been 
proven to be more effective compared to calcipotriol monotherapy and as effective as 
clobetasol under occlusion although, in the latter study, calcipotriol was more irritating 
than the corticosteroid .4 8,49 Further studies are needed to establish the relevance of this 
principle for other topical treatments for psoriasis.
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The present thesis demonstrated that the relapse and the post-treatment 
remission characteristics follow ing discontinuation of treatment with clobetasol-17- 
propionate in conjunction with a hydrocolloid dressing, were analogous to treatment with 
twice daily applications of clobetasol-17-propionate ointment without a hydrocolloid 
(chapter 2.4). There is no indication that a faster remission of the combination of a 
hydrocolloid in conjunction with a corticosteroid is accompanied by a shorter remission 
period compared to corticosteroid monotherapy. Also no differences in atrophogenicity 
between both treatment modalities could be observed (chapter 2.4).
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5.5. GENERAL CONCLUSION AND SUMMARY
In chapter 1 of the present dissertation, a review is given about general aspects of 
the skin-disease psoriasis like: clinical features, histopathology, aetiology and current 
therapeutic possibilities. The subject of focal interest in the present thesis is the topical 
treatment of psoriasis. Lately progress has been made on this territory, mainly on dithranol 
based therapies, treatment with vitamin D3 analogues and the principle of topical therapy 
under hydrocolloid occlusion.
The research that underlies this dissertation contains, besides an analysis of the 
clinical efficacy and safety of several topical antipsoriatics, an assessment of 
immunohistochemical effects of topical antipsoriatic therapies on psoriatic skin and also on 
a new model for a developing psoriatic lesion (UVB-model). Primarily, epidermal 
differentiation processes were studied with the following markers: involucrin, 
transglutaminase, filaggrin and cytokeratin 16. Markers for epidermal proliferation (Ki-67) 
and cutaneous inflammation (T-lymphocytes and polymorphonuclear granulocytes) were 
studied as well. At the end of chapter 1 the following questions were formulated:
1. What are the immunohistochemical effects of different topical antipsoriatics?
2. What are the effects of different topical antipsoriatics on a new in vivo model for a 
developing psoriatic lesion?
3. What is the clinical efficacy and safety of new (combinations of) topical 
anti psoriatics?
In chapter 2, a consistent pattern of in vivo effects of topical treatments on 
epidermal differentiation in psoriasis was found: a decrease of the percentage of involucrin 
and transglutaminase positive cell layers, a reduction of keratin 16 positive cells and an 
increase of the number of filaggrin positive cells. Early modulation of these markers for 
epidermal differentiation suggests that interference with keratinocyte differentiation is an 
important aspect of the topical treatment of psoriasis in general. The topical treatments 
that were studied also proved to inhibit the proliferation rate of epidermal keratinocytes.
In contrast to the in vivo situation, in vitro studies have been shown to have a more 
treatment-specific response pattern. The differences between the in vivo action of various 
topical antipsoriatic treatments were mainly caused by a selective interference pattern with 
cutaneous inflammation. Whereas phototherapy (UVB) and topical corticosteroids both 
inhibited T-lymphocyte accumulation, calcipotriol only caused a small effect on T-cell 
functioning. During treatment with dithranol, the vehicle seemed to be a determining factor 
for the cell-biological effect. Dithranol, in classical vehicles, left the mononuclear 
inflammatory infiltrate unaffected, during a prolonged time, despite evident clinical
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improvement .4 Dithranol in the Micanol formulation induced an obvious reduction of the 
percentage of T-lymphocytes in the inflammatory infiltrate.
The anti-inflammatory and immunomodulatory effect of phototherapy and 
corticosteroids is also expressed during the treatment of inflammatory conditions such as 
atopic dermatitis . 50 The effect of calcipotriol on PMN permits treatment of pustular psoriasis 
with this vitamin D3 analogue. Dithranol, in fact, is a treatment which is specific for 
psoriasis, although some authors have shown efficacy in seborrhoeic dermatitis, a condition 
which shares histological and clinical features with psoriasis .5 1 ,5 2
In chapter 3, a new in vivo skin model was developed for an evolving psoriatic 
lesion. In vivo models for epidermal proliferation permit studies on the induction of the 
recruitment of cycling epidermal cells. The UVB-model proved to be a model suitable for 
interference studies with topical antipsoriatics. Clobetasol-17-propionate modulated many 
aspects of the effect of UVB on normal human skin in contrast to calcipotriol.
In chapter 4 and former chapters, the clinical efficacy of new and existing 
(combinations of) therapies was assessed and discussed. In a case-report, the additive 
value of calcipotriol in the cyclosporin treatment of erythrodermic psoriasis was shown. The 
efficacy of this combination has been demonstrated before in a large, clinical study in 
patients with mild to moderate psoriasis .35
In a left-right comparative study in patients with extensive psoriasis at the in­
patient department, an analogues efficacy was found for the classical dithranol treatment 
and treatment with calcipotriol. From this study, it can be concluded that calcipotriol is a 
therapy that is also suitable for patients with extensive psoriasis, provided that patient- 
compliance is optimal.
The combination of therapies reduces side-effects of individual treatments due to a 
dose-reducing effect. On the other hand, combination treatments may also be more 
effective due to synergism. The efficacy of a therapy with mainly immunomodulating effects 
can be increased by a therapy with effects on epidermal proliferation and differentiation. 
The combination of phototherapy (UVB) and dithranol had synergistic effects on the cell- 
biological level. Clinical studies did also show a synergistic effect of the combination of 
cyclosporin as a selective immunomodulatory treatment with calcipotriol mainly interfering 
with epidermal growth and differentiation .35
Regarding safety aspects of the treatment of psoriasis, potent topical corticosteroids 
under hydrocolloid occlusion were found not to be more atrophogenic compared to 
corticosteroids without this occlusion and to have the same relapse characteristics after 
discontinuation of both treatments.
161
Further it was found that the vitamin D3 analogue, tacalcitol, is an effective therapy with 
only a small irritative potential and without significant side-effects on calcium-, phosphate-, 
creatinin-concentration in the serum and 1 -a-microglobuline in urine.
The assessment of the mode of action of antipsoriatic treatments is complex. It has 
been shown that in vitro effects may not always be relevant in the in vivo situation. Further 
studies are indicated to assess effects of treatment in vivo during treatment of psoriatic 
plaques and should aim for assessment of functional markers with respect to cutaneous 
inflammation and quantitative assessment of cell-biological changes.
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SAMENVATTING
In hoofdstuk 1 van dit proefschrift wordt een overzicht gegeven over algemene 
aspecten van de huidziekte psoriasis waaronder klinische kenmerken, histologie, 
aetiologie en huidige therapeutische mogelijkheden. Het aandachtsgebied in dit 
proefschrift is de lokale behandeling van psoriasis. De laatste tijd is er vooruitgang 
geboekt op dit terrein met name met betrekking tot de dithranol gebaseerde therapieën, 
therapie met vitam ine D3 analogen en het principe van een lokale therapie onder 
hydrocolloïde occlusie.
Bij het onderzoek dat ten grondslag ligt aan deze dissertatie is, naast de analyse 
van klinische effectiviteit en veiligheid van verschillende lokale therapeutica, met behulp 
van immunohistochem ische technieken, het effect van lokale therapeutica op de 
psoriatische huid geïnventariseerd en is tevens het effect van deze therapieën 
geïnventariseerd in een nieuw model (UVB-model) voor een zich ontw ikkelende psoriasis 
laesie. Primair is hierbij gekeken naar epidermale differentiatieprocessen met als 
markers: involucrine, transglutam inase, filaggrine en keratine 16 maar ook naar markers 
voor epidermale proliferatie (Ki-67) en cutane inflammatie (T-lymfocyten en 
polymorfkernige granulocyten). Aan het eind van hoofdstuk 1 werden drie vragen 
geformuleerd:
1. Wat zijn de immunohistochem ische effecten van verschillende antipsoriatica?
2. Wat zijn de effecten van verschillende lokale antipsoriatica op een nieuw in vivo 
model voor een zich ontw ikkelende psoriatische laesie?
3. Wat is de klinische effectiviteit en veiligheid van nieuwe (combinaties van) lokale 
antipsoriatica?
In hoofdstuk 2 werd een consistent patroon gevonden in de wijze waarop lokale 
antipsoriatica hun effect hebben op epidermale differentiatie processen in vivo in de 
psoriatische huid: een verm indering van het percentage involucrine en transglutam inase 
positieve cellagen, een reductie van het aantal keratine 16 positieve cellen in de 
epiderm is en een toename van het aantal filaggrine positieve cellen. Het feit dat deze 
markers voor epidermale differentiatie al vroeg veranderden gedurende lokale psoriasis 
behandeling suggereert dat de differentiatie van keratinocyten belangrijk aspect is van de 
lokale behandeling van psoriasis in het algemeen. De bestudeerde lokale antipsoriatica 
remden tevens de proliferatie van de epidermale keratinocyten.
In tegenstelling tot de in vivo situatie worden met name bij in vitro studies meer 
therapie-specifieke effecten gevonden van de verschillende antipsoriatica. De verschillen 
tussen de lokale
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antipsoriatica die in vivo gezien werden, lijken voornamelijk veroorzaakt te worden door 
een selectief patroon van interferentie met cutane inflammatie. Lichttherapie met UVB en 
lokale corticosteroïden remden beide de accumulatie van T-lymfocyten, in tegenstelling 
tot calcipotriol dat slechts een klein effect had op de T-cel functie. Bij de behandeling met 
dithranol bleek het vehiculum een bepalende factor te zijn voor het cel-biologisch effect. 
Tijdens behandeling met dithranol in klassieke vehicula persisteerde het T-celinfiltraat 
gedurende enkele weken ondanks sterke klinische verbetering. Dithranol in de Micanol 
crème-formulering bleek een duidelijke reductie van het percentage T-lym focyten in het 
ontstekingsinfiltraat te induceren.
In hoofdstuk 3 is een nieuw model ontwikkeld voor een zich ontwikkelende 
psoriatische laesie. Door middel van in vivo modellen kan de inductie van rekrutering van 
epidermale proliferatie worden bestudeerd. Het UVB-model is gebleken een model te zijn 
dat geschikt is voor interventie studies met lokale antipsoriatica. Clobetasol-17- 
propionate moduleerde vele aspecten van het effect van UVB op normale menselijke 
huid, in tegenstelling tot calcipotriol.
In hoofdstuk 4 en eerdere hoofdstukken komt de klinische effectiviteit van nieuwe 
en bestaande (combinaties van) therapieën aan bod. In een case-report werd de 
toegevoegde waarde van calcipotriol bij de cyclosporine-behandeling van een 
erythroderm ische psoriasis gedemonstreerd. De effectiviteit van deze combinatie was al 
beschreven in een grote studie bij milde tot matige psoriasis.
In een links-rechts vergelijkende studie bij patiënten met uitgebreide psoriasis in 
de klinische setting kon een vergelijkbare effectiviteit worden vastgesteld voor de 
klassieke behandeling met dithranol en behandeling met calcipotriol. H ieruit kan worden 
geconcludeerd dat ook calcipotriol een therapie kan zijn voor een uitgebreide psoriasis 
mits de therapietrouw optimaal is.
Combinaties van therapieën kunnen bijwerkingen reduceren door een dosis 
verm inderend effect. Anderzijds kunnen gecombineerde behandelingen ook klinisch 
effectiever zijn ten gevolge van synergie. Zo kan de werking van een therapie met 
voornamelijk immunomodulerende effecten worden versterkt door een therapie met 
effecten op epidermale proliferatie en differentiatie. De combinatie van lichttherapie 
(UVB) met dithranol bleek synergistische effecten te hebben op het cel-biologische 
niveau.
Kijkend naar veiligheidsaspecten, werd gevonden dat potente lokale 
corticosteroïden onder hydrocolloïde occlusie niet meer atrofogeen zijn dan lokale 
corticosteroïden zonder deze occlusie
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en tevens dat de relapse-karakteristieken na het stoppen van deze therapieën 
vergelijkbaar zijn. Verder werd gevonden dat het vitam ine D3 analoog, tacalcitol, een 
effectieve therapie is met een beperkt irritatief effect op de huid zonder significante 
bijwerkingen op calcium , fosfaat, kreatinine in serum en 1 -a-microglobuline in urine.
In hoofdstuk 5 worden alle bevindingen bediscussieerd in het licht van de 
bestaande literatuur over deze onderwerpen.
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